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Myosin is a cytoskeletal motor that uses metabolic energy stored in ATP to do mechanical 
work. Muscle myosin in all mammals consists of a variety of isoforms, each expressed from 
its own gene. All of the striated muscle myosin sequences are highly conserved, but each 
myosin isoform confers distinct contractile characteristics to distinct muscle fibre types. 
How each myosin is tuned for its specific function is not well understood. We combined 
detailed biochemical characterisation with a novel kinetic modelling approach to probe how 
sarcomeric myosin isoforms adapt their mechanochemical cross-bridge cycle to perform 
different functions.  
 
The next question from this was how the sequences of these highly conserved 
isoforms give rise to these contractile differences. Focussing on the β cardiac myosin 
(MyHC-β), we investigated how the sequence of the protein can drive adaptation to 
changes in body mass by altering the rate of ADP-release and velocity of contraction. 
Bioinformatics analysis identified the sequence variants in MyHC-β that directly control its 
velocity and the biochemical validations are presented. This demonstrates how a protein 
can adapt over evolutionary time frames to meet different physiological requirements, which 
remains one of the fundamental questions in structural and molecular biology.  
 
Mutations in the same protein (MyHC-β) are a major cause of the life-threatening 
disease, Hypertrophic Cardiomyopathy (HCM). The specific mechanistic changes to 
myosin function that lead to this disease remain incompletely understood. We hypothesised 
that mutations that result in early onset disease would have more severe changes in 
function than do later onset mutations. Contrary to our hypothesis, no clear distinction was 
observed in the molecular behaviour of MyHC-β between early and late onset HCM 
mutations. One of the existing challenges of a study of this scale is the difficulty in producing 
recombinant myosin protein. This thesis will describe the development of an innovative 
expression system in insect cells which produce C. elegans body wall myosin in a non-
muscle environment. The approach was validated by the biochemical characterisation of 
the resulting protein, which was found to be homologous to human MyHC-β, suggesting it 
could be used as a new model protein to study human disease. 
 
My thesis describes how sarcomeric myosins have fine-tuned their properties to 






A-band Anisotropic band 
AM Actin-myosin complex 
AMD Actin-myosin-ADP complex 
AMDPi Actin-myosin-ADP-phosphate complex 
AMT Actin-mysoin-ATP 
ARM Armadillo repeat 
ARVC Arrhythmogenic right ventricular cardiomyopathy 
DCM Dilated cardiomyopathy  
dpc Days post coitum 
DR Duty ratio 
ELC Essential light chain 
EOM Extraocular muscle 
F-actin Filamentous-actin 
G-actin Globular-actin 
HCM Hypertophic cardiomyopathy 
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I-band Isotropic bands 
IHM Interacting heads motif 
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LECA Last eukaryotic common ancestor 
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Understanding the relationship between protein structure and function remains a primary 
focus in many fields of biology, including (but not limited to) genetics, molecular biology, 
biochemistry and cell biology. The discovery of the motor protein myosin and the 
fundamental mechanism underlying muscle contraction many decades ago led to a surge 
in research to characterise its mechanochemical activity. Underlying this activity is the 
protein’s highly conserved structure, of which we now know many details. The functional 
repertoire of myosin is very diverse - but how has the protein been engineered to enable 
this? This is a question that remains unanswered. The sequence differences between 
muscle myosin isoforms can be very small, yet there exists a plethora of functions that the 
family can perform. Whilst the sequences contain all the genomic information necessary 
for a protein to perform its function, studying these sequences alone does not yield insights 
into how myosin isoforms are able to adapt their behaviour to suit the functional demands 
of the muscle in which they exist. The differences tend to manifest themselves on a 
biochemical or functional level, indicative of a mechanism of ‘fine-tuning’ of the highly-
conserved myosin protein, which most likely occurs on a molecular level. Gaining a deeper 
understanding of this process of fine-tuning of myosin class II isoforms is the basis for the 








Myosin is a ubiquitous and multifunctional motor protein that converts the energy generated 
from the hydrolysis of ATP to power movement. The myosin superfamily comprises 35 
different sub groups, 13 of which have been identified in humans (Odronitz and Kollmar 
2007). Figure 1.1 demonstrates the myriad of known myosin groups. Myosins are involved 
in a wide range of cellular processes including cargo interactions, actin-based projections, 
membrane compartments, cell division, and what this thesis will predominantly focus on, 
muscle contraction. 
 
Figure 1.1 The number of myosins per class. Exact numbers are given in brackets. Figure 
from (Odronitz and Kollmar 2007). 
 
Myosins are structurally related, actin-based molecular motors which can exist 
either as a single or a double headed dimer. They move towards the plus-end of actin 
filaments, with the exception of myosin class VI, which are directed towards the minus-end 
(Park et al. 2007). They have a conserved myosin ATPase cycle, even across different 
families (Sellers 2000). The enzymatic activity of these motors is coupled to structural 
changes associated with track interactions, to produce motile movement. 
 
Myosins share a common structure comprised of head, neck and tail regions, as 
shown in Figure 1.2. The head domain is composed of the motor domain, so-called 
because it contains the sites for catalytic activity, and the lever arm. The motor domain 
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contains the nucleotide- and actin-binding sites. The neck region contains a variable 
number of IQ motifs, which are units of 23 amino acids with the sequence IQXXXRGXXXR 
that serve as a binding site for calmodulin, or calmodulin-like proteins such as myosin light 
chains (Bähler and Rhoads 2002). The binding of light chains stabilises the lever arm and 
allows for some regulation of the myosin protein. Some myosin classes have a cargo 
binding domain at the C-terminal end, to facilitate intracellular transport of vesicles or 




Figure 1.2. Schematic of the organization of the typical myosin molecule. All myosin 
sequences contain a motor domain with conserved elements able to bind ATP as well as 
more variable regions involved in actin binding. The sequence of the tail region is more 
variable, depending on the myosin class, but can contain coiled-coil sequences for 
dimerization. The most C-terminal regions can play a role in targeting the myosin to specific 




1.1.2 Sarcomeric myosin 
 
Myosins were traditionally termed conventional or unconventional. Class II myosins make 
up the conventional myosins, and are responsible for muscle contraction. Class II myosins 
are hexameric protein complexes, composed of 2 heavy chains, 2 essential light chains 
(ELC) and 2 regulatory light chains (RLC). The 2 heavy chains form a dimer, with the motor 
domain found at the N-terminal part. The IQ motifs on the heavy chains facilitate binding of 
the essential and regulatory light chains. The C-terminal region of the heavy chain forms a 
rod-like coiled-coil structure. Proteolytic digestion of the myosin dimer with the enzyme 
papain can generate heavy meromyosin (HMM) and light meromyosin (LMM) (Figure 1.3) 
(Kominz et al. 1965). The HMM fragment consists of the 2 globular head domains, the 2 
neck regions, and a short portion of the coiled-coil tail, leaving the remaining coiled-coil 
portion of the tail in the LMM fragment. HMM interacts with many components of the 
sarcomere, predominantly with actin in the thin filament. The head and tail portions of HMM 
can be separated by further digestion with α-chymotrypsin to generate subfragment 1 (S1) 
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and subfragment 2 (S2) (Gergely, Gouvea, and Karibian 1955; Mihalyi and Harrington 
1959). The S1 is a monomeric motor domain; the remaining dimeric neck region makes up 
S2.  
 
Figure 1.3. Schematic representation of cleavage products of a myosin molecule to generate 
HMM and LMM. HMM can be further digested with α-chymotrypsin to generate subfragment 
1 (S1) and subfragment 2 (S2). Figure from (Hooper and Thuma 2005). 
 
 
 1.1.3 Structure of class II myosin 
 
The first crystal structure of an S1 molecule was obtained in 1994 for chicken skeletal S1, 
in what is now termed the post-rigor state of the cross-bridge cycle (Rayment et al. 1993). 
Since then, more high-resolution crystal structures have become available of myosin in 
different nucleotide-bound states, yielding insights into structural changes that the myosin 
motor is subjected to during the cross-bridge cycle (see section 1.15, Figure 1.12). To note, 








Figure 1.4. Crystal structure of a chicken skeletal myosin motor domain in a post-rigor 
complex.  The lower 50 kDa subdomain is shown in green, the upper 50 kDa subdomain in 
blue, the converter domain in cyan and the essential and regulatory light chains in yellow. 
Figure from (Mansson, Rassier, and Tsiavaliaris 2015). 
 
S1 can be proteolytically digested into 3 fragments, which are named by their 
apparent molecular weights; a 25 kDa N-terminal domain, a central 50 kDa and a 20 kDa 
C-terminal domain (Mornet et al. 1979) (see Figure 1.4). The central 50 kDa fragment is 
composed of the upper 50 kDa and lower 50 kDa subdomains (U50 and L50, respectively). 
The U50 and L50 subdomains are separated by the central beta sheet and surrounding 
alpha helices, which together form a 4-5 nm deep cleft, extending from the nucleotide 
binding site to the actin-binding site. The actin- and nucleotide-binding sites are therefore 
on opposite sides of the seven-stranded β-sheet and are separated by 40–50 Å (Geeves, 
Fedorov, and Manstein 2005). The central β-sheet is composed of 7 strands, 6 of which 





Figure 1.5. Topological map of the myosin motor domain. Helices are shown as circles, β 
strands are shown as triangles. The N-terminal SH-3-like β barrel is coloured yellow, the U50 
subdomain in pink, the L50 subdomain in green and the converter domain in blue. Figure 
from  (Geeves, Fedorov, and Manstein 2005). 
 
The L50 subdomain contains a major portion of the actin-binding site. The U50 
subdomain contains the nucleotide binding pocket, which is made up of switch 1 and switch 
2 and the P-loop. These switches move relative to one another depending on which 
nucleotide is present during the cross-bridge cycle.  Switch 1 is positioned at the bottom of 
the actin-binding cleft, and communicates between the nucleotide- and actin-binding sites. 
The conformation of this switch determines whether the cleft is in a ‘closed’ or ‘open’ 
conformation. Switch 2 recognises γ-phosphate of a nucleotide bound in the pocket. The 
conformation of switch 2 is dictated by the conformation of the active site. Movement of the 
switch 2 helix forces the SH1-SH2 helices to adjust, causing a 60 degree rotation of the 
converter and lever arm, which generates a 5 nm step size (Koppole, Smith, and Fischer 
2006). 
 
The 20 kDa fragment contains a long alpha helix (residues 648-689) that spans the 
structure from loop 2 to the third strand in the central beta sheet, followed by a turn and a 
broken helix. This broken helix is referred to as the SH1-SH2 as it contains two reactive 
thiols at positions 697 (SH2) and 707 (SH1). The distal end of the SH1 helix forms a hinge 
for the ensuing converter domain (Rayment et al. 1993). 
 
The converter domain is juxtaposed to the lever arm, and is located close to the 
essential light chain binding site (Dominguez et al. 1998). The converter domain acts as a 
fulcrum for the lever arm, and amplifies small conformational changes that occur in the 
active site by as much as 10 times. To do this, the converter domain links to the relay helix, 
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which is found in the L50 subdomain. Switch 2 is at the end of the relay helix, which when 
bound to a γ-phosphate	will cause a twisting and bending of the relay helix, so that the 
distal end goes through a large movement. The distal end is in close contact with the 
converter domain, and so the converter domain moves with it to generate a 5-10 nm 
translation of the tip of the IQ domain. Therefore, the position of the relay helix determines 
the movement of the converter domain. 
 
A number of surface loops are present within the structure to provide physical links 
that mediate conformational changes as a result of actin- and nucleotide-binding. Switch 2 
and the P-loop are involved in nucleotide binding, whilst loop 2, loop 3, loop 4 and the 
cardiomyopathy loop are involved in actin binding (Figure 1.4, 1.5). There are a number of 
important linkers in the motor domain such as the SH1 helix, relay helix and the strut loop, 
all of which are joined by key structural domains.  
 
The cardiomyopathy loop (CM loop) is found at positions 406-416, shown at the top-
right of Figure 1.5. Its sequence is important for correct myosin function (Liu et al. 2005). 
The name comes from the hypertrophic cardiomyopathy causing-mutation found at the 
human 403 residue, which is an arginine to glutamine substitution. This was the first 
missense point mutation to be identified in human β-cardiac myosin (Geisterfer-Lowrance 
et al. 1990). Unconventional myosins can be regulated via this loop due to phosphorylation 
of a serine or threonine (termed TEDS site) by members of the p21-activated kinase family 
(Attanapola, Alexander, and Mulvihill 2009; Fujita-Becker et al. 2005; Novak and Titus 
1998). Phosphorylation at this site stimulates actin-activated ATPase and motor activity; 
motors without a negative charge at this position display low ATPase and motility (De La 
Cruz, Ostap, and Sweeney 2001; Ostap et al. 2002; Fujita-Becker et al. 2005). The CM 
loop forms an antiparallel β-strand that is the major site of interaction of the upper 50-kDa 
motor domain with actin. 
 
Another loop in the motor domain is the strut loop, composed of 4 amino acids at 
positions 590-593 which is found on the surface near the actin-binding site. A single 
insertion or deletion into this loop abolished strong binding to actin, although the motor 
activity in the absence of actin was unchanged, showing the loop is important for actin 






1.1.4 Structure of the sarcomere 
 
The mammalian muscular system contains 3 types of muscles – skeletal, cardiac and 
smooth. The underlying contractile mechanism is conserved across all 3 types, but they 
differ in their structural ordering and regulation. Smooth muscle is an involuntary, non-
striated muscle. It is present in the walls of hollow organs such as the intestines and the 
bladder, and is controlled by the autonomous nervous system. In contrast, cardiac and 
skeletal muscle have a highly structured appearance when viewed under the microscope. 
The work of this thesis will focus on the skeletal and cardiac muscle systems. 
 
Cardiac and skeletal muscles have a striated appearance, and are composed of 
muscle fibres, which are individually comprised of myofibrils. It is myofibrils that contain 
repeating units of the basic, contractile unit of a muscle cell – the sarcomere. An electron 
micrograph is shown in Figure 1.6 – the alternating light and dark bands are visible which 
are responsible for the striated pattern. A sarcomere is typically 1.5 - 3.2 microns in length 
(Burkholder and Lieber 2001), depending on muscle type and is composed of thin and thick 
filaments.  
 
Figure 1.6. Electron micrograph of a sarcomere from skeletal muscle. The A-band 
corresponds to the region containing overlapping thin and thick filaments, the I-band 
contains just the thin filaments. The Z-disc and M-bands are where thin and thick filaments 
respectively are anchored. (Agarkova and Perriard 2005). 
 
The thin filaments are seen as light bands, or isotropic bands (I-bands). The thin 
filaments are composed predominantly of actin, tropomyosin and troponin. Running 
through the middle of the I-band is the Z-disc, which in Figure 1.6 can be seen as a dark, 
thick line. The Z-disc anchors the thin filaments in the sarcomere. The dark bands, or 
anisotropic bands (A-bands) are composed of overlapping thin and thick filaments. The 




protein-C (MyBP-C). The slightly darker line running through the middle of the A-band 
represents the M-band, which is where thick filaments are anchored. The H-zone 
corresponds to the part of the A-band that contains no thin filaments. The sliding filament 
theory obtained its name due to the phenomenon by which, when viewed under a 
microscope, the thick filaments slide past the thin filaments during contraction, resulting in 
the I-band and H-zone shortening but the A-band remaining the same length (Huxley and 
Hanson 1953). Myosin thick filaments are bipolar with a bare zone halfway along their 
length, where there is antiparallel packing of myosin molecules (Figure 1.7). The myosin 
heads then appear in the two outer parts of the filaments, termed the bridge regions (AL-




Figure 1.7. Electron micrograph of isolated myosin filaments (M) from the ventricular muscle 
of a human heart. Some actin filaments can be seen in the background, labelled (A). Scale 
bar is 200 nM. Adapted from (AL-Khayat et al. 2013) 
 
 
As well as the major components of the thin and thick filaments, there are a number 
of accessory proteins found within the sarcomere that confer stability on the structure. This 
is fundamental for skeletal and cardiac muscles to function. Titin is one example, which is 
a “giant” protein 1 µM in length, spanning half the length of a sarcomere. It is thought to act 
like a molecular spring, maintaining a continuous filament structure throughout a myofibril. 
The elastic I-band region of titin consists of immunoglobulin sequences with intermittent 
unique regions. Titin’s elastic properties are a result of a region that contains 70% proline, 
glutamic acid, valine and lysine residues (Labeit and Kolmerer 1995). In the A-band, titin 
interacts with MyBP-C and the myosin tail domains, thus linking titin to the thick filaments 
(Houmeida et al. 1995; Soteriou, Gamage, and Trinick 1993). The A-band region of titin is 
composed of super repeats of seven fibronectin III domains and four immunoglobulin 
domains. These domains correspond to the C-zone thick filament repeats and may define 
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the number and position of myosin and MyBP-C (Freiburg and Gautel 1996). Titin has also 
been found to interact with actin (Chung et al. 2011; Nishikawa et al. 2019). 
 
Anchored at the Z-disc is a protein called nebulin. Nebulin has a chain weight of 
around 600–900 kDa and runs along the thin filaments in the I-band from the Z-disc to the 
actin filament tip. Nebulin occurs in many splice isoforms of varying length and this length 
has been shown to determine the length of the actin filaments in the I-band of skeletal 
muscle (Siegfried, Ottenheijm, and Granzier 2011). The thin filament is terminated at the 
end toward the M-band (the pointed end) by the protein tropomodulin (McElhinny et al. 
2001). At the Z-disc, the barbed ends of actin-based thin filaments are cross-linked via α-
actinin (Maruyama and Ebashi 1965).  A schematic of the sarcomere containing thick 




Figure 1.8. Schematic representation of the sarcomere. Actin (grey) forms thin filaments with 
tropomyosin (orange) and troponin. Thick filaments are depicted blue. The lateral boundaries 
of the sarcomere are at the Z-disc (yellow). The I-bands surround the Z-disc, and correspond 
to thin filaments with no over-lapping thick filaments. The M-band is shown in purple, and 
constitutes where thick filaments are anchored. The A-band region contains both thin and 
thick filaments, whereas the H-zone contains only thick filaments. Titin (pink) extends the 
length of a half-sarcomere. Figure from (Henderson and Gregorio 2015). 
 
 
Another component of the thick filament is the myosin-binding protein family 
(MyBP). This family consists of myosin-binding protein C (MyBP-C) and myosin-binding 
protein H (MyBP-H). Both are located in the C zone (A-band region containing cross-
bridges) and are restricted to transverse stripes spaced at 43 nm intervals (Bennett et al. 
1986; Craig and Offer 1976). The structure of MyBPs includes a series of immunoglobulin 
and fibronectin type III repeat domains (Flashman et al. 2004). MyBPs interact with the 
thick, thin, and titin filament systems. The highly conserved C-terminal C10 domain of both 




maintenance and stability of the thick filament (Kampourakis et al. 2014; Moos et al. 1975; 
Mouton et al. 2015). Additionally, the C-terminus binds titin and is necessary to localize 
MyBPs to the A-band (Gilbert et al. 1999; Labeit et al. 1992). The N-terminus of MyBP-C 
binds actin filaments, potentially regulating contraction by altering the actin-activated 
myosin ATPase activity (Hartzell 1985; Squire, Luther, and Knupp 2003), while MyBP-C’s 
N-terminal M-motif interacts with the S2 region of myosin (Gruen and Gautel 1999; Starr 
and Offer 1978). Although the precise function is still being elucidated, MyBPs are involved 
in filament assembly and in regulation of contraction (Weith et al. 2012). MyBP-C is thought 
to link the thick and thin filament systems and further regulate cross-bridge cycling by 
displacing tropomyosin and competing with myosin for actin binding (Ackermann and 
Kontrogianni-Konstantopoulos 2011). 
 
The myosin-containing thick filaments interact with the thin filament in a sarcomere 
to produce movement. The thin filament is primarily composed of three proteins; actin, 
tropomyosin and troponin. Actin is one of the major structural elements of muscle. Actin is 
an activator of myosin; in the absence of actin, myosin can hydrolyse ATP, but its presence 
increases the ATPase rate by a factor of 100 for fast adult skeletal isoforms. Vertebrates 
express 3 main actin isoforms – α, β, and γ. α-actin is predominantly expressed in skeletal 
and cardiac muscles during adulthood, whilst γ-actin is expressed in smooth muscles of 
blood vessels and internal organs. Cytoplasmic β- and γ-actin are ubiquitous and have a 
role in the cytoskeleton with expression occurring in all cells in different ratios (Dugina, 
Shagieva, and Kopnin 2019; Garrels and Gibson 1976).  
 
Actin is a highly conserved protein with a sequence identity of 85% between the 
most divergent family members. Over 50 actin binding proteins have been identified in both 
lower and higher eukaryotes (Geeves, Fedorov, and Manstein 2005); distant but 
undisputable prokaryotic homologues of actin have been identified (van den Ent, Amos, 
and Löwe 2001; Jones, Carballido-López, and Errington 2001). Multiple actin monomers 
(globular actin, G-actin) polymerise to form filaments (filamentous actin, or F-actin), which 
forms the backbone of the thin filament. The critical protein concentration (CC, concentration 
of monomers) for actin polymerisation is 0.1 μM – above this concentration G-actin will 
spontaneously form F-actin (Tilney 1976; Vinson et al. 1998).  
 
The first crystal structure of G-actin was achieved in 1990 (Kabsch et al. 1990). 
Figure 1.9 shows the structure of G-actin at atomic resolution (Geeves, Fedorov, and 
Manstein 2005). The monomer consists of two subunits, called the ‘small’ and ‘large’ 
domains. These domains are separated by a central cleft which contains the nucleotide 
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and cation binding site (Gordon, Homsher, and Regnier 2000). Each domain can be further 
subdivided; the small domain contains subdomain 1 and 2, and the large domain contains 
subunits 3 and 4. Two parallel strands of F-actin can form a double helical structure (as 
seen in Figure 1.10). Subdomains 3 and 4 are located internally in the helix whereas 
subdomains 1 and 2 are solvent-exposed as they are located on the surface of the filament, 
where interaction with myosin heads can occur. The helix repeats every 13 actin 
monomers, or every 360 Å (Graceffa and Dominguez 2003). 
 
 
Figure 1.9. Crystal structure of an actin-monomer, or globular actin, showing the 4 
subdomains. An ADP nucleotide and magnesium cations are shown. Figure from (Otterbein, 
Graceffa, and Dominguez 2001). 
 
 
An extended, fibrous molecule called tropomyosin is also found in the thin filament 
with actin (see Figure 1.10). It is composed of two right-handed α-helices, which form a left-
handed coiled-coil structure. The formation of a coiled-coil is energetically favorable as 
hydrophobic interactions of non-polar residues in the two chains stabilize the molecule. 
Tropomyosin can exist either as homo- or heterodimers (Janco et al. 2013). Mammalian 
fast skeletal and cardiac tissues express variable ratios of α- and β-tropomyosin and 
assemble as αα and αβ dimers. ββ heterodimers have low thermal stability, and so are not 
typically found in most muscle tissues (Janco et al. 2013). Tropomyosin molecules extend 
over and interact with seven actin monomers, which together with troponin subunits confer 
regulation of the thin filament. The formation of an extended filament is achieved through 
N-terminal to C-terminal aggregation of the tropomyosin dimer via an 8-11 amino acid 
residue overlap. Tropomyosin spans seven actin monomers on each strand of an F-actin 
polymer (Gordon et al. 2000). Tropomyosin regulates the binding of myosin to actin as a 




The troponin complex is composed of three subunits – troponin-C (TnC), troponin-I 
(TnI) and troponin-T (TnT) (Greaser and Gergely 1973), which are named after their 
specific functions in the complex. The positions of these three subunits are shown in Figure 
1.10. TnC consists of two globular regions, which are connected through a long α-helix. 
TnC binds Ca2+ via calcium-binding EF-hand motifs. Binding of calcium to the EF-motif 
leads to conformational changes allowing the N-terminal domain of TnC to interact with TnI 
(McKay et al. 1997). TnI is the inhibitory subunit of the troponin complex and is able to block 
actin.myosin ATPase activity in the presence of tropomyosin (Leavis and Gergely 1984). 
When TnC interacts with TnI, it dissociates from actin, shifting tropomyosin to allow for 
weak binding of myosin to actin. The calcium state of TnI changes its affinity for binding 
partners based on the binding of calcium to TnC and its subsequent conformational shift 
(Lehman et al. 2001). TnT is the third component of the complex, which anchors the 
troponin complex to tropomyosin (Franklin et al. 2012; Kobayashi, Jin, and de Tombe 
2008). The function of TnT is somewhat controversial. It is thought to organize the 
regulatory complex as a whole, by anchoring TnC and TnI to the thin filament; however TnT 
may also have roles in muscle contraction through regulation of actin.myosin ATPase 
activity, calcium sensitivity, and force generation in the sarcomere (Potter et al. 1995; Willott 
et al. 2010). 
 
 As detailed above, there are a plethora of interactions that occur between the 
numerous proteins of the thin and thick filaments of a sarcomere. These interactions are 






Figure 1.10. Summary of interactions occurring in thick and thin filaments in a striated 
muscle. Muscle contraction is dependent on the interactions between myosin-based thick 
filament via the head domain and actin-based thin filament. The troponin complex, composed 
of troponin T, troponin C and troponin I (TnT, TnC, TnI, respectively) and tropomyosin 
regulate actin.myosin ATPase in a Ca2+-sensitive manner. Thick filament regulator proteins - 
myosin essential light chain (ELC) and myosin regulatory light chain-2 (MLC2v) and MyBP-C 
- regulate myosin activation and function. MyBP-C interactions with actin, the myosin rod 
domain, MLC2v and titin are shown. The magnified, dashed circle highlights MyBP-C 
interacting with MLC2v, the actin- and nucleotide-binding sites in the myosin motor domain, 






1.1.5 ATPase cross-bridge cycle 
 
The fundamental mechanism of muscle contraction was first described by Huxley and 
colleagues in 1954, who put forward the sliding filament theory when they observed 
sarcomere shortening under a light microscope (Huxley and Niedergerke 1953). The sliding 
filament theory was further expanded by Lymm and Taylor as a cycle containing 4 steps 
(Lymm and Taylor 1971). This is summarised in Figure 1.11. Briefly, myosin is bound to 
actin in the rigor complex (free of nucleotide). ATP binds, which leads to very fast 
dissociation of myosin from actin. The hydrolysis of ATP to ADP and Pi leads to formation 
of a stable myosin.ADP.Pi complex, whereupon actin can rebind. This leads to release of 
the products and return to the rigor state. In the last transition, myosin slides past actin in 
a rowing-like stroke – this event is referred to as the powerstroke. 
 
 
Figure 1.11. The Lymm-Taylor actin.myosin ATPase cycle. The binding of ATP to 
actin.myosin (in a rigor complex) leads to dissociation of myosin from actin. Structural 
changes in the lever arm orientation leads to the recovery stroke, followed by ATP hydrolysis. 
Myosin now rebinds actin weakly. Subsequent phosphate release is coupled to the 
powerstroke. Changes in the orientation of the lever arm and ADP release increases the 
affinity of myosin for actin, returning the complex to a rigor state. Figure from (Yu et al. 2007). 
 
 
Todays widely accepted model of the actin.myosin ATPase cycle, also known as 
the cross-bridge cycle, is composed of coupled mechanical and biochemical events, 
converting biochemical energy into movement. Since the Lymm-Taylor model was 
proposed, numerous structures have been characterised for myosin in different parts of the 
cross-bridge cycle. This has provided insight into how the kinetic cycle is related to 
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structural changes in the myosin molecule, as shown in Figure 1.12. The work in this thesis 





Figure 1.12. Actin.myosin ATPase cycle showing the known structural states of Myosin VI in 
the force-generating cross-bridge cycle. The motor domain of Myosin VI is depicted in four 
structural states: Rigor (nucleotide free, on F-actin); Post-Rigor (detached from F-actin, 
bound to an ATP analog); pre-powerstroke (bound to ADP.Pi, representing post hydrolysis 
with ADP.Pi trapped in the active site) and the Pi release state. Figure adapted from (Llinas 




1.2 Myosin class II isoforms 
 
 1.2.1 Isoform genes 
 
The myosin class II family contain 13 isoforms in humans, which can be divided into three 
groups: smooth, striated and non-muscle. Nine of these 13 isoforms are striated, which this 
thesis will focus on (see Table 1.1). Expression levels vary across species, developmental 
time point and muscle type (Bottinelli and Reggiani 2000; Lu et al. 1999; Toniolo et al. 
2004). ATP turnover and force production vary between different isoforms. Fatigue 
tolerance is also a property of the isoform being expressed (Karatzaferi, Adamek, and 
Geeves 2017). These variations confer unique characteristics to different muscle types, 
and the varied myosin composition within skeletal muscle fibres allows for a wide range of 
contractile velocities and forces among different muscle types.  
 
The relative proportions of isoforms varies between different muscle types (Harridge 
et al. 1996). In humans, adult muscle fibres may contain predominantly one myosin isoform 
(beta, IIa or IId), or they can be found of mixtures of fibre types (beta/IIa, IIa/IId for example 
(Bottinelli and Reggiani 2000)). Early expression patterns define adult fibre types, although 
changes in isoform composition can occur in response to neural, hormonal and mechanical 
factors (Loughna et al. 1990; Pette and Vrbová 1985). A skeletal muscle will have a range 
of mechanical & energy demands exerted upon it – thus, diversity in fibre composition is 
required to meet these demands.  
 
The human MYH genes are highly conserved, sharing 77-95% sequence homology 
when excluding the MyHC-7b (Table 1.2). This is true for both the motor and tail domains 
of myosin isoforms. There is even higher conservation across mammalian species – Table 
1.3 shows the % sequence identity of beta and embryonic isoforms between rat, rabbit, 




Gene Protein Abbrev. 
Chromosome 
position 
Class Human Tissue Expression 
MYH2 MyHC-IIa IIa 17 Striated Skeletal muscle post birth 
MYH4 MyHC-IIb IIb 17 Striated Unknown 
MYH1 MyHC-IId IId 17 Striated Skeletal muscle post birth 
MYH6 MyHC-α Alpha 14 Striated Atrial myocardium 
MYH7 MyHC-β Beta 14 Striated Ventricular myocardium and slow skeletal 
MYH3 MyHC-emb Embryonic 17 Striated Embryo skeletal muscle and regenerating muscle 
MYH8 MyHC-peri Perinatal 17 Striated Embryo skeletal muscle and regenerating muscle 
MYH13 MyHC-EO Extraocular 17 Striated Extraocular and specialised muscles 
MYH7b MyHC-7B 7b 20 Striated Unknown 
MYH9 NMMHC-IIa Non-muscle IIa 22 Non-muscle Cytoplasm 
MYH10 NMMHC-IIb Non-muscle IIb 17 Non-muscle Cytoplasm 
MYH11 SMMHC Smooth 16 Smooth Smooth muscles 
MYH14 NNMHC-IIc Non-muscle IIc 19 Non-muscle Cytoplasm 
 





Table 1.2. Sequence identities for A) full length, B) motor domain and C) rod domains of 
human class II myosin isoforms. Sequences were obtained from NCBI and alignments were 
performed using NCBI protein BLAST. 
 
 
Table 1.3. Sequence identities between 4 mammalian species for A) MyHC-β and B) MyHC-
emb full length myosin. Sequences were obtained from NCBI and alignments were performed 






1.2.2 Cardiac isoforms 
 
The myocardium of mammalian hearts contains two cardiac isoforms of myosin; alpha 
(MyHC-α) and beta (MyHC-β). The two cardiac proteins are encoded by the genes MYH6 
and MYH7, respectively, which are found as a gene cluster on chromosome 14 at position 
12. MyHC-α is the major isoform expressed in atrial myocardium in mammals, although a 
small proportion is also expressed in ventricular myocardium (Lompré, Nadal-Ginard, and 
Mahdavi 1984). MyHC-β is the major isoform expressed in ventricular myocardium in 
mammals, although it is also expressed in slow skeletal muscle fibres, such as the soleus 
muscle fibre (Weiss 1996). 
 
The two cardiac myosin genes are differentially regulated during development and 
respond opposingly to various hormonal stimuli, hemodynamic stress and exercise 
(summarised in Table 2). The ratio of expressed isoforms varies between species - larger 
mammals, including humans, express predominantly β-MyHC in their cardiac ventricles 
while small mammals such as rats and mice express predominantly α-MyHC.  
 
 
Stimuli MyHC-α MyHC-β 
­ Triiodothyronine Hormone ­ ¯ 
¯ Triiodothyronine Hormone ¯ ­ 
Exercise ­ ¯ 
Pressure overload ¯ ­ 
Ageing ¯ ­ 
 




Defining the properties of cardiac isoforms in detail has been limited by the 
availability of pure samples of the individual proteins. Unlike skeletal myosins, the cardiac 
isoforms are unstable and typically generate small quantities of protein. The recent 
advancements in recombinant human muscle myosin production enabled the kinetic 
characterisation of the two cardiac isoforms (Deacon et al. 2012). This work demonstrated 
that the MyHC-α isoform has a 10-fold faster ADP release rate than the MyHC-β, indicative 
of a fast-type myosin. This is supported by the work of Piroddi et al, who showed that single 
human atrial myofibrils have a five-fold faster rate of tension development after a period of 
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rapid shortening than single ventricular myofibrils (Piroddi et al. 2007). MyHC-α also has a 
~10-fold faster ATP hydrolysis step and exhibits a ~five-fold weaker actin affinity than 
MyHC-β. These kinetic differences distinguish the two isoforms, and confers the contractility 
characteristics of the chambers of the heart in which they are found.  
 
The ratio of cardiac myosin isoforms play a major role in the determination of cardiac 
contractility, as demonstrated by Herron et al, who showed that myocyte fragments 
expressing ~12% MyHC-α developed ~52% greater peak power output than fragments 
expressing 0% MyHC-α (Herron and McDonald 2002). There is evidence to suggest that a 
lower expression of MyHC-α is a hallmark of pathology – healthy human hearts contain 
~10% MyHC-α, but end-stage failing hearts contain no detectable MyHC-α (Miyata et al. 
2000; Nakao et al. 1997).  As will be discussed in section 1.4, both isoforms have been 
implicated in cardiomyopathies.  
 
1.2.3 Developmental isoforms 
 
Humans contain two developmental isoforms, embryonic (MyHC-emb) and perinatal 
(MyHC-peri), which are encoded by the genes MYH3 and MYH8 respectively. Both isoforms 
are found in the developing embryo (along with MyHC-β) (Whalen et al. 1981) and 
regenerating muscles (Sartore, Gorza, and Schiaffino 1982). Their expression is down-
regulated after birth when they are replaced by adult skeletal isoforms (Schiaffino et al. 
2015). The embryonic isoform was characterised in 2016 by Walklate et al, who 
demonstrated it is a slow-type motor with similar kinetic properties to the MyHC-β (J. 
Walklate et al. 2016). For example, both have a slow ADP release rate.  
 
MyHC-peri is predicted to be a fast-type isoform, due to the motor domain sequence 
in the MYH8 gene having considerable sequence similarity with skeletal fast MYH genes 
(Weiss, Schiaffino, and Leinwand 1999). Further supporting this is ATPase data, which was 
collected on the two isoforms by Resnicow et al in 2010, and it was observed that the MyHC-
peri isoform had a Vmax similar to the adult skeletal isoforms, whereas the embryonic isoform 
was slower (Resnicow et al. 2010). The kinetic properties of the perinatal isoform will be 






1.2.4 Skeletal isoforms 
 
In vertebrates, 3 skeletal myosin isoforms exist, MyHC-IId, MyHC-IIa and MyHC-IIb, 
encoded by the genes MYH1, MYH2 and MYH4 respectively. The sequence homology 
between the 3 isoforms is 91-96% for both the motor and rod domains. Whilst humans 
encode the MYH4 gene and the mRNA has been detected in extraocular and jaw muscles 
(Horton et al. 2001; Horton et al. 2008), MyHC-IIb is not expressed at the protein level in 
humans (Ennion et al. 1995; Smerdu et al. 1994). However, the MyHC-IIb is expressed in 
skeletal muscles of small mammals such as mouse, rat and rabbit. Interestingly, MyHC-IIb 
is expressed in pig, a mammal similar in size to humans (Lefaucheur et al. 1998); this 
suggests the expression of MyHC-IIb is not simply size-dependent. Kinetic characterisation 
has been conducted for these isoforms, which showed all three had similar properties. In 
particular, the ADP release rate was more than 100 s-1 for these isoforms, which is 
characteristic of a fast-type myosin.  
 
1.2.5 Extraocular isoform 
 
Extraocular muscles (EOMs) surround the eye ball and are responsible for stabilization of 
the eye and for several distinct voluntary and reflex movements. There are six EOMs in 
mammals, the contractile properties of which differ significantly from typical skeletal 
muscles. The specific tension (the maximum muscle force normalised with respect to 
muscle cross sectional area) is lower for EOMs than that observed in limb muscles whilst 
also having a very high speed of contraction alongside a relatively high resistance to fatigue 
(Close and Luff 1974; Lynch, Frueh, and Williams 1994; Porter and Baker 1996). 
 
Many fibres in EOMs express multiple class II isoforms, and localise them 
differentially along the length of the fibre (Walro and Kucera 1999; Wieczorek et al. 1985; 
Park et al. 2012). Mammalian extraocular muscles express all nine of striated myosin 
isoforms (Jacoby et al. 1990; Rubinstein, Porter, and Hoh 2004; Zhou, Liu, and Kaminski 
2010), one of which includes MyHC-EO, the protein product of the MYH13 gene. MyHC-EO 
is a specialised isoform of myosin that is specific for extraocular muscle (Sartore et al. 
1987), although it is has also been found to be expressed in laryngeal muscles (Lucas, 
Rughani, and Hoh 1995). It was first categorized as a fast type myosin likely contributing to 
rapid eye movements (Briggs and Schachat 2000; Schachat and Briggs 2002). This was 
supported by the work of Resnicow et al, who demonstrated that a recombinant MyHC-EO 
had an ATPase rate similar to recombinant adult skeletal isoforms (Resnicow et al. 2010). 
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The same construct also had a weak ADP affinity and fast ADP release rate, which also 




MyHC-7b was first identified by Nagase et al, and the expression profile of the genes 
revealed that MyHC-7b RNA is expressed in cardiac and skeletal muscle, foetal and adult 
brain tissues (Nagase et al. 1998). Low expression levels were also identified in the liver, 
pancreas, spleen, lung, kidney and ovary. MyHC-7b shares the highest sequence homology 
to MyHC-β and MyHC-α (69% and 68% respectively – see Table 1.2). Interestingly, each 
of these myosin genes encodes an intronic microRNA - micro RNAs derived from introns 
can suppress intracellular RNA homologues and regulate the gene function. These intronic 
microRNAs play a role in cardiac stress response, and the MyHC-α and MyHC-7b intronic 
microRNAs also have redundant roles in skeletal muscle fibre-type specification (van Rooij 
et al. 2009; van Rooij, Liu, and Olson 2008). Despite this, MyHC-7b is not detected at the 
protein level in mammalian cardiac or skeletal muscle. The discrepancy between RNA and 
protein expression is due to a splicing event in which the transcript is produced, but 
undergoes some nonsense mediated decay, while the intronic microRNA is still expressed 
(Bell, Buvoli, and Leinwand 2010).  
 
1.2.7 Expression of isoforms 
 
The expression pattern of the two developmental isoforms have been well characterised in 
the mouse and rat models. In mice, MyHC-emb appears 9.5 days post coitum (dpc) and 
MyHC-peri 10.5 dpc (Lyons et al. 1990). In rats, MyHC-emb and MyHC-β are expressed in 
the first muscle fibres to form, so called primary generation fibres (Narusawa et al. 1987; 
Rubinstein and Kelly 1981). Secondary generation fibres express MyHC-emb and MyHC-
peri (Condon et al. 1990). The developmental isoforms disappear at the same time as the 
adult skeletal myosin isoforms (MyHC-IIa, MyHC-IId, and MyHC-IIb) are expressed. In rats, 
the protein is detected a few days after birth (DeNardi et al. 1993) while in mice the 
transcripts can be detected before birth (Lu et al. 1999). The timing of the downregulation 
of the developmental isoforms appears to be dependent on the body muscle at both the 
mRNA and protein level (Agbulut et al. 2003; Lu et al. 1999). 
 
Human muscle developmental pattern of myosin isoform expression has yet to be 
fully elucidated. Figure 1.13 shows in situ hybridisation studies of MYH transcripts in 
developing human skeletal muscle. At week 8 of gestation, primary generation fibre is 
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present in the human skeletal muscle, containing MyHC-emb and MyHC-β (Barbet, 
Thornell, and Butler-Browne 1991; Draeger, Weeds, and Fitzsimons 1987). Secondary 
generation fibres are formed after week 10 and express only MyHC-emb at week 12, MyHC-
peri protein being detected at later stages (Cho, Webster, and Blau 1993).  
MYH3 transcripts account for about 81 % of all MYH transcripts in the human foetal skeletal 
muscle at week 15 of gestation (Racca et al. 2013). At week 16 to 17, a tertiary fibre 
population has been identified, initially composed of adult fast myofibres (Draeger et al. 
1987; Ecob-Prince, Hill, and Brown 1989). In situ hybridization indicates that MyHC-IIa 
transcripts are weakly expressed at week 19 and more strongly at birth, whereas MyHC-IId 
transcripts are barely present at birth but expressed at 30 days after birth. ~95% of human 
skeletal muscle fibres appear to derive from secondary and tertiary fibres and their 
diversification into the fast type IIa or beta lineage occurs before birth, during the third 
trimester of gestation, whereas the differentiation of type IId fibres takes place in the first 




Figure 1.13. MyHC transcripts in developing human skeletal muscle. The transcripts were 
revealed by in situ hybridization using probes specific for the following MYH genes: MYH3 
(MyHC-emb, a–d), MYH8 (MyHC-peri, e–h), MYH7 (MyHC-β, i–l), MYH2 (MyHC-IIa m–p), and 
MYH1 (MyHC-IId, q–t). Muscles examined were quadriceps femoris from 9 and 19-week-old 
fetuses and vastus lateralis from 1-day- and 1-month-old newborns. Scale bar = 30 μm. Figure 
from (Schiaffino et al. 2015).  
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1.3 Myosin evolution 
 
1.3.1 Myosin superfamily evolution 
 
Myosins are molecular motors that diversified very early during eukaryotic evolution 
(Thompson and Langford 2002; Richards and Cavalier-Smith 2005). Most eukaryotes rely 
on myosins, and only a few taxonomic groups, e.g., red algae and diplomonad protists 
appear to live without them (Vale 2003).  Prokaryotes do not contain myosin - a shift in 
nucleotide-binding specificity from GTP to ATP is thought to have occurred to form the 
myosin–kinesin ATPase ancestor at the very origin of eukaryotes (Cavalier-Smith 2002).  
 
To understand the class distribution of myosin in different taxa, Odronitz and Kollmar 
compared the genomic analysis of 2,269 myosins found in 328 organisms (Odronitz and 
Kollmar 2007). Based on the myosin class content of each organism and the positions of 
each organism's single myosins in the phylogenetic tree of the myosin motor domains, a 
eukaryotic tree of life was reconstructed, as shown in Figure 1.14. This identified 35 sub 
groups of myosin. They also identified five new classes, class-XX, class-XXI, class-XXII, 
class-XXVIII, and class-XXXV, which are specific to Metazoan species. 13 of the 35 sub 
groups have been identified in humans. The data show that several taxa have evolved 






Figure 1.14. Phylogenetic tree of 1,984 myosin motor domains divided into 35 subgroups. The 
expanded view shows the sequences of myosin class-VI and distribution within taxa. The 




Sebe-Pedros and colleagues followed on from this to demonstrate the diversity of 
myosin proteins in the last eukaryotic common ancestor (LECA) genome (Sebé-Pedrós et 
al. 2014). They showed that LECA possessed a minimum of six myosin paralog families all 
encoding different protein domain architectures (summarised in Figure 1.15). The authors 
also demonstrated that paralogs and domain architectures were continuously generated 
throughout eukaryote evolution, with a significant expansion of myosin abundance and 
domain architectural diversity at the stem of Holozoa, predating the origin of animal 
multicellularity. Their data demonstrated that the myosin gene family underwent multiple 
large-scale expansions and contractions in paralog families combined with extensive 




Figure 1.15. The six paralog families found within the LECA genome, and their protein domain 
structures. Numbers indicate the number of IQ domains found within a myosin class. Figure 
adapted from (Sebé-Pedrós et al. 2014). 
 
 
Whilst there is an extensive number of myosin classes, Class I and class II 
myosins were proposed to be the most ancient (Thompson and Langford 2002). As shown 
in Figure 1.1 in Chapter 1.1.1, these two classes contain the highest number proteins per 
class for all 35 sub-groups. Class II contains almost twice as many proteins as class I (617 
versus 381, respectively). Whilst there is a high sequence homology between these two 
classes, a novel glycine residue inserted at position 507 in the Dictyostelium discoideum 
sequence was found to distinguish all class II myosins from other classes (Figure 1.16). 
This demonstrates the potential significance a single amino acid change can have on 
diversifying such a complex protein. 
 
 
Figure 1.16. Multiple sequence alignment from residues 488 – 517 showing the glycine 





Another interesting aspect of myosin evolution is the branch which generates 
striated and non-striated muscles. Previous analyses of myosin II proteins in bilaterian 
animals (animals with bilateral symmetry) have recognised two phylogenetic groups; the 
first containing genes expressed in smooth muscle cells and in non-muscle cells, while 
genes of the second group are specifically expressed in skeletal or cardiac muscle cells 
(Hodge and Cope 2000; Sellers 2000). This suggests a gene duplication event gave rise to 
these two distinct phylogenetic groups (Goodson and Spudich 2006; Korn 2000; OOta and 
Saitou 1999). 
 
Steinmetz and colleagues however demonstrated that the gene duplication that 
generated the two groups occurred much earlier than the origin of muscle cells; they showed 
that a muscle protein core set, including a type II myosin heavy chain (MyHC) motor protein 
characteristic of striated muscles in vertebrates, was already present in unicellular 
organisms before the origin of multicellular animals (Steinmetz et al. 2012). Furthermore, 
'striated muscle' and 'non-muscle' myosin orthologues are expressed differentially in two 
sponges (Tethya wilhelma and Amphimedon queenslandica), compatible with a functional 
diversification before the origin of true muscles. Cnidarians and ctenophores possess 
striated muscle myosin heavy chain orthologues but lack crucial components of bilaterian 
striated muscles, such as genes that code for titin and the troponin complex, suggesting the 
convergent evolution of striated muscles (Steinmetz et al. 2012). 
 
1.3.2 Adaptation to body mass in mammals 
 
When studying the structure of myosin, it is known where the changes in sequence occur 
between the different isoforms, but how they alter the behaviour of myosin is harder to 
define. A defining feature of myosin, the rate of muscle contraction, can be controlled in two 
ways. The first is by expression of different combinations of myosin isoforms within a whole 
muscle (Pellegrino et al. 2003). The second process is the adaptation of individual myosin 
isoforms to change in species size to meet physiological demands. The contraction 
parameters of a muscle fibre have to adjust to the size of an organism; as size increases, 
muscle contraction becomes slower to compensate for the greater momentum associated 
with a larger body mass. An example of this is the decrease in heart rate of species as their 
body mass increases; heart rate is correlated with basal metabolic rate and inversely related 
to body size (Savage et al. 2007).  
 
Variations in properties between isoforms are well established, but changes in the 
properties of the same isoforms in different species is less well defined. McGreig et al 
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investigated the evolution of myosin class-II isoforms in mammals to identify if the isoforms 
have adapted to the change in body mass as animals evolved from smaller to larger body 
masses (McGreig et al. 2019). They analysed 730 sequences from 12 class-II isoforms in 
65 mammalian species and found that non-muscle and developmental myosin class II 
isoforms have not adapted to increased species size. Counter to this, there is strong 
evidence for adaptation in the MyHC-β and two adult fast myosin II isoforms, MyHC-IIa and 
MyHC-IIb, motor domains whose sequence divergence is correlated with body mass. Figure 
1.17 shows this relationship for MyHC-emb, MyHC-β, NNM-IIa, MyHC-IIb, NMMHC-IIb, and 
MyHC-IIa isoforms. To note, mammals from three clades were represented. As seen in 
Figure 1.17, the relationship between sequence divergence and body mass is not 
dependent on the clade the species belongs to.  
 
Based on the rate of divergence with body mass, the 12 myosin II isoforms form 
three distinct groups. The first group contains four of the five main adult sarcomeric 
isoforms, with the MyHC-IIb and MyHC-β isoforms showing the greatest mass related 
sequence divergence, followed by the MyHC-IIa and MyHC-IId isoforms. Further, the rate 
of change at the DNA sequence level for the MyHC-β and fast isoforms shows an increase 
in the number of non-synonymous changes, while the rate of synonymous changes remains 
relatively stable with increasing body mass. This implies there has been a specific increase 
in non-synonymous changes. At the other extreme, five of the isoforms (MyHC-7b, MyHC-
emb, MyHC-peri, NMMIIa and NMMIIb) exhibit little divergence of sequence with body 
mass. This result with quite distinct dependence upon mass suggests different selection 
conditions apply to the two groups. This is compatible with the adult muscle myosins 
adapting to the requirements of changes in size whilst the cellular myosins were not 
exposed to this selection pressure. The remaining three isoforms (MyHC-α, MyHC-smooth 
and MyHC-EO) are intermediate between the two groups with a lower rate of sequence 




Figure 1.17. Sequence Identity (%ID) vs Mass (kg) for the motor domains of six myosin II 
isoforms; MyHC-emb (EMB), non-muscle A (NMA), non-muscle B (NMB), MyHC-β (β), MyHC-
IIa (2A) and MyHC-IIb (2B). Symbols indicate the clade that each species belongs to; grey 
squares (Euarchontoglires), black triangles (Laurasiatheria) and clear circles (Afrotheria and 
Metatheria). Sequence identity is pairwise to the mouse. Figure from (McGreig et al. 2019). 
 
 
Pellegrino et al showed that for a muscle fibre expressing a single myosin heavy 
chain, the maximum shortening velocity was characteristic of the myosin isoform expressed 
(Pellegrino et al. 2003). As the myosin motor domain contributes to muscle contraction 
velocity, it is hypothesised that the changes in velocity can occur via variation in the amino 
acid sequence of the myosin motor domains for the MyHC-IIa, MyHC-IIb and MyHC-β 
isoforms. Unlike the ventricle tissue in which MyHC-β is expressed, skeletal muscles in 
mammals use their muscles and myosin isoforms in many different ways for different 
purposes. Thus, the selective pressure on a specific myosin isoform in skeletal muscle may 
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be different in each mammal. However, the heart and slow muscle fibres are relatively 
similar in function across mammals and the simple relationship between heart rate and size 
is well established. This makes MyHC-β an attractive protein to study to investigate the 
adaptation of sequence identity to match changes in body mass.  
 
1.3.3 Velocity and ADP-release 
 
The mechanical activity a myosin can perform is an inherent characteristic of the motor, and 
this property varies between myosin types. It was proposed in 2011 by Bloemink and 
Geeves that myosin motors can be classified into four distinct types;  1) Slow, efficient force 
holders; 2) fast, powerful movers; 3) strain sensors and 4) processive/signal transducers 
(Bloemink and Geeves 2011). A defining feature that differs between these types, and 
hence different isoforms, is how the ADP release step affects the overall cycle. This can 
include differences in the thermodynamic and kinetic coupling of actin and ADP binding to 
myosin, different load sensitivity of ADP release step and changes in duty ratio (Nyitrai et 
al. 2006; Nyitrai and Geeves 2004). 
 
Duty ratio (DR) refers to the fraction of time a myosin motor spends strongly bound 
to actin during the cross-bridge cycle. Changes in DR facilitate adaptation of a myosin 
molecule to suit its individual function. For example, fast myosins which work in groups have 
a DR of 0.05-0.1 (O’Connell, Tyska, and Mooseker 2007), whereas processive myosins 
have a DR of >0.7, enabling a single myosin molecule to track along an actin filament and 
drag a cargo (De La Cruz et al. 1999). Other motors can adjust their DR in response to load, 
calcium and magnesium concentration, or phosphorylation states (Adamek, Coluccio, and 
Geeves 2008; Durrwang et al. 2006; Fujita-Becker et al. 2005). The rate constants that 
define detachment and reattachment of myosin to actin govern the DR; detachment of 
myosin from actin is controlled by ADP release from an actin.myosin.ADP complex, or by 
ATP binding to actin.myosin. For fast type myosins, measured ADP-release is typically too 
fast to limit the shortening velocity, and so the rate of cross-bridge detachment after 
completion of the powerstroke limits the maximum shortening velocity of the muscle fibre 
(Iorga, Adamek, and Geeves 2007; Nyitrai et al. 2006). For class III, IV and slow myosins, 
shortening velocity is limited by ADP release (or the isomerisation leading to ADP release) 
(Iorga, Adamek, and Geeves 2007; Bloemink et al. 2007).  
 
It has been shown for some isoforms (although it may be true for all) that 
isomerisation of an actin.myosin.ADP complex is required for ADP release, as described in 
Scheme 1 (Nyitrai and Geeves 2004). Equilibrium between these two states varies for 
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different myosins, both between and within classes. After phosphate release and swinging 
of the myosin lever arm, ADP is retained in the nucleotide pocket which is in a closed 
conformation. A further rotation of the lever arm in the direction of the load the motor is 
bearing is required for the nucleotide pocket to open (Batters et al. 2004; Cremo and 
Geeves 1998; Smith and Geeves 1995). The protein conformational change that drives the 
nucleotide pocket from a closed to open state is termed KCO, and is required to facilitate 
ADP release. The apparent affinity of ADP for actin.myosin and thermodynamic coupling is 
controlled by KCO (Bloemink and Geeves 2011). The apparent ADP affinity, KADP, is typically 
weak (of the order of 100 μM), meaning that KCO is the driver of the ADP affinity, and k+CO 
is rate-limiting for ADP release. Indeed, this constant varies between different myosin 
classes (Bloemink and Geeves 2011; Walklate, Ujfalusi, and Geeves 2016). 
 
Scheme 1. The two-step process of ADP release from an actin.myosin.ADP complex. A = 
actin, M = myosin, D = ADP. 
 
Further highlighting this is the relationship between maximum shortening velocity 
and body mass of a mammal, as seen on a logarithmic plot in Figure 1.18A. The allometric 
equation was fitted to the data points to determine whether maximum shortening velocity 
has scaled with changes in body mass. For IIa, IIb and IId fibres, the allometric coefficients 
were -0.098, -0.041 and -0.048 respectively (Pellegrino et al. 2003). Slow fibres showed a 
steeper decrease of maximum shortening velocity with mass, and had an allometric 
coefficient of -0.175. This suggests that the slow isoform has adapted to changes in body 
mass.  
 
A well-established relationship of sliding velocity (v), the lifetime of a cross-bridge 
(τ) and the working stroke (d) can be defined by τ = d / v (Siemankowski and White 1984; 
Siemankowski, Wiseman, and White 1985). τ can be no greater than d / v without producing 
drag on moving filaments, so 1 / τ is the minimum rate constant (kmin) for any event during 
the attached part of the cycle, i.e., kmin = v / d. From this, the rate constant controlling ADP 
release can be predicted from shortening velocity data, as shown in Figure 1.18B for MyHC-
β. This shows a very close fit between the measured values and the predicted values; the 
two parameters show a high correlation with a slope close to 1, which indicates that the rate 
of ADP release controls velocity. Further, the rate constant controlling ADP release does 
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vary for different myosins (Weiss et al. 2001), highlighting its importance in tuning the 




Figure 1.18. Relationship between myosin isoform, muscle shortening velocity and the rate 
constant for ADP release. (A) Maximum shortening velocity of muscle fibres expressing a 
single myosin isoform, plotted against the average mass of the species the muscle came 
from. (B) Relationship between the measured rate constant for ADP release from the 
actin.myosin cross-bridge and that predicted from the measured velocity of muscle 
shortening for MyHC-β. Figure from (J Walklate et al. 2016). 
 
 
The relationship between myosin sequence and velocity of contraction remains to 
be elucidated. How MyHC-β has adapted this ADP release step to generate changes in 






Myopathies are muscular and neuromuscular disorders, characterised by muscle weakness 
as a result of dysfunction of the muscle fibre. Myopathies have been reported in five of the 
nine striated MYH class II genes (see table 1.5). As shown in Table 1.5, the highest number 
of mutations reported in a single MYH gene is that of the MYH7 gene. These mutations 
have been implicated in a number of myopathies, including Hypertrophic Cardiomyopathy 
(HCM), Dilated Cardiomyopathy (DCM), left ventricular non-compaction, Laing distal 
myopathy, Scapuloperineal and limb girdle syndromes. More than 300 of these mutations 
give rise to HCM (Buvoli et al. 2008; Colegrave and Peckham 2014; Walsh et al. 2010). 
 
Table 1.5. Summary of myopathies caused by mutations in MYH genes. Table adapted from 
(Marston 2018). 




MYH2 MyHC-IIa Inclusion body myopathy, distal and proximal myopathy, opthalmoplegia 15 
MYH3 MyHC-emb 
Distal arthrogryposis types 1, 2A (also known 
as Freeman-Sheldon syndrome), 2B (also 
known as Sheldon-Hall Syndrome), 8 
33 
MYH6 MyHC-α HCM, DCM atrial-septal defect, other congenital defects 33 
MYH7 MyHC-β 
HCM, DCM, left ventricular non-compaction, 
Laing distal myopathy, Scapuloperineal and 
limb girdle syndromes 
>800 




1.4.1 Hypertrophic cardiomyopathy 
 
Cardiomyopathies refer to diseases of cardiac muscle. The 3 most common types of 
cardiomyopathy are; dilated cardiomyopathy (DCM),  arrhythmogenic right ventricular 
cardiomyopathy (ARVC), and hypertrophic cardiomyopathy (HCM), which this thesis will 
focus on. HCM is an inherited form of cardiovascular disease, characterised by hypertrophy 
of the interventricular septum, which separates the left and right ventricles (Figure 1.19). 
This hypertrophy impedes the flow of oxygen-rich blood from the heart due a decreased left 
ventricular chamber volume. Patients often present with impaired diastolic dysfunction, 
fibrosis and myocyte disarray (Ho et al. 2002, 2010; Varnava et al. 2000) (Figure 1.20). The 
most common HCM phenotype is also accompanied by non-dilated, hyperdynamic left 
ventricle ejection fraction of less than 65% (Soler et al. 2018). This can lead to adverse 
remodelling with progressive dilation and subsequent thinning of the interventricular 
septum, leading to heart failure which simulates other cardiomyopathies such as restrictive 
or dilated cardiomyopathies (Olivotto et al. 2012).  
 
 
Figure 1.19. Schematic comparison of a healthy (A) and HCM diseased heart (B). Asymmetric 
hypertrophy of the interventricular septum as well as the left ventricular posterior wall and 
apex is present. Figure adapted from (Harvey and Leinwand 2011).  
 
 
HCM is a common cause of sudden cardiac death in young adults and athletes. It is 
currently unclear why the natural history of HCM is so variable; some individuals remain 
asymptomatic throughout life, and others may develop progressive symptoms with or 





Figure 1.20. Examples of histological images of myocardium in A) normal myocardium and 
B) patient with HCM myofibre disarray and fibrosis. Figure adapted from (Yilmaz et al. 2010). 
 
 
The first case of HCM was described in 1958 (Teare 1958). HCM has a disease 
prevalence of 1:500 (Maron et al. 1995), although this figure is now thought to be closer to 
1:200 (Semsarian et al. 2015). Over 50% of cases of HCM are inherited, the most common 
inheritance pattern being an autosomal dominant trait (Poutanen et al. 2006). A large 
number of genetic studies have established that HCM can be caused by mutations in 10 
cardiac sarcomeric proteins (Figure 1.21). Mutations in MyHC-β account for 40% of the 
known mutations (Maron and Maron 2013). 
 
 
Figure 1.21. Schematic representation of the prevalence for each of the 10 known HCM-
causing genes in a cardiac sarcomere. Figure from (Maron and Maron 2013).  
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1.4.2 Early and late onset mutations 
 
The first single point mutation, R403Q, in human MyHC-β of heart muscle was identified in 
1990 as a cause of a particularly malignant form of familial HCM (Geisterfer-Lowrance et 
al. 1990). Since then, a further 300 have been identified, ~65% of which occur in the motor 
domain (Colegrave and Peckham 2014). Offspring of an affected individual have a 50% 
probability of inheriting a mutation and risk for the disease, although sporadic cases have 
been reported due to de novo mutations (Greber-Platzer et al. 2001). 
 
Genetic causation is very complex because HCM typically shows variable 
penetrance and expressivity, even within the same family (Cahill, Ashrafian, and Watkins 
2013; Ingles et al. 2017). The range of ages at clinical diagnosis of HCM is broad; however, 
manifestations before 14 years of age are atypical (Maron et al. 2003). The early age at 
diagnosis and the striking differences between childhood cardiomyopathies from adult-
onset cardiomyopathies in terms of morbidity and mortality indicate distinct causes of these 
pathologic conditions (Maron 2004; Yetman and McCrindle 2005). To investigate this, 
Morita et al in 2008 assessed family medical histories of 84 children diagnosed with HCM 
before the age of 15 (Morita et al. 2008). 33 of these children had a family history of 
cardiomyopathy, 21 of which carried a mutation. 51 children did not have a family history of 
cardiomyopathy, 25 of which carried a mutation. Sequence analysis of the MYH7 gene of 
these children identified nine mutations, five of which were novel. Four of these mutations 
were found in the motor domain.  
 
A similar study from 2009 (Kaski et al. 2009) investigated causes of HCM in 79 
patients diagnosed before or at the age of 13. 42 were found to be mutation positive. Many 
of these mutations were known mutations in MyHC-β, actin, myosin binding protein-C 
(MyBP-C), myosin light chain, TnI and TnT. However, six novel mutations in MyHC-β were 
also identified; among these four were found in the motor domain. Prior to these studies, 
little data was available for the causes of HCM in children, due to the low reporting frequency 
of the disease in children (Colan et al. 2007).  
 
Over 50 mutations have been identified in the converter domain of the MyHC-β 
motor, which suggests this region is a hot spot for cardiomyopathy mutations (Homburger 
et al. 2016). Three such mutations are classically linked with adult-onset HCM, and are 
predicted to be likely-pathogenic - R719W, R723G and G741R (Anan et al. 1994; Enjuto et 
al. 2000; Fananapazir et al. 1993). At present, it remains unclear as to what drives clinical 




It is also important to note what constitutes a disease-causing HCM mutation. A 
mutation can be considered pathogenic, or likely pathogenic, on the basis that the clinical 
data meet the following criteria: 1) presentation of a HCM phenotype (i.e., left ventricular 
hypertrophy) in family members; 2) previously reported or identified as a cause of HCM; 3) 
absent from unrelated controls; 4) protein structure and function is importantly altered (e.g. 
frameshift with truncation); and 5) amino acid sequence change in a region of the protein 
otherwise highly conserved through evolution with virtually no variation observed among 
species, suggesting its importance to basic cellular function (Tester and Ackerman 2011; 
Richards et al. 2008). As shown in Tables 1.2 MyHC-β is a highly conserved protein, and 
Table 1.3 demonstrates the high sequence homology between species. The problem with 
novel mutations is the lack of data to suggest it is disease-causing. Such mutations, when 
reported in only a single individual, may be assigned as VUS (variants of uncertain 
significance). This is true for three of the mutations studied in this thesis; the H251N, P710R 
and V763M mutations.  
 
To address the problem of whether the molecular changes in function of MyHC-β is 
different between early- and late-onset mutations, the work in Chapter 5 aims to elucidate 
the kinetic properties of the cross-bridge cycle of four early-onset mutations (H251N, 




1.5 Myosin folding 
 
Correct activity and function of myosin is dependent on precise assembly and folding of the 
protein in the sarcomere. Whilst the components and overall architecture of the sarcomere 
is well established, less is known about the assembly process (Sanger et al. 2006). Myosin 
incorporation into thick filaments is one element of this assembly process that is not well 
understood. So far, it has been shown that folding of the myosin motor domain involves the 
assistance of the general chaperones Heat Shock Protein 70 (Hsp70) and Heat Shock 
Protein 90 (Hsp90) (Du et al. 2008; Etard et al. 2007; Gaiser et al. 2011; Hawkins et al. 
2008; Srikakulam and Winkelmann 2004) and of UCS-domain-containing proteins that 
function as myosin-specific chaperones (Barral et al. 2002; Hutagalung et al. 2002; Kachur 
and Pilgrim 2008; Lord and Pollard 2004; Wesche, Arnold, and Jansen 2003; Yu and 
Bernstein 2003).  
 
 1.5.1 UCS family 
 
The UCS (named after UNC-45 in Caenorhabditis elegans, CRO1 in Podospora anserina 
and She4p in Saccharomyces cerevisiae) family of proteins encompass chaperones that 
are required for the folding, assembly and function of myosin (Lee, Melkani, and Bernstein 
2014). Homologs of UCS proteins can broadly be divided into animal UCS proteins, 
generally referred to as UNC-45 proteins which contain an N-terminal tetratricopeptide 
repeat (TPR) domain (Das, Cohen, and Barford 1998), and fungal UCS proteins which lack 
this TPR domain. Both of these two sub-classes contain the canonical C-terminal UCS 
domain that is required for interactions with myosins. The presence of the TPR domain 
confer different functions of UCS proteins, as demonstrated in Figure 1.22 (Hellerschmied 
and Clausen 2014). Biochemical studies show that the fungal She4 UCS protein serves as 
a ligand for a 27-residue epitope of a yeast myosin V motor domain, which is located in 
close proximity to the nucleotide- and actin-binding sites (Shi and Blobel 2010). This 
suggests that the She4 dimer may physically link two myosin motor domains to determine 
the step size of myosin molecules walking along actin filaments. Contrastingly, TPR-
containing UCS proteins are able to form multi-chaperone complexes with the chaperones 
Hsp70 and Hsp90 (Gazda et al. 2013). TPR-containing UCS chaperones form oligomers 
which can fold myosin and assemble thick filaments (Gazda et al. 2013; Hellerschmied and 




Figure 1.22. UCS proteins exert their chaperone activity with or without a TPR domain. On the 
left panel, TPR-containing UCS chaperones form chains to initiate myosin and partner 
chaperone (Hsp70, Hsp90) interactions and assemble thick filaments by arranging myosin 
head domains, as shown for myosin class II filaments. On the right panel, UCS chaperones 
without a TPR domain function as dimers. Interaction with folded myosin can also determine 




UNC-45 (uncoordinated-45) was originally identified as a result of mutations causing 
structural disruption of thick filaments in body wall muscle in the nematode Caenorhabditis 
elegans (C. elegans) (Epstein and Thomson 1974;Venolia and Waterston 1990). The unc-
45 gene is essential in C. elegans, but missense mutations result in disorganized and 
reduced numbers of myosin-containing thick filaments giving rise to a slow-moving, or 
uncoordinated, phenotype of adult worms (Barral et al. 1998; Ao and Pilgrim 2000). 
Mutations affecting the UCS domain of C. elegans UNC-45 result in paralyzed worms with 
reduced amounts of thick filaments and severe myofibril disorganization (Barral et al. 1998; 
Epstein and Thomson 1974; Hoppe et al. 2004; Venolia et al. 1999), indicating that UNC-
45 is important for myosin maturation and sarcomere organization (Ao and Pilgrim 2000; 
Kachur and Pilgrim 2008). 
 
UNC-45 homologs are present throughout metazoans, including worms, flies, frogs, 
mice and humans (Epstein and Thomson 1974; Etheridge, Diiorio, and Sagerström 2002; 
Price et al. 2002; Geach and Zimmerman 2010; Lee et al. 2011). In vertebrates, two 
homologs of UNC-45 have been identified, with different expression patterns and functions 
(Etheridge et al. 2002; Price et al. 2002); one that is expressed in general cell types (UNC-
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45a) and another that is specific to striated muscle (UNC-45b). UNC-45a is ubiquitously 
expressed and has been implicated in a diverse array of activities from chaperoning the 
progesterone receptor (Chadli et al. 2006; Chadli et al. 2008; Chadli, Felts, and Toft 2008) 
to cell proliferation and oncogenesis (Bazzaro et al. 2007; Price et al. 2002). In zebrafish 
and mice, UNC-45b has been implicated in myogenic processes in skeletal and cardiac 
muscles; when UNC-45b is absent the myosin containing thick filaments in trunk muscles 
are reduced and disorganized (Etard et al. 2007; Etheridge et al. 2002; Price et al. 2002). 
In line with this tissue specificity, abnormal UNC-45b function is associated with severe 
muscle defects resulting in skeletal and cardiac myopathies (Janiesch et al. 2007; Walker 
2001).  
 
1.5.2 C. elegans UNC-45 structure  
 
Gazda et al recently reported the crystallisation of the C. elegans UNC-45 protein (Figure 
1.23) (Gazda et al. 2013). UNC-45 contains a TPR domain that binds Hsp70/Hsp90 partner 
chaperones (Barral et al. 2002; Rajani Srikakulam, Liu, and Winkelmann 2008), a central 
armadillo repeat (ARM) domain of unknown function and a C-terminal UCS domain that 
interacts with the motor domain of myosin (Barral et al. 1998; Barral et al. 2002; Lee Venolia 
et al. 1999). 
 
As shown in Figure 1.23, the TPR domain of UNC-45 is assembled by three TPR 
motifs, each containing two antiparallel α helices. The helices are packed in a curved, right-
handed superhelix featuring a shallow groove at its concave side that is critical to recognize 




Figure 1.23. Structure of the C. elegans UNC-45 protein. (A) Ribbon model and folding 
topology of UNC-45 illustrating its domain architecture and the used helix nomenclature (TPR: 
green; central: orange; neck: yellow; UCS: grey). Each TPR motif is made of two α helices A 
and B, whereas the ARM repeats are composed of three helices H1, H2 and H3. (B) The central 
domain serves as a scaffolding unit that arranges TPR and UCS domain. The two close-up 
views illustrate the corresponding UNC-45 domain interfaces (polar interactions represented 
as dotted lines). Upper panel: Interface of the central and UCS domains. Lower panel: 
Interface of central and TPR domain highlighting several short-distanced salt-bridges formed 
between Asp62-Lys269, Arg53-Asp279, Lys72-Glu281 and Glu29-Lys277. Figure adapted from 
(Gazda et al. 2013). 
 
The central domain is a flat, rectangular protein ribbon that is structured by helices 
H1, H2, and H3 of ARM repeats 1–5. The consecutive ARM hold the TPR domain in place. 
Interactions with the second functional domain, the UCS domain, are mediated by residues 
located on the H3 side of the central domain. Here, helices 4H3 and 5H3 form a flat binding 
surface to accommodate the loops protruding from ARM repeats. The UCS and central 
domains are connected by the neck domain. The helix pairs of the neck domain adopt a 
super-turn structure. In the slightly open UNC-45 fold, the UCS domain protrudes in a 20° 
angle from the central domain and is situated above the interface of the central and TPR 
domains. The UCS domain itself forms an almost regular right-handed superhelix. The 
parallel packed helices of neighbouring repeats assemble a spiralling scaffold with a long 
shallow groove that is lined by the H3 helices (Figure 1.23A). The UCS domain 
encompasses an extended loop (residues 602–630) that is inserted after helix 10H3 and 




1.5.3 UNC-45 function 
 
In muscle cells, UNC-45 ensures proper folding of myosin to allow its assembly and function 
in the sarcomere (Ao and Pilgrim 2000; Barral et al. 1998; Etard et al. 2007; Lee et al. 2011; 
Melkani et al. 2011; Price et al. 2002; Srikakulam and Winkelmann 2004). During normal 
development, myosin maturation involves chaperones such as TriC/CCT and Hsp70 
(Srikakulam and Winkelmann 1999, 2004). Data from zebrafish studies suggest myosin 
then forms a complex with UNC-45 and Hsp90 in the cytosol (Etard, Roostalu, and Strähle 
2008).  
 
 The elucidation of UNC-45’s crystal structure (Lee et al. 2011; Gazda et al. 2013) 
suggested that it serves as a scaffold-like protein that can present Hsp90 bound at the TPR 
domain to myosin bound in the surface groove of the UCS domain, with the myosin possibly 
held in place by a binding loop (Fratev, Ósk Jónsdóttir, and Pajeva 2013; Gazda et al. 2013). 
Gazda et al proposed that the UNC-45 multimer establishes a multisite docking platform, 
which can recruit Hsp70 and Hsp90 partner chaperones to perform their activity in a periodic 
pattern on the unfolded myosin substrate. This is summarised in Figure 1.24. It is important 
to note, however, that direct observation of UNC-45 oligomers in vivo has not yet been 
reported. 
 
Figure 1.24. UNC-45 self-assembles a docking platform for multiple chaperone and myosin 
proteins. Hsp70/90 and myosin bind to specific sites on the TPR and UCS domains of UNC-
45. The UNC-45 multimer confers the proper spacing required to simultaneously fold and 




UNC-45 may also have a protective role against in stress response (see Figure 
1.25). UNC-45 prevents heat-induced aggregation of myosin in vitro (Barral et al. 2002; 
Melkani et al. 2010). In fact, UNC-45 relocates from the Z-disks to the myosin-containing A-
bands during stress in zebrafish muscle (Etard et al. 2008). Once myosin successfully 
incorporates into thick filaments, UNC-45 and Hsp90 dissociate from myosin and move to 
the Z-disk for storage. In cases where UNC-45 needs to be cleared, this is accomplished 
by the ubiquitin/proteasome protein degradation system. UNC-45 associates with various 
enzymes such as ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2 and 
ubiquitin ligases E3/E4 (Hoppe et al. 2004). This complex can then transit to the 26S 
proteasome for degradation (Figure 1.25) (Janiesch et al. 2007). 
 
Figure 1.25. Model of UNC-45 chain formation in muscle maintenance. UNC-45 forms tandem 
modules that allow the simultaneous binding of Hsp70/Hsp90 and myosin, enabling the 
folding and assembly of myosin in regular spacing. In the fully developed muscle, monomeric 
UNC-45 might be stored at the Z-disk, which anchors the thin actin filaments of the I-band. 
Under stress conditions, UNC-45 is relocated to damaged myosin filaments of the A-band and 
might assemble into short chaperone chains to maintain the sarcomeric structure. Figure 
from (Pokrzywa and Hoppe 2013). 
 
As detailed above, the C. elegans UNC-45 has been well studied and characterised. 
However, the molecular basis for the activity of UNC-45 is not completely understood. In 
chapter 6, the interaction between the C. elegans UNC-45 and the C. elegans body wall 
myosin will be investigated in a cellular context. It will also deal with the question of whether 




1.6 Techniques used to probe functional properties of myosin  
 
The work of this thesis is focused on understanding how the kinetic signatures of myosin 
class II isoforms allow them to carry out diverse mechanical functions. To do this, stopped-
flow spectroscopy and a kinetic modelling approach were used.  
 
1.6.1 Stopped-flow spectroscopy 
 
Transient kinetic analysis is a useful tool for deducing the mechanisms of chemical 
interactions and complements traditional steady-state approaches which determine the 
overall behaviour of a reaction. Transient kinetics refers to the time course of a reaction 
before it reaches the steady-state - the concentrations of species change in time according 
to the Law of Mass action, and hence monitoring the progress of a reaction can lead to 
determination of the rate constants of the steps that make up a pathway (Bagshaw 2013b). 
Stopped-flow spectroscopy (hereon in referred to as stopped-flow) is a powerful technique 
used for studying such transient reaction kinetics. A typical stopped-flow spectrophotometer 
is shown in Figure 1.25, and consists of two air-driven drive syringes, mixing and 








Small volumes (typically 60 μL) of solutions are rapidly driven from the two syringes 
(labelled A and B in Figure 1.26) containing the reactants into a mixing chamber. The 
resultant reaction volume then displaces the previous contents of the observation cell, thus 
filling it with freshly mixed reagents. The solution entering the observation cell is typically ~ 
two milliseconds old. The volume injected is limited by the stop syringe which provides the 
“stopped-flow”; as the solution fills the stopping syringe, the plunger hits a backstop, causing 
the flow to be stopped instantaneously and trigger data collection (Figure 1.27). The 
detectors can measure any optical signal, such as the absorbance or fluorescence of the 
solution, which is monitored as a function of time. It is important to note that the 
concentration of the reactants inside the observation cell is half that of the concentration in 




Figure 1.27. Three phases can be identified in the progression of the stopped-flow reaction. 
First, the old solution from the previous reaction is washed out; second, there is a brief 
continuous-flow phase as new solution passes though the cell; and third, the flow is stopped 
and the reaction profile is measured, which is when the detector is triggered. Figure adapted 
from (Bagshaw 2013a). 
 
There are a number of benefits to using stopped-flow to measure rapid kinetics of 
myosin and the ATP-driven cross-bridge cycle, most notably the kinetic identification of 
reaction intermediates formed throughout the cycle, and their corresponding lifetimes (De 
La Cruz and Ostap 2009). Furthermore, many of the experimentally observed rate constants 
in the cross-bridge cycle occur around the order of several hundred per second, and so 
data collection with millisecond time resolution is required to measure these rate constants. 






1.6.2 Kinetic Modelling 
 
The transient kinetic analysis outlined in 1.6.1 and 2.3 can define a number of biochemical 
events of the actin.myosin ATPase cross-bridge cycle. This cycle is conserved for all 
myosins classes (De La Cruz and Ostap 2004). Unknown parameters of the cross-bridge 
cycle that cannot be determined experimentally, be that because of lack of experimental 
resolution or limited protein sample, can be predicted using kinetic modelling programs. 
Such programs fit multiple kinetic parameters determined from transient kinetics to steady-
state ATPase data. To investigate how such closely related myosin class II isoforms yield 
such a wide range of physiological properties, a modelling program called MUSICO (Muscle 
Simulation Code) was developed by Mijailovich and colleagues (Mijailovich et al. 2017). 
MUSICO simulates ATPase data from experimentally determined cross-bridge kinetics to 
predict the occupancy of the intermediates of the cross-bridge cycle. Within myosin class II 
isoforms, changes in the overall cycling speed and the fraction of the cycle spent in 
intermediate states determine distinct properties of an isoform, tuning it for its specific 
function (De La Cruz and Ostap 2004; Bloemink and Geeves 2011; Heissler and Sellers 
2016). Understanding how each isoform is adapted for its specific role, or how single point 
mutations can alter the behaviour of the motor, requires the contribution of each step in the 
cycle to be defined. This will be discussed in Chapters 3 and 5. 
 
The kinetic modelling approach used in this thesis is based upon an 8-state 
actin.myosin ATPase cycle, as shown in Figure 1.28 (Walklate, Ujfalusi, and Geeves 2016; 
Mijailovich et al. 2017). This is a more detailed description of the cross-bridge cycle, built 
on the Lymm-Taylor model shown in Figure 1.11. In the absence of nucleotide, myosin is 
bound to actin in a rigor complex (A.M). Upon ATP binding to the nucleotide pocket of the 
myosin motor domain, fast, irreversible detachment of myosin from actin occurs as a result 
of a conformational change in the myosin head (Sweeney and Houdusse 2010). This is 
caused by switch 1 closing around the ATP molecule, which pulls the U50 subdomain away 
from the L50 subdomain, opening the actin-binding cleft and resulting in a weaker affinity to 
actin. The subsequent release of actin from myosin leaves ATP bound to myosin (M.T), and 
is followed by switch 2 being brought into close proximity to the bound nucleotide, causing 
the SH1-SH2 helix to rotate and subsequently the converter domain to rotate by 60 degrees 
(Geeves and Holmes 2005). This action is termed the recovery stroke, and is necessary to 
prime the myosin for the power stroke (Muretta et al. 2015). The catalytic activity of myosin 
will then hydrolyse ATP to form ADP and Pi once switch 1 and 2 are closed. A stable 
myosin.ADP.Pi complex is formed (M.D.Pi), which has a higher affinity for actin than the 
M.T complex, meaning that actin is now able to rebind to the L50 subdomain (De La Cruz 
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and Ostap 2004; Heissler and Sellers 2016). This induces another conformational change; 
the 7-stranded central beta sheet twists to bring the U50 subdomain close to the L50 
subdomain, closing the actin-binding cleft.  Next, 2 events occur but the order in which they 
take place is still under debate (Houdusse and Sweeney 2016; Woody et al. 2019). Switch 
2 changes from a closed to open state, which opens the γ-phosphate binding pocket and 
facilitates phosphate release. Phosphate release coincides with the transition of myosin 
from a weakly bound to a strongly bound state with actin. The relay helix rotates, generating 
the power stroke (Sweeney and Houdusse 2010). Movement of the converter domain in the 
same direction as the working stroke opens the nucleotide binding pocket to facilitate the 
subsequent release of ADP, forming either the rigor complex in the absence of nucleotide 





Figure 1.28. The ATP-driven actin.myosin cross-bridge cycle. Myosin is shown as 2 ellipses 
and a rod; the larger ellipse represents the U50 and L50 domains, the smaller ellipse and rod 
representing the converter domain, lever arm and light-chain binding region. An actin 
polymer is represented by 3 grey circles. The nucelotide-free complex of actin.myosin (AM) 
can bind to ATP (AMT), leading to an isomerisation step (A-MT) with subsequent detachment 
of actin from myosin (MT). Hydrolysis of ATP generates a the myosin.ADP.Pi complex (MDPi). 
Actin rebinds to this complex (AMDPi), leading to phosphate release and the power-stroke 
occur (the exact order is still unknown). The actin.myosin now has a weaker affinity for ADP 
(AM-D), leading to ADP release (AM), completing the cycle. Figure adapted from (J Walklate et 





Despite decades of research into myosin, research activity in the field is still as lively, both 
in terms of basic research and disease-therapy focussed studies. There are still a number 
of unanswered questions within the field, one of which is how different myosin isoforms 
meet a wide spectrum of physiological needs whilst having such a high sequence identity. 
The work presented in chapters 3-6 aims to address this question. To do this, this thesis 
has four aims: 
 
1. To understand how human sarcomeric myosins from the class II family adapt their 
mechanochemical ATPase cycle to perform different functions within different 
muscle types. A combination of kinetic data and computer modelling was used to 
predict how myosin class II isoforms change the fraction of time spent in different 
occupancies of the cross-bridge cycle to bring about differences in contractile 
properties, such as economy of ATP usage, duty ratio and shortening velocity.  
 
2. Having identified some of the differences in contractile properties between myosin 
isoforms, the MyHC-β isoform was then used to further investigate how the 
sequence of the protein can drive adaptation to changes in body mass. In particular, 
the sequence changes that drive acceleration in ADP-release rates as body mass 
increases was explored. The relationship between ADP-release and velocity has 
been well documented, so we set out to identify if these sequence changes could 
contribute to the faster heart rates observed in smaller mammals. 
 
3. Having used MyHC-β to probe how the protein adapts to selective pressures, 
attention was then turned to understanding what goes wrong in the 
mechanochemical ATPase cycle of the same isoform during diseased states. More 
specifically, a number of mutations have been identified in childhood patients with 
HCM (early-onset), and it has been hypothesised that the effect of the mutations are 
more severe than mutations found in adults with HCM (or late-onset mutations). 
Stopped-flow was used to characterise kinetic parameters of the cross-bridge cycle 
for four early-onset and three late-onset HCM mutations. The mechanochemical 
cycle was then further explored using MUSICO, to try to understand the different 





4. One of the main problems with studying human cardiac disease, such as HCM, is 
the lack of available samples to study muscle function in health and disease. 
Recombinant expression systems currently enable myosin and its associated 
disease-causing mutations to be produced, but protein yields are limited and the 
method is very technical. Folding and assembly of myosin is critical for correct 
functioning of the protein, so using insights into the UNC-45 chaperone that is 
responsible for myosin folding we attempted to improve the current expression 
systems to purify sarcomeric myosins.  
 
 The overarching theme of this thesis is the aim to understand at a molecular level, 
how myosin can fine-tune its properties to allow such a diverse range of functions to be 








2.1.1. Chemicals, Hardware and Software 
 
All reagents and chemicals were supplied from Melford laboratories, Sigma-Aldrich or Fisher 
chemicals, except for those listed in Table 2.1. 
 
Table 2.1 List of chemicals, hardware, software and apparatus used throughout this thesis. 
Chemical/Hardware/Software/Apparatus Supplier/Address 
Nucleotides (ATP, ADP) Roche 
Pyrene Molecular Probes 
EDTA free protease inhibitor tablets Roche 
Stopped-flow SF-61 DX2 TgK Scientific, UK 
LED light sources Ocean Optics 
Optical filters Schott, Germany 
Temperature controlled water baths K20, Haake, Germany 
Cary UV-50 spectrophotometer Varian, Germany 
Quartz cuvettes Hellma, Germany 
Eppendorf 5415R centrifuge Eppendorf, Germany 
Beckman J-26 XP centrifuge Beckman, USA 
Beckman Optima Ultracentrifuge Beckman, USA 
AKTA FPLC GE Healthcare, UK 
HisTrap 1 mL columns GE Healthcare, UK 
Sepharose 500 ml column GE Healthcare, UK 
IX71 Microscope Olympus 
Microscope slides and coverslips Thermo Scientific 
Weighing scales Sigma-Aldrich 
pH meter Sigma-Aldrich 
Pipettes, pipette tips Gilson, USA 
Unicorn GE Healthcare, UK 
Cary UV Varian, Germany 
Kinetic Studio TgK Scientific, UK 
Origin Studio OriginLab Corporation 
Methamorph Molecular Devices, USA 





2.1.2 Buffers  
 
Buffers used throughout this thesis are described in Table 2.2.  
 
 
Table 2.2 List of buffers used in this thesis. All buffers were prepared at room temperature. 
Where applicable, pH was adjusted using 1 M HCl and 1 M KOH. 
 
Buffer Ingredients pH 
Standard stopped flow 25 mM KCl, 5 mM MgCl2, 20 mM MOPS, 1 mM NaN3 7.0 
Acetone-actin powder 
resuspension 
10 mM NaHCO3, 10 mM NaCO3, and 0.1 mM 
CaCl2   7.5 
Actin depolymerisation 10 mM Tris, 0.5 mM ATP, 0.2 mM CaCl2, 1 mM DTT  8.0 
F-actin 100 mM KCl, 2 mM MgCl2, 10 mM Tris, 1 mM ATP 7.5 
Lysis Buffer 
20 mM Imidazole, 100 mM NaCl, 50 mM Tris, 1 x 
EDTA free protease inhibitor, 3 mM ATP, 0.5% 
Tween-20, 1 mM DTT  
 7.4 
HisTrap Buffer A 50 mM Tris pH 7.0, 500 mM NaCl, 0.05 % Tween-20, 1 mM DTT,  7.0 
HisTrap Buffer B 50 mM Tris pH 7.0, 500 mM NaCl, 0.05% Tween-20, 1 mM DTT, 1 M Imidazole 7.0 
Guba-Straub 100 mM KH2PO4, 50 mM K2HPO4, 300 mM KCl 6.6 
S1 digestion buffer 125 mM KCl, 10 mM KPi (pH 6.2), 2 mM EDTA, 2 mM DTT  6.5 
Myosin storage 500 mM KCl, 10 mM KPi, 1 mM DTT, equal volume of glycerol  7.0 
5X SDS-PAGE sample 
buffer 
10% SDS, 0.05 % Bromophenol Blue (w/v), 10%  
2-mercaptoethanol, 40% glycerol (w/v), 0.625 M 
Tris base 
6.8  
In vitro motility assay 
buffer 
25 mM imidazole, 25 mM KCl, 4 mM MgCl2, 1 mM 
EGTA, and 1 mM DTT  7.0  
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2.2 Protein preparation 
 
2.2.1 Rabbit psoas and rat soleus myosin and S1 preparation 
 
The psoas muscle was extracted from the back and leg muscles of two rabbits, which were 
dissected immediately post mortem and stored on ice. After removing all fat and ligaments, 
the muscle was minced and left to stir in 3 L of Guba-Straub for 30 minutes at 4 °C. This 
was then centrifuged at 5,000 RPM for 30 minutes. The supernatant was used for the 
myosin preparation while the pellet was used to purify actin (section 2.2.2). 
 
Rabbit myosin was prepared by the method of Margossian and Lowey (Margossian, 
Lowey 1982). The supernatant was filtered through a cheese cloth to remove large parts of 
unhomogenised muscle, and subsequently through homogenised filter paper to remove fat. 
The filtrate was added rapidly to 30 L of cold water and left overnight at 4 °C to allow the 
myosin to precipitate. The water was siphoned off and the precipitated myosin centrifuged 
for 45 minutes at 5,000 RPM. The pellet was re-suspended in 1 L 0.5 M KCl and the 
overnight precipitation repeated. The precipitated myosin was centrifuged for 20 minutes at 
12,000 RPM. Myosin could either be stored in -20 °C by dissolving the pellet in myosin 
storage buffer and storing in 50% glycerol, or further digested to produce S1 fragments. 
 
Fresh myosin or myosin from a glycerol stock was allowed to precipitate in a large 
volume of distilled water overnight. The supernatant was siphoned off and the remaining 
precipitate centrifuged for 45 minutes at 5,000 RPM. The pellets were dissolved in the rabbit 
S1 digestion buffer. The mixture was warmed to 23 °C and 0.1 mg Chymotrypsin per mL of 
solution was added and left to stir at 23 °C for 10 minutes. To stop the digestion, 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF) was added and the solution left to stir for 10 minutes. 
The digested myosin solution was dialysed against 5 mM KPi pH 6.5 for 12 hours. After 
dialysis, the solution was centrifuged for 1 hour at 12,000 RPM and the S1 was then purified 
by anion-exchange chromatography on a DEAE-sephacel column (500 mL gel bed volume), 
which had been equilibrated with 50 mM Imidazole pH 7.0. A KCl gradient of 0-250 mM KCl 
was used to elute the S1 which resulted in a peak with an absorbance at 280 nm. The 
fractions with high S1 content were checked for purity on a 4-12% Bis-Tris SDS-Page gel. 
UV spectroscopy was used to determine the final concentration of the S1 using the 
extinction coefficient ε1% = 7.9 cm-1 and a molecular weight of 115 kDa. 3% sucrose (w/v) 
was added, before the solution was drop frozen in liquid nitrogen, and stored at -20 °C. 
Once defrosted, the S1 was stable at 4 °C for 4-6 weeks. 
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 Rat soleus muscle was purified using the same method as for rabbit psoas S1 
outlined above, with some modifications. The soleus muscle was dissected from the calf 
muscle of male rats immediately post mortem. Minced muscle was left to stir in 100 ml of 
Guba-Straub. Myosin was precipitated using 250 ml of cold dH20 for 1 hour. Digested 
myosin was purified using a 20 ml gel bed volume DEAE-Sephacel column. After purification 
the S1 was stored at 4 °C and used within 5 days. 
 
2.2.2 Rabbit actin preparation 
 
The pellet obtained from the first centrifugation from the myosin extraction which contained 
the actin and thin filament proteins was dissolved in 5 L of buffer containing 4% NaHCO3 
and 0.1 mM CaCl2. This was left to stir at 4 °C for 30 minutes. The solution was then filtered 
through a cheese cloth, and the filtrate discarded. The residue from the filtration step was 
re-suspended in 1 L of acetone powder resuspension buffer. At room temperature, 10 L of 
water was added, stirred for 1 minute and the filtration step repeated. The residue was 
dissolved in 2.5 L cold acetone and left to stir for 20 minutes. This was filtered through 
cheese cloth and the filtrate discarded; this step was repeated a further three times until the 
residue became fibrous. The residue was then dried between two pieces of blotting paper 
for 48 hours and was sieved to form a fine powder, which can be stored at -20 °C.  
 
F-actin preparation was performed as described by Lehrer and Kerwar (Lehrer and 
Kerwar 1972), with modifications. 3 g of acetone powder was dissolved in 500 mL of cold 
actin acetone-powder resuspension buffer and left to stir for 30 minutes. Using a double 
layer of cotton cloth, the mixture was filtered under vacuum. The filtrate, which contained 
the actin, was centrifuged for 1 hour at 30,000 RPM. In order to polymerise the actin, the 
concentration of KCl and MgCl2 were increased to a final concentration of 100 and 2 mM, 
respectively. This was left to stir for 1 hour, followed by centrifugation for 3 hours at 30,000 
RPM. The pellet was dissolved into depolymerising buffer, homogenised, and dialysed for 
12 hours against 4 litres of depolymerisation buffer. Centrifuging the actin the next day at 
30,000 RPM for 1 hour removed any remaining filamentous actin. Using UV spectroscopy 
the actin concentration was determined using the extinction coefficient ε1% = 11.04 cm-1 and 
molecular weight of 42 kDa. This was then either drop-frozen in liquid nitrogen and stored 
at -80 °C, or used to prepare pyrene-labelled actin. 
 
Preparation of pyrene actin labelling is based on the method by Criddle et al (Criddle, 
Geeves, and Jeffries 1985). Actin was polymerised at room temperature by increasing the 
concentration of KCl and MgCl2 to a final concentration of 100 and 2 mM, respectively, and 
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was left to stir for 1 hour. The actin was diluted to 1 mg/ml. N-(1-pyrenyl)-iodoacetamide 
(pyrene; 5 mg/mL dissolved in dimethylformamide) was added stepwise to the F-actin 
solution while stirring to a final concentration of 1% (w/w) pyrene. The solution was stirred 
at room temperature for 18 hours in the dark and then centrifuged at 8,000 RPM for 1 hour 
to remove residual pyrene. The labelled actin was then pelleted by centrifugation at 30,000 
RPM for 3 hours. The actin pellet was dissolved, homogenised and dialysed overnight 
against standard stopped-flow buffer. The labelled actin was assayed by actin content 
(extinction coefficient ε1% = 11.04 cm-1 and molecular weight of 42 kDa) and pyrene content 
(extinction coefficient at 280 nm ε1% = 10.59; at 344 nm ε1% = 23.3). The final concentration 
of labelled actin was usually 100-200 μM and the efficiency of labelling was typically 80-
95%. 
 
When the concentration of actin is below 1 μM, F-actin will spontaneously 
depolymerise. To prevent this in stopped-flow assays, the F-actin was stabilised by the 
addition of phalloidin (Kurzawa and Geeves 1996). An equimolar stock of 10 μM actin and 
phalloidin (from Amanita phalloides) was incubated over night at 4 °C and remained stable 
for 4-5 days.  
 
 2.2.3 C2C12 cell protein expression and purification 
 
Shuttle plasmids containing the coding regions of the human MYH7 gene were constructed 
upstream of a 6x-Histidine tag. For the rat-human chimera studied in Chapter 4, the coding 
region was Met1-Ser843. For the HCM mutations studied in Chapter 5, a shorter S1 (sS1) 
was used, with translation terminating after ELC-binding IQ domain at Arg808. Using the 
pAdEasy kit (MP Biomedicals), the plasmids were used to construct recombinant 
replication-deficient adenovirus that expressed MYH7, as described by Resnicow and 
colleagues (Resnicow et al. 2010).  
 
To generate the rat-human chimera clone, a pUC19 plasmid containing the human 
β-myosin motor domain gene was digested with NsiI and NgoMIV to excise DNA encoding 
for residues 310 – 599 of the human β-myosin. This region was replaced with a 
complementary pair of synthetic oligos encoding for the same region, but with nine amino-
acid substitutions (Ala326Ser, Ser343Pro, Leu366Gln, Ile421Ala, Thr424Ile, Ala430Ser, 
Arg434Lys, Phe553Tyr, Pro573Gln). The HCM mutations were created using site directed 
mutagenesis to produce the His251Asn, Asp382Tyr, Pro710Arg, Arg719Trp, Arg725Gly, 
Gly741Arg, and Val763Met mutants. All clones were confirmed by sequencing. HEK293 
cells were used to amplify the viral particles, and the cell lysates were clarified using 
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caesium chloride gradients with the concentrated virus being stored in a glycol buffer at -20 
°C. 
 
For the culturing of C2C12 cells, 4-layer Nunc™ cell factory systems (Thermo 
Fisher) were used to increase culturing capacity. After the cells were seeded into these 
factories and had reached full confluency, they were differentiated from myoblasts to 
myotubes by addition of Differentiation Media, containing Dulbecco's Modified Eagle 
Medium, 2% Horse serum, 1X Pen/Strep and 1X L-Glutamine. The cells were incubated for 
3 - 4 days, after which the surface area in the factories were covered in myotubes and ready 
to infect. The myotubes were infected with 1 × 106 – 1 × 108 plaque forming units of 
adenovirus and incubated for 5 days in infection media containing Dulbecco's Modified 
Eagle Medium, 5% Fetal Bovine Serum, 1X Pen/Strep and 1X L-Glutamine. The cells were 
harvested by lifting off the surface with trypsin and collecting in a buffer of 30 mM HEPES, 
15 mM KCl, 135 mM NaCl, 2 mM EDTA, 60 mM sucrose, 0.2% Pluronic F-68 (cell 
membrane stabilizer from Sigma), at pH 7.5 and 4 °C. The cells were then pelleted at 4,000 
rpm at 4 °C for 30 min and fast-frozen in liquid N2. 
 
S1 or sS1 was purified from cell pellets as described by Resnicow et al and Deacon 
et al (Resnicow et al. 2010; Deacon et al. 2012). One cell pellet was incubated at 37 °C for 
1 minute before addition of 3 mL of lysis buffer. When the pellet was fully defrosted the 
volume was made up to 18 mL with lysis buffer. The sample was homogenised using a 
glass homogeniser (Fisher Scientific). The cell lysate was centrifuged at 80,000 RPM for 20 
minutes to remove the majority of the cell contents. The supernatant was then filtered 
through a 5 μm Minisart single use syringe filter (Sartorius Stedim Biotech, Germany), and 
the volume was increased to 18 mL using lysis buffer. 5 M NaCl was added to the solution 
to increase the final NaCl concentration to 0.5 M. A HisTrap HP 1 mL nickel column was 
equilibrated with HisTrap buffer A. The recombinant S1 was then eluted using a 0-1 M 
stepped imidazole gradient, eluting from the column at around 350 mM Imidazole using His-
Trap buffer B. The fractions were run on a 4-12% Bis-Tris SDS gel to identify the fractions 
with the highest purity, which were collected and pooled. Samples were dialysed overnight 
into the recombinant S1 stopped-flow buffer. The concentration of the S1 was determined 
using UV spectroscopy (extinction coefficient ε1% = 7.9 cm-1 and a molecular weight of 115 
kDa). Cell pellets weighing approximately 0.6 g derived from 1500-3000 mL would yield 
between 1-2 mL 2-20 μM active S1. S1 proteins were stored at -20 °C with 3% sucrose (w/v) 





2.2.4 SDS-PAGE gels 
 
Pre-cast polyacrylamide NuPAGE® 4-12% Bis-Tris Gels (1.0 mm thick, 10 or 15 wells) were 
used to check protein purity after purification. 5x sample buffer containing 2-
mercaptoethanol was added to samples and heated at 90 °C for 10 mins before loading. 
The gels were run in MOPS buffer (50 mL of 20 x NuPAGE® MOPS running buffer (Life 
Technologies) mixed with 950 mL dH2O) at 200 volts for 45 minutes. The gels were 
incubated in Coomassie blue staining solution (1 g Coomassie Brilliant Blue dissolved in 1 
L of: 50% (v/v) methanol, 10% (v/v) glacial acetic acid, 40% (v/v) dH2O). The stained gels 
were transferred to a de-staining solution (7% (v/v) glacial acetic acid, 25% (v/v) methanol, 
68% (v/v) dH2O) 3 times to reveal the protein bands. Proteins of interest were identified by 
comparison with PageRuler™ unstained protein ladder ranging from 10 to 200 kDa 





2.3 Kinetic measurements 
  
2.3.1 Stopped-flow and Fluorescence  
 
As described in section 1.6.2, stopped-flow spectroscopy was utilised to characterise kinetic 
properties of a number of different human isoforms or mutations. To do this, both intrinsic 
and extrinsic fluorescence was used.  
 
Intrinsic fluorescence is a result of fluorescence from a tryptophan residue at position 
508 (residue position in human MyHC-β sequence).  This residue is found on the end of the 
relay helix which moves relative to the rest of the motor domain during the ATPase cycle. 
Upon ATP binding, the conformational change associated with the recovery stroke causes 
the tryptophan to move, and resulting changes in fluorescence of this residue can be 
monitored. The intensity of this fluorescence varies between myosin isoforms, but for human 
cardiac isoforms a fluorescence change of 10% can typically be observed. Intrinsic 
fluorescence was excited at 290 nm and emission monitored through a WG320 cut off-filter.  
 
Extrinsic fluorescence is the result of a signal change from a fluorophore added to a 
protein of interest. As described in 2.2.2, pyrene can be chemically linked to polymerised 
actin, which attaches via a disulphide bond to a cysteine residue at position 374. Pyrene 
can be excited at 365 nm, but addition of myosin will quench this fluorescence. 
Fluorescence is restored upon myosin dissociation from actin. Pyrene fluorescence was 
excited at 365 nm and emission monitored through a KV399 cut-off filter. Human class II 
myosin isoforms quench pyrene fluorescence by 60 - 65%, and the C. elegans MHC-B 
protein by ~76%. 
 
Stopped-flow experiments were performed to measure transient kinetics of the 
acto.myosin ATP-driven cross-bridge cycle, which are outlined in 2.3.2. To note, all stopped-
flow experiments in this thesis were conducted with the motor domain of myosin proteins 






2.3.2 Transient Kinetics 
 
The simplest, unimolecular reaction possible is described in scheme 2.1. 
 
A à B 
Scheme 2.1. The rate law of a first order reaction with respect to A, where k is the first order 
rate constant (s-1).  
 
The Law of Mass Action states that the rate at which B is formed is proportional to the 
concentration of A. The rate at which A is lost can be expressed as: 
 −𝑑[𝐴]&𝑑𝑡 = 𝑘[𝐴]& 
 
Integration gives the integrated first order rate law: 
 −𝑘𝑡 = 𝑙𝑛[𝐴]& − 𝑙𝑛[𝐴], 
 
where [A]t is the concentration of A at time t and [A]0 is the concentration of A at time 0. 
Rearranging the equation gives: 
 [𝐴]& = 	 [𝐴],𝑒/0& 
 
This equation can be used to describe the enzymatic reactions measured in stopped flow, 
which behave either as single or double exponentials. All single exponential transients from 
stopped-flow measurements were fitted to a single exponential equation: 
 𝐹 = 𝐴21 − 𝑒/0&4 + 𝑐 
 
whilst all double exponential transients were fitted to a double exponential equation: 
 𝐹 = 𝐴7(1 − 𝑒/09&) + 𝐴;21 − 𝑒/0<&4 + 𝑐 
 












There are a number of different types of reactions that can be measured with 
stopped-flow, as summarised in Table 2.3. Each type of reaction is characterised by a 
number of assumptions or conditions, which then determine the definition of the observed 
rate constant (kobs) in the assay. 
 
Table 2.3 Summary of kinetic reactions. 
Reaction Assumptions kobs 
A à B 1st order, irreversible 𝑘 
A+BàAB 




A+B⇌AB 2nd order, 1-step, reversible  
[B]>>[A] 
[𝐵]𝑘?7 + 𝑘/7 
A+B⇌AB⇌A’B 2nd order, 2-step, reversible [B]>>[A] 
Step 1 fast 
𝐾7𝑘?;[𝐵]1 + 𝐾7[𝐵] + 𝑘/; 
 
 
2nd-order 1-step and 2-step reversible reactions are difficult to analyse because they 
involve two variables. The experimental conditions are therefore altered in stopped-flow 
assays to mimic first-order reactions, also known as pseudo-first order. In these conditions, 
one reactant is used in large excess (a minimum of 5-fold) over the concentration of the 
second reactant to ensure the concentration of the first reactant remains constant over the 
time course of the reaction being studied, and so does not become second order. Reactions 
of this type which have been studied in this thesis are described below. 
 
2.3.3 Pseudo-first order reactions 
 
Let us consider a second-order 2 step reversible reaction, as shown below for the ATP 
induced-dissociation of actin.S1 as an example. In a second-order 2 step reversible 
reaction, one of the two steps needs to be faster in order to differentiate the two steps. As 
shown in scheme 2.2, step 1 involves ATP binding to an actin.myosin complex, and the 






Scheme 2.2 – ATP induced dissociation of myosin or S1 from actin. A = actin, M = myosin, T 
= ATP. 
 
A·M + T 
k-1 k-2 
⇌ A·M-T A+ M·T k+1 k+2 à 
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We can make the assumption that step 1 is very fast compared to step 2, and k+2 is very 
small. Therefore: 
 𝑑[𝑀𝑇]𝑑𝑡 = [𝐴𝑀𝑇]	𝑘?; 
 
To find the total concentration of AM:  
 [𝐴𝑀]CDCEF = [𝐴𝑀] + [𝐴𝑀𝑇] + [𝑀𝑇] 
 
Putting AM in terms of AMT and MT: 
 𝐾7 = [EGC][EG][C]     which rearranges to   [𝐴𝑀] = [EGC]H9[C]  
 
Inserting equation 2.8 into 2.7: 
 [𝐴𝑀]CDCEF = [𝐴𝑀𝑇]𝐾7[𝑇] + [𝐴𝑀𝑇] + [𝑀𝑇] 
 
Solving for AMT gives: 
 [𝐴𝑀𝑇] = [𝐴𝑀]CDCEF − [𝑀𝑇]1 + 1𝐾7[𝑇]  
 
Inserting into equation 2.6: 
 𝑑[𝑀𝑇]𝑑𝑡 = I[𝐴𝑀]CDCEF − [𝑀𝑇]1 + 1𝐾7[𝑇] J𝑘?; 
 
This can be simplified to: 
 𝑑[𝑀𝑇]𝑑𝑡 = [𝐴𝑀]CDCEF𝐾7𝑘?;[𝑇]𝐾7[𝑇] + 1 − [𝑀𝑇] K𝐾7𝑘?;[𝑇]1 + 𝐾7[𝑇]L 
 











𝑘MNO = 𝐾7𝑘?;[𝑇]1 + 𝐾7[𝑇] +	𝑘/; 
 
Where k+2 defines the maximum rate constant, 1/K1 gives the concentration of T to reach 
50% kmax and k-2 is the overall dissociation rate constant. The initial linear part of the 
hyperbola defines K1k+2. 
 
This hyperbola was used to fit the kobs values obtained from stopped-flow transients. 
 
2.3.4 S1 affinity for actin 
 
The method for determining the affinity of S1 for actin was described by Kurzawa and 
Geeves (Kurzawa and Geeves 1996). This is a titration assay in which a fixed concentration 
of actin is preincubated with increasing concentrations of S1. This can then be rapidly mixed 
with ATP in the stopped-flow to induce complete dissociation of S1 from actin. With 
increasing [S1], the amplitude will also increase as more pyrene fluorescence is quenched 
at the beginning of the reaction. Therefore, the amplitude provides an estimate of the fraction 
of actin bound to S1 at increasing S1 concentrations. As the affinity value is close to the 
total protein concentration in the assay, the data cannot be fit with a hyperbola. The 
amplitude was plotted against [S1] and fitted to the physically significant root of the following 
quadratic equation: 
 
𝑎 = [𝑀] + 𝐾Q + [𝐴]M − R([𝑀] + 𝐾Q + [𝐴],); − 4[𝑀][𝐴],2[𝐴],  
 
where [M] = concentration of free S1 at equilibrium, KD = the actin affinity equilibrium 







Figure 1.28 shows the ATP-drive acto.myosin cross-bridge cycle. The cycle is defined by 
18 rate and 9 equilibrium constants. Each step 𝑖 in the cycle can be defined by: 
 𝐾V = 𝑘?V𝑘/V 
 
where Ki is the equilibrium constant, k+i is the forward rate constant, and k-i is the reverse 
rate constant. Transient kinetics is able to define 13 of these parameters (see Chapter 3). 
Estimates of the remaining unknown parameters can be obtained by fitting the transient 
kinetic data to steady-state ATPase data in a process called global fitting. 
 
Global fitting refers to simultaneous curve fitting using numerical integration to 
simulate kinetic data and calculate the rate of transition between different intermediates in 
a pathway or cycle. A number of kinetic software packages are available to do this, such 
Berkeley Madonna, Dynafit or KinTek, and all work on the same principle. These programs 
allow numerical solving of differential kinetic equations, to simulate the time course of 
kinetically complex systems. This yields insights into the time dependence of reactant 
disappearance or product appearance, as well as the concentration of intermediates in the 
pathway. It is possible to optimise rate constants for steps in the model using best fit 
procedures. During the global fitting process, the rate constants are adjusted iteratively to 
give the best fit to the experimental data. This generates estimates for rate constants that 
cannot be determined experimentally. 
 
Whilst the ATPase cycle in Figure 1.28 can be modelled using any kinetic modelling 
program, the work presented in this thesis was modelled using MUSICO, as described by 
Mijailovich et al (Mijailovich et al. 2017). This programme estimates rate transition constants 
by the Damped Least-Square method (or Levenberg-Marquardt inversion), as set out in 
(Mijailovich et al. 2010). The DLS method is based on the iterative minimisation of the mean-
square error of the model predictions with respect to experimental observations.  This was 
done by minimising the variance between the predicted steady-state ATPase rates over a 
range of actin concentrations, to simulate steady-state ATPase experiments. The model 
parameters are uniquely resolved, and the deviation of the model predictions from the 
experimental observations is represented by the mean-square error, which is an integral 
measure of the accuracy of the model-prediction fit to the observations. Minimization of the 




using the iterative procedure. The programme also allows varying any one of the fitted 
parameters by ± 20% (the minimum precision of the transient kinetic measurements) to 
estimate the effects on the best fit values of the remaining parameters. This confirms the 
findings of the sensitivity matrix that the parameters are well defined by the fitting procedure. 





2.5 In vitro motility assay  
 
To measure the velocity of myosin along actin filaments, an in vitro motility assay was 
performed as described in (Adhikari et al. 2016; Aksel et al. 2015). To ensure no inactive 
myosin heads were present during the assay, a ten-fold molar excess of F-actin and 2 mM 
ATP was added to the S1, and incubated for 15 minutes at 4 °C. 50 mM MgCl2 was added 
and incubated for a further 5 minutes. Actin and bound, inactive myosin heads were 
sedimented at 100,000 RPM for 15 minutes at 4 °C. The supernatant, containing active 
myosin heads, was collected and diluted in assay buffer to a final concentration of 1 μM. All 
reagents were dissolved in assay buffer containing 0.1 mg/ml bovine serum albumin 
(ABBSA), unless other stated. 
 
All motility experiments were performed at 20 °C. Glass coverslips were coated with 
0.2% nitrocellulose and air-dried before use. Reagents were sequentially flowed through the 
channels in the following order: 50 μL of 4 μM SNAP-PDZ18  incubated for 3 min; 100 μL 
of ABBSA to block the surface from nonspecific attachments and incubated for 3 min; 50 μL 
of 100 nM 8-residue (RGSIDTWV)-tagged S1 and incubated for 3 min; 100 μL of ABBSA  
to wash any unattached proteins; 50 μL of 30 nM rhodamine-phalloidin-labelled rabbit actin; 
100 μL of an oxygen-scavenging system consisting of 5 mg/ml glucose, 0.1 mg/ml glucose 
oxydase and 0.02 mg/ml catalase; 50 μL 2 mM ATP. Actin filaments were detected using a 
widefield fluorescence imaging system (as described in Johnson et al (Johnson, East, and 
Mulvihill 2014)) with UAPON 100XOTIRF NA lens and QuantEM emCCD camera (Cairn, 




3. The ATPase cycle of Human Muscle Myosin II 
isoforms: Adaptation of a single mechanochemical cycle 
for different physiological roles 
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3.1 Context of research 
 
The data in this publication is a follow up study from two papers utilising the MUSICO 
modelling programme to study the ATP-dependent acto.myosin cross-bridge cycle. 
Mijailovich et al first described the programme, and used it to characterise contractile 
parameters for rabbit MyHC-IIa, human MyHC-a and MyHC-β, and the MyHC-β R453C 
HCM mutation using experimentally defined cross-bridge kinetics (Mijailovich et al. 2017). 
Ujfalusi et al used the same methodology to predict contractile properties of 5 DCM-causing 
and 2 HCM-causing mutations (Ujfalusi et al. 2018). They also extended the analysis to 
predict economy of ATP usage in these mutated motor proteins. Using newly acquired data 
on MyHC-peri, and published data on 5 human class II isoforms (MyHC-IIa, MyHC-IIb, 
MyHC-IId, MyHC-emb and MyHC-exoc), the same approach was used to investigate 
functional properties of human class II isoforms. The human MyHC-a and MyHC-β was also 
re-examined to predict ATP economy. This research provides a comprehensive overview 
of characteristics of the fundamental ATPase cycle for 8 of the 9 striated class II myosins. 
 
3.2 Aims of research 
 
Muscle myosin II isoforms in mammals, including humans, are adapted for a variety of 
functions, which when expressed in a muscle fibre confers distinct contraction 
characteristics to each muscle fibre type. Combinations of different fibre types cooperate to 
produce contractile activity tuned to the functional demands on the muscle. The isoform of 
myosin expressed in a muscle fibre therefore plays a central role in determining the 
contractile properties of muscle fibres. However, the way in which each myosin is tuned for 
its specific function is not understood, so the aim of the research was to understand how 
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human sarcomeric myosins adapt their mechanochemical ATPase cycle to perform different 
functions within different muscle types. Whilst fibres of MyHC-β and the skeletal isoforms 
have been well studied, experimental data on the MyHC-emb, MyHC-peri, MyHC-exoc and 
MyHC-a is limited. The MUSICO approach allowed experimentally defined solution data of 
these isoforms to be modelled to the ATPase cross-bridge cycle. This predicts the 
differences in the fraction of time spent in different occupancies of the cycle. These 
occupancies were then studied to predict the duty ratio and shortening velocities, ATP 
economy and load dependence. This analysis was completed for 8 human class II isoforms.  
 
3.3 Contribution to publication 
 
The initial design of the study arose from discussions between myself and my supervisor, 
Professor Michael Geeves. The study was initially intended to model the MyHC-emb data 
as a follow up study to the (Mijailovich et al. 2017) paper, but after I collated all published 
transient kinetic data on the MyHC-IIa, MyHC-IIb, MyHC-IId, MyHC-emb and MyHC-exoc 
isoforms, the study was extended to include these isoforms. I performed kinetic modelling 
with MUSICO on all isoforms, and performed the analysis on ATP economy. Marina 
Svicevic and Dr Srbolujub Mijailovich assisted me with the error analysis on the modelled 
data. Dr Jonathan Walklate performed transient kinetic analysis on the MyHC-peri isoform, 
which was provided by Dr Carlos Vera and Dr Anastasia Karabina from Professor Leslie 
Leinwand’s laboratory. Professor Geeves and I wrote the first draft of the manuscript, which 
was reviewed by all authors. 
 

























































































































4. Cardiac/slow muscle contraction velocity has evolved 
to match heart rate with body size through variation in β-
cardiac myosin sequence. 
 
 
Chloe A. Johnson*, Jake E. McGreig*, Carlos D. Vera, Daniel P. Mulvihill, Martin Ridout, 
Leslie A. Leinwand, Mark N. Wass, Michael A. Geeves 
 
* Contributed equally 
 
E-life, under review 
 
4.1 Context of research 
 
Whilst the work in Chapter 3 identified how myosin class II isoforms adapt their 
mechanochemical cycle for different functions, it is still not fully understood how these 
differences arise from the sequence changes of the isoforms. As shown in Table 1.2, the 
isoforms have a high sequence homology. To explore how sequence changes in myosin 
can contribute to different properties of the muscle in which it is found, McGreig et al 
investigated the relationship between muscle contraction and body mass (McGreig et al. 
2019). This is a well-documented relationship; the larger the species, the slower muscle 
contraction. If velocity of contraction is matched to body mass in mammals, then there may 
exist changes in the sequence of myosin to tune its properties to the species size and thus 
give rise to alterations to the physiology of the muscle. The sequences of 12 myosin class 
II isoforms from 65 mammals (ranging from 0.006 – 10,000 kg) were examined, and the 
authors proposed that MyHC-β, MyHC-IIa and MyHC-IIb have adapted to changes in body 
mass. The data in the following manuscript continues this work to focus on the MyHC-β 
isoform, to investigate the relationship between sequence and velocity of contraction. 
 
4.2 Aims of research 
 
For the MyHC-β isoform, the rate of ADP release from an actin.myosin complex is predicted 
to limit contraction velocity (as described in Chapter 1.3.3). We therefore set out to identify 
if the sequence changes found within the motor domain of MyHC-β could contribute to the 
slower contraction observed in larger mammals by a slowing of ADP release, and hence 
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velocity. Using a combination of bioinformatics analysis and biochemical characterisation, 
we set out to identify the sequence changes that drive a change in the rate of ADP-release. 
We identified 14 amino acid changes in the β-myosin motor domain with a strong 
association with species size.  Of these 14 sequence changes, 9 differ between the well-
characterised human and rat MyHC-β.  We introduced these 9 amino acid changes into the 
human MyHC-β, and used stopped-flow spectroscopy and In vitro motility assays to 
experimentally test the computational predictions. This approach aims to address how 
small sequence variations, as seen between myosin class II isoforms, can alter protein 
function. This has wider impactions for our understanding of evolution and the role of 
genetic variation. 
 
4.3 Contribution to publication 
 
Jake McGreig, with supervision from Dr Mark Wass, performed computational research and 
bioinformatics analysis with suggestions from Professor Michael Geeves and myself. 
Professor Geeves and I designed an initial outline for a study which biochemically tests the 
predictions from the computational analysis. When visiting Professor Leslie Leinwand’s 
laboratory to gain experience in producing recombinant myosin, I held extensive 
discussions with both Leslie and members of her lab to gain their support in producing a 
chimera protein using the C2C12 system Leslie’s lab specialises in. With the help of 
Professor Daniel Mulvihill, I planned and performed the cloning strategy of the chimera. 
With Dr Stephen Langers in Professor Leslie Leinwand’s group, I produced the adenovirus 
containing the chimera gene for transfecting C2C12 cells. Dr Carlos Vera grew the 
transfected C2C12 cells expressing both MyHC-β and the chimera protein, and sent to me 
for purification. I purified the two recombinant proteins, as well as the endogenous rat 
soleus MyHC-β. I then designed, performed and analysed the biochemical characterisation 
of all of the proteins. Professor Geeves, Jake McGreig, Dr Wass and myself wrote the first 
draft of the manuscript, which was reviewed by all authors. 
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Heart rate and the maximum velocity of contraction of striated muscle are inversely related 
to species size. As mammals evolve to different sizes, adaptations are required such as 
slower contracting heart and skeletal muscles.   Analysis of the motor domain of β-myosin 
from 67 mammals from two clades identifies 14 sites, out of 800, strongly associated with 
body mass (p<0.01) but not with the clade (p>0.05).  Nine of these sites were mutated in 
the human β-myosin to make it resemble the rat sequence. Biochemical analysis revealed 
that the rat-human β-myosin chimera functioned like the native rat myosin with a two fold 
increase in both motility and in the rate of ADP release from the actin.myosin cross-bridge 
(the step that limits contraction velocity).  Both clades use the same small set of amino 
acids to adjust contraction velocity, suggesting a limited number of ways in which velocity 
can be manipulated. 
 
Introduction 
Proteins adapt and evolve over long time periods tuning their function to the specific needs 
of the organisms in which they are expressed.  Understanding how proteins adapt to 
different physiology is one of the challenges of current molecular and structural biology.  
One approach is to consider a protein expressed as different isoforms within a species 
(paralogues) or in different species (orthologues) where adaptation has taken place.  Such 
a study is easier if a close link can be established between different phenotypes in the 
organism for which a specific protein function is needed.  Striated-muscle myosin motors 
represent a protein family where such evolutionary relationships can be explored. The 
maximum contraction velocity of a muscle, V0, is a key attribute of muscle contraction 1,2. It 
is a parameter which contributes to the Force-Velocity realtionship of a muscle, the power 
output (force x velocity) and the velocity at which power and efficiency are maximum. These 
properties can be  expected to be under selective pressure. The maximum shortening 
velocity of a muscle is a property of the myosin isoform expressed in the muscle 3. The 
maximum shortening velocity varies more than-ten fold among both paralogues and 
othologues of myosin.  In contrast, the maximum force a myosin can generate varies little 
between myosin isoforms.   Maximum velocity is therefore a central parameter that defines 
both the Force-Velocity relationship, power output and the efficiency of muscle contraction.  
Note larger forces can be generated by increasing muscle mass (e.g. through exercise) but 
maximum velocity is an intrisic property of the muscle and the myosin isoform present.  
 
In mammals, there are 10 different striated muscle myosins, each expressed from a 
different gene; many of which have been shown to have distinct biochemical and 
mechanical properties 3–6. Larger mammals tend to have slower contracting muscles than 
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small mammals where the movement of a larger mass results in slower velocity.  This 
phenomenon is well-established in heart muscle where heart rate is inversely related to 
body mass for a wide range of species 7.   Since velocity of contraction is matched to the 
size of the animal expressing the myosin, then there should be changes in the myosin 
sequence to tune the myosin properties to the species size and correspondingly, to the 
physiology of the muscle.  In a recent study we tested the hypothesis that muscle myosin-
II isoforms from mammals would have adaptations in protein sequence associated with 
mean body mass8.  In this study, of ~730 sequences from 12 myosin-II isoforms from an 
average of 65 mammalian species, there was a strong correlation of the number of 
sequence changes with differences in species mass.  The correlation was strongest in adult 
striated muscle myosins IIa and IIb and β. β-myosin is found in the heart and in slow Type 
I muscle fibers. Here we examine in greater detail the sequence differences within the 
mammalian β-myosin to establish the relationship between sequence and velocity of 
contraction.   
 
The contractile properties of mammalian muscles have been widely studied but detailed 
mechanical and biochemical studies have been completed on only a few species and 
myosin isoforms. Such data are available for Type 1/β-cardiac/slow muscle fibres from four 
species (see Fig 1).  Each of these muscles expresses only the β-myosin isoform (MYH7), 
and each species has a characteristic contraction velocity that varies approximately five-
fold across the set of four muscles. Moreover, it is well established for the β-myosin isoform 
that the contraction velocity is limited by how fast ADP escapes from the actin.myosin cross-
bridge after the working stroke is completed 9.  Data in Fig 1 show that like velocity, the 
ADP release rate constant differs 4-5 fold across the set of four myosins.  Furthermore, the 
measured rate constant for ADP release from the actin.myosin complex, measured using 
the purified β-myosin isoform, is exactly that predicted to limit the contraction velocity 
(based on the detachment limited model of contraction (see Fig 1 legend) 9–11. It is therefore 
expected that this set of myosins will have changes in the amino acid sequence that alter 
the ADP release rate and hence contraction velocity.  
 
Examining the sequences of the 800 amino acid motor domains of the four β-myosins in 
Fig 1 show them to be 96% identical which means there are 49 sequence differences 
among the four, with 34 differences between rat and human.  These differences in 
sequence are scattered throughout the motor domain (see Fig 2 and alignment in Fig S1).   
It seems likely that groups of amino acids and not a single amino acid change determine 
the functional differences between the β-myosins.  If the correlation between body size and 
contraction velocity  is a general phenomenon amongst mammals, as is seen for resting 
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heart rates 7, then a bioinformatics study of β-myosin sequences would be a way to identify 
which sequence changes correlate with size.   We hypothesised that the variation of β-
myosin contraction velocity (and rate of ADP release from the cross bridge) with the size of 
the mammal is due to a subset of the sequence changes observed for different mammals, 
and that these tune myosin velocity to that appropriate for the size of species. Here, we 
examine a set of 67 mammalian β-myosin sequences 8 using a bioinformatics approach to 
identify a group of 12 amino acids which have the strongest association with the size of the 
mammal.  Of these 12 amino acids, nine differ between human and rat β-myosin and we 
test our hypothesis through the construction and subsequent biochemical characterisation 




The alignment of the β-myosin sequences from four mammals (Fig 2 & Fig S1) 
demonstrates that while the sequences are highly conserved, the 49 sites of variation 
among the species are scattered throughout the motor domain.   High levels of variation 
are found in the N-terminal domain (1-60) and near the surface loops, Loop 1 (near residue 
210) and Loop 2 (near 630).  These loops are known to be hypervariable across the larger 
myosin family23.  The broad distribution of the sequence variants means that an 
experimental approach to define which residue changes are linked to the change in ADP 
release (and hence velocity of contraction) is too complex to consider.  Instead, we used a 
bioinformatics-based approach to identify the residues most likely to be linked to the change 
in velocity of contraction.  
 
Distinguishing between variation due to clade and body mass: 
 
We analysed 67 complete sequences of the β-myosin motor domains from species ranging 
in size from 7g (Brandt’s bat, Myotis brandtiibat) to 42,000 kg (sperm whale, Physeter 
catodon). Of these, about half were Euarchontoglires (32, e.g. rodents and primates) and 
half were Laurasiatheria (30, e.g. bats, ungulates, cetaceans).  We used this set of 
sequences to distinguish between sequence changes that were primarily associated with 
the clade versus those that correlated with the size of the animal (see Methods). A total of 
171 sites were identified where a sequence change occurred.  At the majority of these 
positions, variation occurred in a small number of species and is unlikely to be associated 
with changes in function relevant to body mass, so 119 positions where a sequence change 
was present in less than 10% of the species were excluded.  This included 84 sites where 
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a change occurred in only one species, while changes in two species occurred at 20 sites 
and in three species at four sites.   
 
The remaining 52 sites of variation were analysed to distinguish between changes that 
correlated with clade and those that correlated with body mass (as illustrated in Fig 3 for 
four sites with the remaining plots in Supp Info – Fig S2).  In most cases, only two residues 
were observed at each specific site; in the small number of cases (11 of 52) with multiple 
amino acids, only the two most frequent residues were considered.  The identity of the two 
most frequent amino acids were coded as 0 and 1 and a logistic regression model was 
fitted with log(mass) as the explanatory variable (Fig 3, Fig S2; see methods) to model the 
transition between residues.  Data for four sites are presented in Fig 3 and of the sites 
shown, two had a strong correlation with species body mass (the amino acid common in 
small mammals is given first P343S, I349P; padj ≤ 0.01. Note the adjusted one percent 
significance threshold is p= 9.50x10-4 and the 5% significance threshold is p=9.62x10-4. padj 
will be used to indicate the adjusted significance threshold). Each of the positions has a 
distinct midpoint mass for the transition between the two amino acids (see below).  In 
contrast, I125V has a low association with mass (p = 0.03) and M77L has an intermediate 
association (p= 9.50e-04), however both M77L and V125I have a strong association with 
the clade (Fig 4); L77 and I125 are found almost exclusively in Laurasiatheria.  
 
Overall, only 12 sites had a very strong association with clade (padj ≤ 0.01) and a further 
two were significant at the five percent level (padj ≤ 0.05; Fig 4A). Some of these residues 
occur in two groups; one group of four in the N terminal region below residue 135 (4, 11, 
52, 77, 110, 125) and four residues near surface loop 2 (610, 616, 627, 629).  The remaining 
four are at D208E, E509T, T585I and I684M. Twenty positions were strongly associated 
(padj ≤ 0.01) with body mass and a further four were significantly associated at padj ≤ 0.05 
(Fig 4B). Nine positions were associated with both clade and body mass (Fig 3C), which is 
likely to represent that the very largest mammals (body mass > 500 kg) in the data set are 
all Laurasiatheria (Fig S5). 
 
Twelve of the 24 sites associated with body mass occur in the known hypervariable regions, 
four in the N terminal region (11,15, 52, 65, bold residues also occur in the clade list), one 
in loop 1 (D208E), and a further six  occur in or near loop 2 (607,610,616,627,629, 631)) 
and one at I684M.  The remaining 12 sites (Table 2) group into three sets of four; most with 
padj ≤ 0.01 (coloured in Fig 4 & 5).  Comparing the strength of association between clade 
and body mass, these 12 sites, are strongly associated with body mass but not with clade 
(Fig 4C).  Hence, we propose that these 12 positions are likely to be important in 
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determining the β-myosin velocity of contraction. At eight of the twelve positions only two 
amino acids are observed, one position contains three amino acids, although the third is 
only present once (residue 366). Multiple amino acids (4-7) were observed at the remaining 
three positions. For two of the positions, 421 and 424, this reflects a subset of the species 
from one clade having an alternate amino acid in some of the larger species (see Sup Fig 
S4).  
 
The first group of residues is in a region 331-371 (Orange in Fig 4 and 5) adjacent to the 
exon 7 region of Drosophila myosin II (and the “linker region”).  This region is equivalent to 
one of the four exons in the single myosin II gene of Drosophila which are alternately spliced 
to generate all isoforms of myosin II in Drosophila 24.  We have previously shown 25 that the 
alternatively spliced forms of this region alter ADP release in the Drosophila myosin. The 
second set (426-439; Magenta in Fig 4 and Fig 5) is in a long helix (Helix-O) in the upper 
50 kDa domain that links an actin binding site (the myopathy loop) to the nucleotide binding 
pocket (via switch 2).  The third region (560 - 587; Red in Fig 4 and Fig 5) is in the lower 50 
kDa domain and lies close to loop 3, an actin binding site in the lower 50kDa domain.  
 
Experimental testing of the computational predictions: 
 
We have previously expressed the motor domain of human β-myosin in mouse C2C12 
muscle cells and isolated the protein using His tags attached to the co-expressed human 
light chain.   This is currently the only way to express mammalian striated muscle myosin 
motors but is complex and time consuming and yields just a few mg of protein 6,26,27.  To 
test the hypothesis that the highlighted group of 12 residues are responsible for a significant 
part of the adjustment of ADP release rate constant, we generated a chimeric human-rat β-
myosin motor domain where the nine positions (of the 12) that vary between human and 
rat were replaced with the amino acid present in rat (A326S, S343P, L366Q, I421A, T424I, 
A430S, R434K, F553Y, P573Q – human residue number and amino acid listed first). The 
other three positions are the same in rat and human (354, 576 & 587).  At residue 421 we 
replaced Ile with Ala as present in rat, although Ser is present in most of the smallest 
mammals (See Fig 6). 
 
As shown in Fig 1, the velocity of contraction for β cardiac/Type I slow muscle fibres in rat 
and humans differ by a factor of ~4.  Given that these residues have a range of transition 
masses (see Fig 5 & 6) the hypothesis is that each of these nine residues will contribute a 
fraction of the difference between the rat and human β-myosin ADP release rate constant 
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and hence, velocity.  With all nine residues changed, our prediction is that the differences 
in the rate constant should be large enough to be easily detectable.  
 
The S1 fragment of human β-myosin and the chimera were expressed in C2C12 cells and 
purified with the human essential light chain attached.  Few details of the kinetic 
characterisation of the rat β-myosin S1 have been published 28.  The rat β-myosin S1 was 
therefore purified from rat soleus muscle to use as a comparator for the chimera. The 
supplementary data include the SDS PAGE of all three proteins used in this study and 
demonstrates that all three proteins are pure and contain the appropriate light chains (Fig 
S5). 
 
As a test of the behaviour of the chimeric protein, the ATP-induced dissociation of the 
chimera from pyrene labelled actin was monitored and compared to the recombinant human 
and the native rat S1.  A typical transient is presented inset in Fig 7B and the observed 
amplitude of the signal change was the same for all three proteins.  The similarity of 
observed amplitudes of the pyrene signal changes for the chimera, human and native rat 
proteins indicates that the chimera binds actin and releases it on ATP binding as for the 
human and rat S1. This is consistent with the chimera being a fully folded and active protein.  
A plot of the observed rate constant (kobs) vs [ATP] gives a straight line which defines the 
apparent 2nd order rate constant for the reaction (Fig 7B) and appears the same for all three 
proteins. The observed rate constant of this reaction has been defined for many myosins 
and has two components, kobs = [ATP] K’1k’+2.  The reaction is sensitive to both the affinity 
of ATP for the complex (K’1) and the efficiency with which ATP induced a major 
conformational change in the myosin (k’+2).  This involves the closure of switches 1 and 2 
onto the ATP and the opening of the major cleft in the actin binding site of myosin. The 
absence of any change in K’1k’+2 is consistent with a well preserved nucleotide pocket and 
a preserved communication pathway between the ATP binding pocket and the actin binding 
site.  
 
The affinity of ADP for actin.S1 was measured in a competition assay with ATP (Fig 7C) 
and the affinity of ADP for the rat actin.S1 complex  (14 μM) was 2.3 fold weaker than for 
the human WT protein (6.3 μM).  These values are consistent with published values 29.  The 
chimera was distinct from the human S1 and indistinguishable from the rat S1. To confirm 
this result the ADP release rate constant was measured directly by displacing ADP from 
actin.S1.ADP through addition of an excess of ATP.  The results (Fig 7D) for human and 
rat S1 are again consistent with published values with ADP leaving the rat complex at ~ 2X 
the rate of the human complex (107 vs 59 s-1).  The chimera was indistinguishable from 
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the rat S1. As predicted, the amino acids introduced into the human β-myosin motor domain 
weaken ADP affinity for actin.myosin by accelerating ADP release to make the human β-
myosin S1 behave like the rat β-myosin S1.  
 
Footnote to the inset shown in Fig 7D; a complication of the ADP displacement 
measurement is that ADP displacement from human β-myosin occurs in two phases (fast 
and slow). The fast phase corresponds with ADP released at the end of the normal ATPase 
cycle while the slow phase is a trapped ADP which is released much slower and at a much 
slower rate than the overall cycling.  This is therefore a dead-end side branch of the pathway 
commonly seen in slow muscle & non muscle myosins 14,28,30.  The fraction of ADP trapped 
in this way is characteristic of each myosin.  The rat β-myosin S1 has no apparent slow 
phase, the human has ~10% of ADP released in the slow phase while the chimera has a 
larger fraction (~40%) of the total ADP released in the slow phase.  The role of the 
substituted amino acids in the slow phase requires further study, but the reader is referred 
to the literature for a broader study of this phenomena14,28,30. 
 
Motor activity of the recombinant human β-myosin S1 and the chimera protein was 
measured using an in vitro motility assay (Fig 7A, Supplementary movie 1). This assay 
determines the myosin-mediated velocities of fluorescent actin-filaments moving on a 
nitrocellulose-coated slide surface. The human WT β-myosin moved actin at a velocity of 
0.49 μm.s-1 at 20 °C. Introduction of the nine rat amino acids into the WT protein increased 
the mean filament velocity by almost 2-fold, from 0.49 μm.s-1 to 0.9 μm.s-1 for the chimera, 
which is consistent with the ~ 2 fold increase in ADP release-rate data. Our human S1 
velocity was similar to the 0.612 μm.s-1 value reported by Ujfalusi et al, which was measured 
at 23 °C 31. A similar velocity of 0.378 μm.s-1 was reported for full length human-β myosin 
at 25 °C 3 and  a velocity of 0.624 μm.s-1 for the rat. This gives a rat/human ratio of 1.65, 
very similar to our chimera/human ratio (1.84). Note this data from motility assays gives a 
different ratio of velocities form that taken from muscle fiber contraction velocity data quoted 
in Fig 1. The motility assay was not performed for the rat S1 as we do not have an 
expression system for the protein.  The native rat S1 has only a single light chain and lacks 
a tag to attach the protein to the surface.  The rat protein will not therefore give a valid 
comparable measurement.  However, it is known from the literature (Table in Fig 1 & 
references therein) that the rat protein moves 3-5 times faster than the human protein, 







Our analysis confirmed our hypothesis that there is a set of sequence changes in the β-
myosin, among mammals, that have a high probability of association with species mass.  
In the 67 species examined, for 52 sites in the motor domain the residue present varied in 
more than six species. Of these 52 sites a set of 24 sequence changes had the strongest 
association with mass (padj<0.05) and little association with clade (padj>0.05).  These sites 
were found throughout the motor domain but we noticed three clusters of four residues (Fig 
4) within the group that would allow a cloning approach to test if these residues do play a 
role in adjusting the velocity of muscle contraction.  Of these 12 residues, nine differ 
between the rat and human β -myosin. We have an expression system for the human 
myosin motor domain and therefore made a human/rat chimera by exchanging these nine 
residues. 
 
The chimera displayed a two-fold weakening of ADP binding to actin.myosin due to a two-
fold acceleration of the rate constant controlling ADP release from the complex.   The two 
fold faster ADP release rate constant, since it is believed to limit contraction velocity, 
predicts a two-fold acceleration of the velocity of muscle contraction and a two-fold 
acceleration of the speed at which actin would move over a bed of myosin.  The motility 
assay confirmed this prediction.  The mutations could have caused a generalised loss of 
nucleotide binding to the protein but a control examining the ability of ATP to bind to 
actin.myosin and displace actin was indistinguishable among the three proteins (Fig 7B). 
 
Thus our bioinformatics approach has successfully identified nine residues with a role in 
modulating the velocity of muscle contraction which have been selected over time to adjust 
the velocity to that required for the slower contraction in human vs rat hearts. 
 
Before considering the sites in the motor domain of myosin where these changes occur we 
should consider the role of the remaining 40 sites. As shown in Fig 4C, 21 sites have no 
apparent association with clade or mass and therefore the functional significance of these 
residue changes remains undefined. Eight sites have a strong association with clade but 
no or only modest association with mass. A further four sites had a strong association with 
both clade and mass. Each of these four sites that have strong association with both mass 
and clade along with the four sites with a strong association with mass, which were not 
made in the chimera, may contribute to the changes in contraction velocity between 
mammals. Our approach here was to establish the principle of the effect rather than 
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delineate the contribution of every sequence change. Thus we focussed on three groups of 
amino acids.  
 
As stated in the introduction making single point mutations in the motor domain is unlikely 
to give sufficient experimental resolution to define the contribution of each residue to the 2-
3 fold changes we were expecting between rat and human.  However, groups of changes 
could possibly define the relative contributions of each of the three groups of residues.  At 
the moment the complexity and expense of expressing the protein in mouse cell lines 
prohibits a larger scale study. 
 
What was unexpected was the finding that a set of 12 residues with the highest correlation 
with mass are predicted to have a narrow mass range over which each sequence change 
is found (Fig 5 & 6).  Additionally, each of the residues has its own distinct midpoint for the 
transition.  This implies that as mass increases, there is a limited number of ways in which 
the ADP release can be modified step-wise and mammals from distinct clades utilise the 
same set and order of sequence changes.   This is illustrated for seven mammals in Fig 6 
where the amino acid present at each of the 12 sites is listed in the order of the mass at 
which the switch occurs between the amino acid for small vs large mammals. The plot 
shows the gradual shift between the two sets of amino acids. Note that the small and large 
Laurasiatheria (bat and cow) differ at every one of the 12 sites as do the small and large 
Euarchontoglires, mouse and human.  In contrast, the mouse sequence is identical to the 
bat, and human sequence is the same as cow at nine of the twelve sites. A similar plot for 
all 67 mammals is include in the supplementary materials (Fig S3) and, in addition to 
demonstrating the same relationships for the larger group of mammals, shows that the 
small number of Metatheria, and Afrotheria fit into the same pattern.  This is consistent with 
the same set of amino acids being selected for, at each site, in each clade. This is an 
example of convergent evolution.   
None of the mutated residues are in direct contact with the nucleotide binding pocket (Fig 
5), thus suggesting that the mutations have allosteric effects.   Four of the changes occur 
in helix-O, a long helix in the upper 50 kDa domain that links the actin binding site 
(cardiomyopathy loop) with switch 2 in the nucleotide binding site. It is therefore in a position 
to influence the communication between these two important functional sites.  However, 
the available crystal structures published from a variety of myosins show this helix to move 
with the whole of the upper 50 kDa domain (e.g. see Fig 7 in M. Bloemink et al., 2014).  The 
other two groups of changes (three residues in the upper 50 kDa domain and two in the 
lower 50 kDa domain) are not close to each other in space.  Understanding how the 
changes (for the most part conservative substitutions) in these regions alter the behaviour 
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of the myosin will require a detailed molecular dynamics study. Seven of the twelve 
positions include amino acid changes that introduce or remove side chains that are capable 
of forming hydrogen bonds, thus it is possible that the sequence changes result in minor 
changes to hydrogen bonding networks in the protein.   None of these sites appear in the 
ClinVar web site as sites of mutations in human β-myosin associated with cardiomyopathies 
or the Genome Aggregation Database (GnomAD) of sites of polymorphisms in humans.  
This means there are three distinct sets of sites of variation in β myosin, the benign 
(changes have no known effect on function) the pathological (where there is a relative mild 
loss of function since the patients typically live into adulthood) and those associated with 
species adaptation which can induce a more significant change in function. 
The results presented here show how a direct link between an organism’s physiology and 
a specific protein sequence allows the exploration of how selection may have adapted 
protein function to match the physiological requirements.  The observation that the same 
set of amino acids have independently changed in two clades suggests constraints on the 
way a protein sequence can adapt whilst maintaining function.  A wider study of muscle 
myosin sequences may show if different isoforms use the same or distinct sets of amino 







Amino acid sequences for the β-myosin motor from 67 different mammalian species were 
aligned using Clustal Omega 12 comprising organisms from the clades Euarchontoglires 
(32), Laurasiatheria (30), Metatheria (4) and Afrotheria (1). The start and end points of the 
motors in Homo sapiens were considered to be residues 1 and 800 (based on UniProtKB 
– P12883).  
 
Statistical analysis: 
For each position in the alignment that had more than one amino acid present, species 
masses were compared between the two highest frequency amino acids at that position 
using the Mann-Whitney U test, a nonparametric two-sample test.  Multiple testing was 
accounted for by applying the Bonferroni correction. To avoid very imbalanced 
comparisons, the analysis was not run if the frequency of the second amino acid was less 
than 10% of the frequency of the most frequent one. Where more than two amino acids 
were present at an alignment position, only the two most frequent amino acids were 
considered. See Fig S3 for details of sites with more than 2 amino acids.  
 
Alignment positions were divided into three groups: those with an adjusted p-value (padj) 
less than 0.01 (with Bonferroni correction applied this is equivalent to a p-value of p= 
9.50x10-04), those with 0.01 < padj  < 0.05 (5% significance threshold equivalent to 
p=9.62x10-4), and those with a padj  >0.05.  In addition, the two highest frequency amino 
acids were coded as 0 and 1 and a logistic regression model was fitted with log(mass) as 
the explanatory variable (Fig 3 & Supplementary Fig 2). In order to overlay these residue 
plots, as the coding of the amino acids as 0 and 1 was arbitrary, it was done in such a way 
that the slope of the fitted logistic regression line was positive (Fig 3). The value of mass at 
which the two amino acids were predicted to be equally likely to occur was estimated from 
the regression line.  
 
For each alignment position, a 2x2 table was constructed classifying the species by amino 
acids present (most frequent and second most frequent) and clade. Fisher’s exact test was 
used to test whether these two factors were associated. The residue and -log10 of the P-
value from the Fisher’s exact test were plotted to identify residues for which the amino acid 
variation was likely to have resulted from clade associated changes. The residue and -log10 
of the p-value from the Mann-Whitney U test were also plotted to determine when residue 
variation was likely attributed to mass changes. Finally, the -log10 p-values obtained from 
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both tests were plotted against each other. For each of these plots, lines at positions of the 
Bonferroni adjusted p-values 0.01, and 0.05 were added to assess the confidence in each 
residues association with mass or clade. 
 
All statistical analyses were run in R 13. 
 
Molecular Biology of the chimera: 
A pUC19 plasmid containing the human β-myosin motor domain gene was digested with 
NsiI and NgoMIV to excise DNA encoding for residues 310 – 599 of the human β-myosin. 
This region was replaced with a complementary pair of synthetic oligos encoding for the 
same region, but with the nine amino-acid substitutions listed (Ala326Ser, Ser343Pro, 
Leu366Gln, Ile421Ala, Thr424Ile, Ala430Ser, Arg434Lys, Phe553Tyr, Pro573Gln). The 
subsequent clone was confirmed by sequencing. This chimera gene was cloned into a 
pShuttle CMV vector to allow recombinant replication-deficient adenovirus production, as 
previously described (Deacon et al 2012). 
 
Protein purification: 
The chimera and the human β-myosin motor domains (known as subfragment 1  or S1) 
were expressed and purified as descried previously 14. Briefly, the adenoviruses were used 
to infect C2C12 myotubes in culture and resulted in overexpression of recombinant myosin 
proteins.  The heavy chains (residues 1-842) were co-expressed in C2C12 myotubes with 
His-tagged human ventricular essential light chain. The recombinant proteins also carried 
the endogenous mouse regulatory light chain (MLC3). This is homologous to subfragment 
1, S1, generated by proteolytic digestion of myosin. For motility assays the heavy chain 
was additionally tagged with an eight residue (RGSIDTWV) C-terminal extension. Cell 
pellets were homogenized in a low salt buffer and centrifuged, and the supernatants were 
purified by affinity chromatography using a HisTrap HP 1 ml column. The proteins were 
then dialyzed into the low salt experimental buffer (25 mM KCl, 20 mM MOPS, 5 mM MgCl2, 
1mM DTT, pH 7.0).  
 
The SNAP-PDZ18 affinity tag used for in vitro motility measurements were purified as 
described in 15,16. SNAP-PDZ18 was expressed through a pHFT2 expression vector, and 
the plasmid transformed into E. coli BL21 DE3 cells. The protein was purified using nickel-




Actin was prepared from rabbit muscle as described by 17. The actin was labelled with 
pyrene at Cys-374 as described in 18. When used at sub-micromolar concentrations the 
actin was stabilized by incubation in a 1:1 mixture with phalloidin. 
Rat β-myosin S1 was prepared from soleus muscle which was dissected immediately post 
mortem and stored on ice. The muscle was homogenised into Guba-Straub buffer and left 
to stir for 30 minutes. After centrifugation at 4600 RPM for 30 minutes at 4 °C, the 
supernatant was subject to myosin precipitation as described in 19. The resulting myosin 
was digested with 0.1 mg chymotrypsin per ml of solution and left to stir for 10 mins exactly, 
at room temperature. To stop the digestion, 0.5 mM phenylmethylsulfonyl fluoride (PMSF) 
was added and the solution left to stir for 10 minutes. The digested myosin solution was 
dialysed into the low salt experimental buffer overnight (25 mM KCl, 20 mM MOPS, 5 mM 
MgCl2, 1mM DTT, pH 7.0). Precipitated myosin and light meromyosin was pelleted and 
removed via centrifugation at 12,000 RPM for 10 minutes, with the supernatant containing 
the purified soleus S1.  SDS-Gels of the purified protein were run and compared to the 
expressed human β-myosin and chimera S1.  
 
Stopped flow: 
Kinetic measurements for S1 of chimera, human β-myosin and rat soleus myosin were 
performed as described previously 5,14,20. Solutions were buffered with 25 mM KCl, 20 mM 
MOPS, 5 mM MgCl2, 1 mM DTT at pH 7.0, and measurements were conducted at 20 °C 
on a High-Tech Scientific SF-61 DX2 stopped-flow system. Traces were analysed in Kinetic 
Studio (TgK Scientific) and Origin. 
 
In vitro motility assay: 
Motility assays were performed essentially as described previously 16,21. Briefly, flow 
chambers were constructed with coverslips coated with nitrocellulose mounted on glass 
slides. Reagents were loaded in the following order: 1) SNAP-PDZ18 affinity tag; 2) BSA to 
block the surface from non-specific binding; 3) S1 of human β-myosin or the chimera with 
an eight amino acid C-terminal affinity clamp; 4) BSA to wash the chamber; 5) rhodamine-
phalloidin-labelled rabbit actin; 6) an oxygen-scavenging system consisting of 5 mg/ml 
glucose, 0.1 mg/ml glucose oxydase and 0.02 mg/ml catalase 7; 2 mM ATP. Partially 
inactivated myosin heads in S1 preparations were removed by incubating with a 10-fold 
molar excess of actin and 2 mM ATP for 15 minutes, then sedimentation at 100,000 RPM 
for 15 minutes. Supernatant was collected containing active myosin heads. All solutions 
were diluted into 25 mM imidazole, 25 mM KCl, 4 mM MgCl2, 1 mM EGTA, 1 mM DTT, pH 
7.5. Actin filaments were detected using a widefield fluorescence imaging system 
(described in 22) with UAPON 100XOTIRF NA lens (Olympus) and QuantEM emCCD 
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camera (Photometrics). The system was controlled and data analysed using Metamorph 
software (Molecular Devices, Sunnyvale, USA). Assays were performed at 20 °C and were 
repeated with three fresh protein preparations, with at least three movies of 30 second 
duration, recorded at a rate of 0.46 sec per frame. Individual velocities were determined 
from motile filaments that demonstrated a smooth consistent movement over 10 frames 
(4.6 sec). 100 individual measured velocities were used to calculate the mean velocity for 
each recombinant myosin.  
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Table 1. Comparison of ATP and ADP binding parameters of native rat S1, and the C2C12 
cell expressed human β-myosin and chimera S1. Errors reported are SEM, except for 







































Data are from three separate preparation of protein from either different cell pellets 
(expressed protein) or different soleus muscles from the rat. Experimental conditions were 











Measured Predicted τ (sec) 
 k-ADP (s-1) V0 
(µm/sec/half 
sarcomere) 
τADP = 1/k- 
ADP (msec) 




Rat 119 1.42 8.4 7.04 1.19 
Rabbit 63 0.67 15.9 14.9 1.06 
Human 30* 0.33 33 30.3 1.08 
Cow 27 0.27 37 37.0 1.00 
Experimental data was collected at 100 mM KCl and 12 °C. 
k-ADP values for bovine, rabbit and human are from Deacon et al 14, the rat from 
this study. NB the value for human k-ADP at 12 °C was estimated from an 
Arrhenius plot of values between 20 and 10 °C 32. These values are consistent 
with rat and porcine β-HMM data carried out at 100 mM KCl and 15 °C 33. Vo data 
for rat, rabbit & human are from Pellegrino et al 3, bovine from Toniolo et al 34. 
 
Figure 1. The relationship between the predicted and measured parameters for four 
slow/beta cardiac myosin isoforms. Figure adapted from (Nyitrai & Geeves, 2004). In 
terms of the actin myosin cross bridge cycle the dominant model proposes that the 
maximum velocity (V0) is limited by the lifetime of the strongly attached force holding state 
(τ) the “detachment limited model” (V0 = d/τ   where d is the working stroke of the cross 
bridge; assumed here to be 5 nm (Siemankowski, Wiseman, & White, 1985). For the 
mammalian, β-cardiac/slow-muscle myosin isoform, it is well established that τ is defined 
by the rate constant controlling ADP release k-ADP = 1/τ (see table below). Thus, values of 
k-ADP measured using myosin motor domains isolated from β-cardiac/slow muscle of a 
mammal, predict remarkably accurately the maximum shortening velocity of a muscle fibre 






Figure 2. Distribution of sequence variations for the β-myosin sequences listed in 
Figure 1.  The sequence which is ~96% conserved was divided into blocks of 30 residues 
and the number of sites within that group showing a change is plotted.  The maximum 











Figure 3. Residue-mass transition plots. Binomial regression mapping the 
transition of the most frequent amino acid at positions in the motor region of β-
myosin to the second most frequent amino acid at that position. The residue 
numbering is that of the human β-cardiac myosin, as oppose to the alignment 
position. The blue squares are Euarchontoglires, and the triangles are 
Laurasiatheria. The P-value with each plot arises from a test of the null hypothesis 






Figure 4. Residue mass change association with mass, clade, and each other. The 
association of each residue with clade (A), mass (B), and the association of the P-values 
of clade vs mass (C) are plotted. The significance of the P-values is shown with the 
Bonferroni adjusted lines drawn onto the plots (blue and grey). The three groups of residues 
investigated are highlighted in orange, purple and red, and labelled with the human residue 









Figure 5. Location of residues switched in the chimera. Structure of human β-myosin 
(PDB:ID 4DB1). The actin-binding site is highlighted in brown, exon 7 in blue, the nucleotide 
binding site in marine blue, and the converter region in yellow. The three groups of residues 
investigated are highlighted and labelled in orange (326, 343, 349, 366), purple (421, 424, 
430, 434), and red (553, 569, 573, 580) in each plot, and those that were switched are in 











Figure 6. Residue mass transition plots. Overlapping binomial regression mapping the 
transition of the most frequent amino acid at positions in the motor region of β-myosin to 
the second most frequent amino acid at that position.  The amino acids (AA) that occur 
most frequently and second most frequently are at the extremes of the y-axis. The groups 
of residues investigated are highlighted and labelled in orange (326, 343, 366), purple (421, 
424, 430, 434), red (553, 573), and black (349, 569, 580) which show the three groupings 
of the nine residues changed in the chimera, and the three additional residues predicted to 
transition as a result of mass changes respectively.  The table below shows the residues in 
seven species across each of the twelve positions, sorted by the mid-point of the transition.  






Figure 7. Stopped-flow analysis of the chimera, rat and human β-S1 proteins. A. 
Histogram of in vitro velocity of 100 rhodamine-labelled-phalloidin actin filaments moving 
over human β-S1 or chimera S1. The solid line shows the data fitted to a single Gaussian 
curve. The mean velocity for the human β-S1 was 0.49 ± 0.028 μms-1 and for the chimera 
0.90 ± 0.015 μms-1. B. The effect of ATP concentration on kobs for ATP-induced dissociation 
of pyrene-actin.S1. The gradient generates a second order rate constant of ATP binding; 
the values for the 3 proteins are highlighted next to the plot. Inset shows an example 
transient of 50 nM pyrene actin-chimera S1 mixed with 20 µM ATP, resulting in a 
fluorescence change of 26 %. C. Plot of kobs dependence on [ADP] for the ATP induced 
dissociation of pyrene-actin.S1. 50 nM pyrene-actin.S1 was mixed with 10 µM ATP and 
varying [ADP] (0-100 µM). Numbers indicate the values of ADP affinity for acto.S1, kADP, for 
the 3 proteins. D. To measure k+ADP, ADP is displaced from pyrene-actin.S1.ADP complex 
by an excess of ATP. 2 mM ATP was mixed with 250 nM S1 which was pre-incubated with 
500 nM pyrene-actin and 100 µM ADP. k+ADP values for the 3 proteins are given 7D. Inset 
showing data on a longer log time scale showing the slow phase components of the 
transients. The average values from 3 independent measurements for experiments shown 
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Supplementary Figure 1. Multiple sequence alignment of rat, rabbit, human and 

























Supplementary Figure 2. Residue-mass transition plots. Binomial regression mapping 
the transition of the most frequent amino acid at positions in the motor region of β-myosin 
to the second most frequent amino acid at that position. The residue numbering is that of 
the human β-myosin, as oppose to the alignment position. The black squares are 
Euarchontoglires, and the triangles are Laurasiatheria. The P-value with each plot indicate 












Supplementary Figure 3. Distribution of amino acids at twelve positions. This table 
shows the amino acids that occurs in each of the twelve residues, those predicted to be 
assocaited with mass and that are of interest, in each species, sorted by mass. Yellow 
background is the predominant amino acid in small mammals. Blue background is the 
predominant amino acid in large mammals. The clades Laurasiatheria, Euarchontoglires, 





Supplementary Figure 4. Highly variable residue mass vs amino acid frequencies. 
Residues which had more than two sites of variation, with the third most frequent amino 
acid being close in frequency to the second most common amino acid. The black squares 
are Euarchontoglires, and the triangles are Laurasiatheria. The residue numbering is that of 







Supplementary Figure 5. SDS-PAGE of the three protein preparations. A. Recombinant 







Supplementary Figure 6. Frequency of organisms at different mass levels. Plot to 
show the counts for organisms from each clade at different mass levels. Pink, dark, yellow, 
blue and purple shows organisms from the clades Afrotheria, Euarchontoglires, 
Laurasiatheria, and Metatheria clades. 
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5. Myosin motor domains carrying mutations implicated in 
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Srboljub M. Mijailovich, Ariana C. Combs, Stephen J. Langer, Kathleen M. Ruppel, James A. 
Spudich, Leslie A. Leinwand, and Michael A. Geeves 
 
* Contributed equally 
 
Journal of Biological Chemistry, 2019. In press. 
 
5.1 Context of research 
 
As described in section 1.4, research into HCM has been extensive since the first identification 
of a single point mutation in MyHC-β (Geisterfer-Lowrance et al. 1990). The collaboration 
between University of Colorado and University of Kent has contributed to the effort in 
understanding the molecular basis of the disease. The expertise of the Leinwand laboratory in 
recombinant myosin production has been coupled with the experience of the Geeves laboratory 
in rapid kinetic techniques, who are able to measure kinetic properties of myosin to a high 
precision using limited quantities of protein. Two well-known HCM-causing mutations, R453C 
and R403Q, were investigated in Bloemink et al and Nag et al, respectively (Bloemink et al. 
2014; Nag et al. 2015). The development of MUISCO in 2017 lead to the kinetic characterisation 
using stopped-flow spectroscopy being complemented by kinetic modelling. This was 
conducted for 5 DCM-causing mutations in the MyHC-β motor domain (Ujfalusi et al. 2018). 






5.2 Aims of research 
 
Single point mutations have been identified in the MyHC-β motor domain in both adolescent 
(early-onset) and adult (late-onset) patients with HCM. We hypothesised that the effect of 
mutations is more severe in patients with early-onset HCM compared to late-onset HCM.  Why 
disease progression is triggered earlier in life in the early-onset patients has yet to be 
elucidated. Stopped-flow spectroscopy was used to characterise kinetic parameters of the 
cross-bridge cycle for four early-onset and three late-onset HCM mutations. The 
mechanochemical cycle was then further explored using MUSICO, with the aim of 
understanding if the mutations have altered contractile properties (such as duty ratio, ATP 
economy, load dependence or shortening velocity) that may give rise to pathology.  
 
5.3 Contribution to publication 
 
Dr Carlos Vera, Dr. Stephen Langers, and Ariana Combs from Professor Leslie Leinwand’s 
laboratory cloned the sequences of all seven mutations, grew the viruses, transfected and grew 
the C2C12 cells. C2C12 cell pellets were shipped to Dr Jonathan Walklate and myself for 
purification. I designed, performed and analysed stopped-flow experiments for six of the seven 
mutations (all except H251N, which was characterised by Dr Walklate). Dr Vera made two trips 
to the University of Kent to assist with stopped-flow experiments and learn the technique; I 
supervised and mentored him during his training. I performed kinetic modelling of the transient 
kinetic data using MUSICO, with assistance from Marina Svicevic and Srboljub Mijailovich on 
the error analysis. Dr Arjun Adhikari, Dr Kathleen Ruppel and Professor James Spudich kindly 
provided motility and ATPase data. Dr Vera, Professor Leinwand, Professor Michael Geeves 
and myself wrote the first draft of the manuscript, which was reviewed by all authors. 
 























































































































6. Molecular features of the UNC-45 chaperone critical for 
binding and folding muscle myosin. 
 
 
Doris Hellerschmied, Anita Lehner, Nina Franicevic, Renato Arnese, Chloe Johnson, Antonia 
Vogel, Anton Meinhart, Robert Kurzbauer, Luiza Deszcz, Linn Gazda, Michael Geeves, Tim 
Clausen 
 
Nature Communications, 2019. In press.  
 
6.1 Context of research 
 
The Clausen lab at the Institute for Molecular Pathology are a structural biology laboratory, with 
expertise in protein folding. The extensive knowledge and experience of myosin biochemistry 
in the Geeves lab fostered the collaboration between the two groups.  
 
The folding and assembly of the striated muscle myosin relies on the specific chaperone 
UNC-45. The study presented in the following manuscript continues the work of Gazda et al, 
who resolved the crystal structure of the C. elegans UNC-45 protein and identified the 
organisation of UNC-45 in tandem oligomers to facilitate thick filament formation and stability 
(Gazda et al. 2013). Their work also described the mechanism of UNC-45’s interaction with the 
co-chaperones Hsp90 and Hsp70. The following paper describes the expression of a C. 
elegans skeletal myosin (UNC-54, or MHC-B) in insect cells when co-expressed with the C. 
elegans chaperone UNC-45. This work makes possible the probing of the role of UNC45 and 
other co-chaperones in myosin folding. 
 
6.2 Aims of research 
 
The aim of this research was 2-fold. Firstly, to produce sarcomeric myosin using baculovirus 
vectors and insect cells (High Five cells).  The reason for this being that protein yields are 
currently limited by the C2C12 expression and purification system which was used to produce 
recombinant myosins described in Chapters 3-5. This worked aimed to investigate if 
recombinant myosin could be produced and folded in a non-muscle environment if co-
expressed with the UNC-45 chaperone. The second aim of the research was to show the direct 
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effect of the temperature sensitive-mutations on the myosin folding activity of UNC-45. Using 
the insect cell/baculoviral system, a mutational analysis of UNC-45 was conducted. Crystal 
structures of the temperature sensitive mutations were generated to uncover the molecular 
basis of the temperature-sensitivity, with a focus on the flexible myosin-binding UCS domain. 
This could advance the understanding of the folding mechanism of this chaperone.  
 
6.3 Contribution to publication 
 
My contribution to this manuscript was with regards to aim 1. I worked closely with Renato 
Arnese from the Clausen lab when he visited the University of Kent. Together, we conducted 
the initial biochemical activity of the purified MHC-B. We did this through single turnover 
experiments and F-actin co-sedimentation assays. The manuscript was received by Nature 
Communications, who recommended a more thorough biochemical characterisation of the 
purified MHC-B protein to confirm that the protein is active. I then completed this through 
stopped-flow spectroscopy. I designed, performed and analysed the stopped-flow 
characterisation of the MHC-B protein. For this publication I provided figure 3d, supplementary 
figure 3, and supplementary table 1. These were added to the following revised manuscript.  
 




















































































































































As described in Chapter 1.7, the aims of this thesis were part of an effort to understand the 
mechanism by which the properties of myosin can be modulated to achieve a multitude of 
functions. With a focus on class II myosins, this was achieved by looking at different 
contraction characteristics between class II isoforms, the way in which MyHC-β myosin can 
modulate ADP release and velocity, and how single point mutations can disrupt myosin 
function. To improve the current methodology to produce recombinant myosin that allow us 
to answer such questions, we also attempted to address if the myosin chaperone UNC-45 
could be utilised to increase protein yields, and characterised the MHC-B myosin from the 
body wall of C. elegans. The extent to which this work has successfully addressed these 
problems will be discussed below, chapter by chapter. 
 
7.1 The ATPase cycle of Human Muscle Myosin II isoforms: Adaptation of a single 
mechanochemical cycle for different physiological roles 
 
The first aim of this thesis was to predict how human sarcomeric myosins may adapt their 
mechanochemical ATP-driven cross-bridge cycle to perform different functions within 
different muscle types. The physiology of a muscle is determined by the muscle fibres 
present, which typically express a single myosin isoform. Chapter 3 demonstrated that all 
isoforms studied have unique fractional occupancies of the states in the ATPase cycle, and 
the balance between the different molecular events in the cycle can be altered to produce 
a range of mechanical activities. 
 
 The work presented in Chapter 3 is the first of its kind, combining data from multiple 
groups and applying a novel modelling approach to predict how parameters of the cross-
bridge cycle govern the major physiological characteristics of a muscle fibre. Some key 
conclusions from this work include the finding that each isoform has a unique relationship 
between the ATPase cycling rate and the three significant events in the cycle (phosphate 
release, ATP hydrolysis and ADP release). Interestingly, whilst being a developmental 
myosin, the MyHC-peri isoform shared similar characteristics with the fast skeletal isoforms 
rather than the MyHC-emb isoform. Our results additionally demonstrated that the slow 
isoforms are more economical at holding loads. This allows the slow isoforms to sustain 
force and velocity when contracting for longer periods compared to the fast isoforms. Taken 
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together, these findings reveal distinct characteristics between different sarcomeric myosin 
isoforms. 
 
One of the parameters that is predicted from the modelling approach is the rate 
constant of ATP hydrolysis. The rate and equilibrium constants that control this step 
precedes the entry into the M.D.Pi state (see Figure 1.28). The rate of ATP hydrolysis, along 
with phosphate release, is thought to control the rate of force development (Sleep, Irving, 
and Burton 2005). To determine the rate and equilibrium constant of ATP hydrolysis, 
previous assays in our laboratory use a combination of quenched-flow spectroscopy and 
High Performance Liquid Chromatography (HPLC) (Bloemink et al. 2007). This assay 
measures the time dependence of phosphate production using a quench-flow apparatus; 
myosin is mixed with ATP, aged for a specified time, and then quenched with acid, which 
denatures the myosin and stops the ATPase reaction. Phosphate that was sequestered in 
the active site in the M.ADP.Pi state is also measured. Phosphate, along with ADP and ATP 
nucleotides can be then be quantified using HPLC. The limitation of using this assay with 
the human proteins generated from C2C12 expression and purification is the large quantity 
of protein required. The assay generally uses 2 mg for one experiment, which is double the 
1 mg of protein generated from one batch of culture of C212 cells.  However, the parameter 
has been measured in other species for the MyHC-β and MyHC-IIa isoforms. MyHC-β from 
bovine masseter muscle has a rate constant of 18 s-1 (Bloemink et al. 2007), from rabbit 
21.6 s-1 (Iorga, Adamek, and Geeves 2007), and from porcine 24.5 s-1 (Stein, White, and 
Annis 1989). This agrees well with the modelled human value of 12.5 s-1. MyHC-IIa from 
rabbit had a rate constant for ATP hydrolysis of 131 s-1 (Ritchie et al. 1993); our model 
predicts the human fast skeletal isoforms to have values 92.8-125.2 s-1. This demonstrates 
the accuracy of the model to predict unknown parameters, therefore we applied the model 
to other isoforms (such as the perinatal and extraocular isoforms) for which this parameter 
has not been reported. 
 
Another parameter predicted from the modelling is the rate constant of phosphate 
release. This is a significant part of the cycle, as it precedes the force-holding, strongly 
attached AMD state. The work of White et al and Heeley et al estimated Pi release to be 
75–77 s−1 for rabbit skeletal S1 (White, Belknap, and Webb 1997; Heeley, Belknap, and 
White 2002). The modelled human IIa isoform was predicted to be 44.5 s-1. Whilst the 
measured value is almost double our predicted value, it should be noted that it was obtained 
at different ionic strength to our solution data. The salt dependence of this parameter is not 
known. However, measurements performed at identical salt conditions to our experiments 
on porcine MyHC-β S1, which has a sequence identity to human MyHC-β of 95%, estimates 
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phosphate release to be 17 s−1. This compares well with our estimate of 15.95 s−1 (Liu et al. 
2015), further highlighting the precision of the model. 
 
To constrain our model further, we could measure the rate constant or equilibrium 
constant of ATP hydrolysis. Classically the method to measure this constant used 
radioactively-labelled nucleotides. Other methods that have the sensitivity to measure 
nucleotides at low concentrations could be explored. In 2017, Olaffson et al described the 
combination of HPLC with mass spectrometry to measure deoxyribonucleoside 
triphosphate concentrations in tissues and isolated cells (Olafsson et al. 2017). The assay 
successfully separated and quantified down to the femtomole level dCTP, dTTP, dATP, and 
dGTP nucleotides. If this resolution could be applied to ATP and ADP nucleotides, it may 
present an attractive method to measure the rate constant of ATP hydrolysis. My initial 
studies (not presented in this thesis) have investigated the use of NMR spectrometry. Guo 
et al reported the use of one-dimensional proton NMR spectroscopy to measure the ratios 
of different nucleotides, which can then be used to infer information about ATPase and 
kinase activities (Guo et al. 2014). The authors also claim that the technique can directly 
monitor ATP turnover. I performed initial experiments testing this method and proof-of-
concept measurements were successful. Optimising this method is an area that could 
enhance the current scope of our modelling approach, and may also have implications for 
the work described in Chapter 5, as will be discussed in section 7.3. 
 
The modelling conducted with MUSICO in this thesis is not reflective of the 
sarcomere environment in which actin and myosin are found. The larger aim of MUSICO is 
the development of an accurate multiscale model of a contracting sarcomere  (Mijailovich 
et al. 2016). Such complex modelling would require the combination of single molecule force 
measurements, muscle fibre data, motility assays and transient ATPase kinetics. The 
modelling performed in Chapter 3 does not take into account regulatory proteins such as 
tropomyosin and troponin, thin filament regulation, Ca2+ sensitivity or thick filament 
regulation (such as myosin binding to MyBP-C and titin, phosphorylation of RLC). However, 
whilst the modelling approach used here is simple, and does not fully exploit the capabilities 
of the MUSICO programme, the basics of the ATPase cycle have to be understood before 
progressing to more complex models. To obtain a highly constrained model, the ATPase 
cycle should be well-defined, which the data in Chapter 3 achieves.  
 
To fully understand the mechanical behaviour of a muscle fibre, the force-velocity 
relationship needs to be defined. When studying the in vivo mechanics of a muscle, 
maximum shortening velocity is not the most relevant parameter. Muscles contracting in 
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vivo do not shorten at their maximum shortening velocity, but rather at the velocity at which 
power output is maximal (i.e. the optimum performing conditions for a muscle) (Bottinelli et 
al. 1996). The force generated by a muscle is a function of its velocity; power = force x 
velocity. The force of a muscle defines the velocity at which power output is maximal. 
Currently, our data is on single protein, and extrapolating solution biochemistry to muscle 
fibre data is beyond the scope of the model. However, of note is the work of Fenwick et al, 
who used a modelling approach to show how myosin force production is co-ordinated with 
energy utilisation during lengthening and shortening (Fenwick, Wood, and Tanner 2017). 
They report that the fraction of bound cross-bridges increased during slow-velocity 
concentric and eccentric contractions, but that ATP utilization increased during shortening 
transients due to faster cross-bridge cycling. This work demonstrates how contractile 
efficiency and power output are modulated throughout dynamic contractions, which may be 
another way in which myosin can fine-tune its properties.  
 
As with any modelling approach, there are a number of assumptions that are made 
to allow a detailed description of the system to be achieved. For the class II myosins, load 
dependence has only been measured for the human MyHC-β. We applied this load 
dependence to all isoforms studied in our analysis; this is unlikely to be the same between 
the isoforms. This parameter needs to be determined for more isoforms. The recent 
developments in force measurements using single molecule assays will enable this 
(Greenberg, Shuman, and Ostap 2014; Sung et al. 2015). Another assumption in our 
modelling was the effect of temperature on myosin ATPase. The experimental ATPase data 
for the perinatal, extraocular and fast skeletal isoforms were conducted at 37 °C; a Q10 value 
of 1.5 has been reported for the ATPase of MyHC-β (Siemankowski, Wiseman, and White 
1985), and so this value was used to correct value to a temperature of 20 °C. However, it is 
possible that this temperature-dependence is different between isoforms, thus this remains 
a limitation of the data. 
 
One of the limitations of using such an approach as kinetic modelling is the varying 
experimental conditions between different labs if parameters are not all collected within the 
same group. All the assays included in the model in Chapter 5 were completed under the 
same experimental conditions (i.e., ionic strength, temperature). Where possible this was 
also true for the data in Chapter 3, with a few exceptions. Kinetic data for the fast skeletal 
and extraocular isoforms were completed at 100 mM KCl (Deacon et al. 2012), but all other 
data was collected at 25 mM KCl (Nag et al. 2015; Walklate et al. 2016). However, salt 
dependence has been reported for rabbit MyHC-IIa and human MyHC-β kinetics (Mijailovich 
et al. 2017), so we corrected for this difference. Perhaps one limitation is the different tags 
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that have been added to the recombinant myosins as the production process has been 
refined over the last decade. The fast skeletal and extraocular isoforms were purified with a 
GFP-tagged moiety, which was absent in all other isoforms. Bloemink et al demonstrated 
that there were few differences in measured parameters of MyHC-β with and without a GFP-
tag (Bloemink et al. 2013), but the effect of the presence of the GFP-tag on the steady-state 
ATPase rates has not been measured.  
 
All kinetic parameters in the model were collected in solutions containing 25 mM 
salt, and simulations were run assuming this ionic strength. Simulations were performed at 
this ionic strength to allow comparison between stopped-flow and ATPase data, the latter 
of which requires low salt to achieve saturation of the actin-activated ATPase. This is not 
reflective of physiologically relevant salt conditions, but as the modelling is dependent on 
steady-state ATPase parameters, this must be a well-defined parameter. Whilst this may 
not be physiologically relevant, as all isoforms were under the same conditions, a direct 
comparison between them can be made.  
 
As the fundamental ATPase cycle, which the model is based on (Figure 1.28) is 
conserved between myosins, this analysis can be performed for myosins from different 
classes. The work presented in Chapter 3 was focussed on human sarcomeric myosins, 
which contain a wide repertoire of properties alone. Whether the difference in structural 
domains are coupled with changes in mechanochemical cross-bridge cycle properties to 
give rise to different functions between different myosin classes could be explored. A further 
application of the model could be in the use for predicting potential therapeutic agents for 
disease from small molecule screens. If kinetic parameters of disease-causing mutations 
were known, the model could be used to assess if the parameters are restored to WT values 




7.2 Cardiac contraction velocity has evolved to match heart rate with body 
size through variation in β-cardiac myosin sequence 
 
The work from Chapter 3 demonstrated some of the different contractile properties of 
different myosin class II isoforms, but the question still remains as to how these differences 
arise from the sequences of myosin. Chapter 4 aimed to address this question by focusing 
on MyHC-β and its adaptation of the rate of ADP-release to control velocity as body mass 
increases through evolution. 
 
The instructions for life are encoded within the DNA sequence of proteins, so we 
analysed the sequences of class II myosins. As described in section 1.3.2, the work of 
McGreig et al demonstrated a correlation in sequence identity with body mass for MyHC-β, 
MyHC-IIa and MyHC-IIb isoforms (McGreig et al. 2019). In this study we focussed on the 
MyHC-β isoform. Velocity data of the MyHC-IIa and MyHC-IIb isoforms are only available 
for a few species, whereas heart rates have been recorded for a large cohort of mammals. 
To be clear, heart rate is not solely a function of myosin composition within the heart; it is a 
function of very many inter-species variables. These variables exist at the protein, 
anatomical and physiological levels. However, the maximum shortening velocity, which is 
one of the parameters that defines the force-velocity relationship of a muscle, is a property 
of the myosin isoform expressed. We therefore propose MyHC-β can be used to probe 
adaptation of contraction velocity with increasing body mass. 
 
MyHC-β is expressed both within slow skeletal muscle and the ventricles of large 
mammals, including humans. The endogenous rat protein which was used as a control in 
Chapter 4 was obtained from the soleus muscle, not cardiac tissue. Cardiac muscle contains 
an abundance of fibroblasts and other cell types, which makes purifying cardiac MyHC-β 
less efficient. One consideration is that different post-translational modifications (PTMs) 
may occur in cardiac and skeletal muscle. To understand the effects of PTMS such as 
phosphorylation, serine to aspartate mutations can be introduced into a protein to mimic the 
phosphorylated states. Kampourakis and colleagues recently reported the limitations of 
generating and studying such mutations (Kampourakis et al. 2018). They found three Ser-
Asp mutations in cardiac MyBP-C did not reproduce the same effects as tris-
phosphorylation of these sites Protein Kinase A. This is likely due to the additional negative 
charges introduced with phospho-mimetic mutations. It can therefore be misleading to 
interpret the effects of phosphorylation sites in a protein using such an approach. Whilst the 
full extent of the effect of PTMs on MyHC-β is currently unknown, it is unlikely that such 
modifications generate significant alterations to the rate of ADP-release or maximum 
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shortening velocity. Bloemink et al demonstrated that the ADP release rate was not 
significantly different between MyHC-β from bovine masseter and cardiac muscles. 
Therefore, rat MyHC-β purified from soleus muscle is expected to have the same kinetic 
properties as that of cardiac MyHC-β. 
 
The sequence changes introduced into the MyHC-β were found in three distinct 
clusters of the motor domain. Whether all three of these regions contribute equally to the 
changes in ADP release, and hence velocity, or if they all work in unison is not yet defined. 
As shown by the table in Figure 6 in Chapter 4, the rate of ADP release is modified step-
wise. It is therefore unlikely that a single one of these residues is the sole determinant of 
the change in the rate of ADP release and velocity between the rat and human MyHC-β. 
Instead, we predict that each of the nine residues will contribute a fraction of the difference 
in the measured parameters. What would be interesting is whether 3 locations in the motor 
domain are also responsible for the adaptation to body mass in the MyHC-IIa and MyHC-
IIb isoforms, or if these isoforms vary alternate regions of the motor domain to suit their 
physiological requirement. It should be noted that any changes made to the sequence of 
the motor domain are likely to be subtle; to alter the function of the protein in a positive 
manner without exerting any negative consequences requires a careful balance of tuning 
the ADP-release rate whilst maintaining motor function. 
 
Whilst the work in Chapters 3 and 5 were completed with sS1, the WT human MyHC-
β and chimera proteins in Chapter 4 were extended S1 molecules. These S1 constructs 
contained 2 IQ domains, and so were purified with the endogenous mouse essential and 
regulatory light chains. Deacon et al demonstrated no significant difference in kinetic 
parameters between sS1 and S1 (Deacon et al. 2012).  
 
The velocity value for human MyHC-β obtained in Chapter 4 was 0.49 ± 0.129 μm.s1. 
A similar experiment in Ujfalusi et al reported a motility of 0.612 ± 0.21 μm.s-1 (Ujfalusi et al. 
2018), although this value was obtained at 23 °C (compared with our experimental condition 
of 20 °C). It has been reported previously that the effects of salt, pH and temperature can 
alter velocity values (Homsher, Wang et al. 1992). Higher temperatures can increase motility 
by a factor of 4 over 10 °C, as shown by Sheetz et al (Sheetz, Chasan, and Spudich 1984). 
Moreover, the construct used in Ujfalusi et al was sS1 with only single light chain, compared 
to the S1 construct with two light chains used in this study. Lowey et al showed that light 
chain content can affect velocity (Lowey, Waller, and Trybus 1993a). Indeed, in skeletal 
muscle removal of both light chains slowed velocity by a factor of 10, but reconstitution of a 
single light chain restored velocity only to an intermediate level (Lowey, Waller, and Trybus 
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1993b).  Other studies have also shown the importance of light chain content on velocity 
(Fewell et al. 1998; Matthew et al. 1998; Toepfer et al. 2013; Kim et al. 2019). Thus, the 
differences in temperature and light chain content may account for the differing velocity 
values.  
 
Velocity values for human MyHC-β are also reported in Chapter 5, which were 
collected by the Spudich group. They report a range of velocity values; data in Table S8 
show that values range from 0.579 to 0.858 μm.s-1 between different protein preparations. 
This suggests there is variability between protein preparations. In this study, all 
measurements were completed from 3 independent protein preparations from different cell 
pellets. Despite this, all cell pellets were transfected with the same adenovirus stock, and 
were grown simultaneously in the same incubator, resulting in growth under identical 
conditions. This reduced the variability we observed in our measurements. To note, the 
errors are larger in our velocity values as the errors from the Spudich laboratory represent 
Standard Error of the Mean (SEM), whereas we report Half Width at Half Maximum 
(HWHM). This is to account for the distribution of the velocity values around the mean.  
 
The site of cleavage by chymotrypsin is found after the first IQ domain; therefore, 
the chymotryptic-digested rat soleus myosin contained 1 IQ domain and hence 1 light chain. 
As the light chain content differs from the recombinant human MyHC-β and chimera 
proteins, and because light chain content affects motility as outlined above, a direct 
comparison of motility cannot be made between the recombinant proteins and the native rat 
soleus S1. Whilst a motility assay was not performed for the native rat protein, studies in 
the literature indicate that rat myosin moves 3-5 times faster than the human myosin (the 
absolute value varies depending on conditions of the experiment) (Pellegrino et al. 2003). 
Velocity data has been reported for rat and human fibres. However, comparison of velocity 
data from muscle fibres does not directly correspond to values obtained with single protein. 
It is thought that the orientation of the myosin on the surface will contribute to this (Homsher, 
Wang et al. 1992). Indeed, the presence of the C-terminal extension on the MyHC-β and 
chimeric proteins tether the myosin to the surface resulting in a uniform attachment of 
proteins to the coverslip and stable geometry, which is not the case for fibre data. Whilst the 
absolute values cannot be directly compared, the ratio of rat-human motility is comparable 
to our chimera-human ratio. 
 
The motility assay was performed under unloaded conditions. It would be interesting 
to measure the load-dependence of the chimera protein with harmonic force microscopy 
(Sung et al. 2015). Both load-dependence and the step-size of human MyHC-β have been 
206 
 
measured, although we would not expect to see a difference in these parameters in the 
chimera protein. The force-velocity relationship defines the mechanical performance under 
various loads as a function of maximum force and maximum velocity.  For individual muscle 
myosins the maximum force is a property of a myosin isoform but is largely invariant 
amongst different orthologues.  Maximum shortening velocity of a single myosin type, 
however, does vary among orthologues. This would suggest that the load-dependence of 
the chimera protein would be equivalent to the human MyHC-β, although this remains a 
prediction and has not been experimentally determined. 
 
Figure 5 in Chapter 4 shows the location of the residues changed in the chimera 
protein. Interestingly, none of the changes were found in the converter domain, which, as 
described previously, is a hot-spot for cardiomyopathy-causing mutations. This suggests 
that mutations introduced into this domain are not well-tolerated. Whilst none of the residues 
have been reported in ClinVar (a database that reports human variations and phenotypes, 
with supporting evidence), a study from Robert-Paganin et al reported two of the residues 
as sites with reported disease-causing mutations (Robert-Paganin, Auguin, and Houdusse 
2018). This study was a comprehensive analysis of 178 reported HCM-causing mutations 
which aimed to categorise the mutations based on the effects on the motor. At residue 349, 
a methionine to threonine substitution has been reported in a single adolescent by Jeschke 
et al (Jeschke et al. 1998). The authors predict that this mutation leads to altered motor 
function. Similarly at residue 434, an arginine to threonine substitution is predicted to likely 
effect both motor function and stability. However, like the 349 residue, this mutation has 
only been seen in one patient (Wang et al. 2014). It is therefore hard to predict whether the 
mutations are clearly causative of HCM; the two mutations could be normal variants in the 
population. 
 
This study may have wider implications on the field of evolutionary biology. One of 
the fundamental challenges in current molecular and structural biology is to understand how 
a protein can adapt, over evolutionary time frames, to different physiological requirements. 
To begin to understand this, we must grasp how DNA sequence variation alters protein 
function. This is pivotal to our understanding of evolution and the role of genetic variation. 
Now with the availability of the genomes of different species and many individual human 
genomes, it would be possible to use this approach for any measurable phenotype.  
 
As shown in Figure 1.16, point mutations can have long-reaching effects on protein 
function, both locally and globally. Of the ~800 amino acid motor domain, 9 amino acid 
substitutions were sufficient to alter properties of the motor such that the behaviour of the 
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protein was altered to match that of a different species. Physiologically, multiple mutations 
are not well tolerated within the myosin protein. Table 1.5 demonstrates the sheer number 
of mutations identified in MyHC-β. Just single amino acid substitutions are sufficient to 
cause HCM. The molecular mechanisms underpinning the cause and progression of this 
disease are incompletely understood. Chapter 5 aimed to address this and is discussed in 




7.3 Myosin motor domains carrying mutations implicated in early or late onset 
hypertrophic cardiomyopathy have similar properties 
 
Chapter 5 described a large-scale study on seven well-known heart HCM-causing mutations 
to identify the molecular changes in the MyHC-β motor that give rise to either early or late 
onset disease. This work is the key for understanding disease progression and identifying 
potential therapeutic targets for HCM. We initially hypothesised that early onset mutations 
would be more severe in their properties compared to late onset. Interestingly, we disproved 
our original hypothesis. 
 
Whilst no clear distinction was observed between early and late mutations, a pattern 
of behaviour was observed based on the location of the mutation within the motor domain. 
As discussed previously, the converter domain is a hotspot for HCM mutations, and is critical 
for the swing of the myosin lever arm during force production. All three late onset and two 
of the four early onset mutations studied in Chapter 5 are located in the converter domain. 
These five mutations showed some distinct characteristics which were not observed in the 
two non-converter domain mutations. For example, all converter domain mutations had a 
lower actin-activated ATPase rate, a lower duty ratio, and a lower AMD state. As stated in 
Chapters 3 and 5, the AMD state represents the ADP-bound myosin head in a force-
producing state bound to actin. A decrease in the AMD population will result in a decrease 
in the population of myosin heads strongly bound to actin in a force-producing state, 
suggesting a decrease in the ensemble force. Recent data shows that the myosin intrinsic 
force is little affected by adult-onset HCM converter mutations (Kawana et al. 2017). Taking 
together, these results suggest there exists a more complex mechanism by which mutations 
alter myosin activity or its regulation, leading to HCM pathology.  
 
Recently, a hypothesis has been proposed that suggests the number of myosin 
heads in a sequestered state in cardiac filaments is altered during disease. Myosin can form 
an auto-inhibited state, termed the interacting-heads motif (IHM). It has been reported that 
when myosin filaments disassemble, the tail folds into three segments and the heads bend 
back and interact both with each other and with the folded tail (Lee et al. 2018). The activity 
of the two heads are highly inhibited; the so-called blocked head is prevented from binding 
to actin through its interaction with the other free head. The free head, in turn, has its 
ATPase activity inhibited by binding to the blocked head. It has been suggested that these 
head–head and head–tail interactions may be the basis of the super-relaxed (SRX) state of 
myosin (Stewart et al. 2010). 
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The work of Cooke and colleagues first hypothesised that myosin exists in three 
states with different nucleotide turnover lifetimes; active (1 s-1), disordered relaxed (~ 30 s-
1) and super relaxed (150 s-1 in cardiac muscle fibres, ~ 300 s-1 in skeletal muscle fibres). 
The super relaxed state (SRX) of myosin was first identified in single nucleotide turnover 
experiments on permeabilized, relaxed skeletal muscle fibres, which showed a biphasic 
decay in fluorescence intensity. The authors postulated that there exist two subpopulations 
of relaxed cross-bridges (disordered relaxed and super-relaxed) with ATP-turnover rates 
that differ by approximately a factor of 10. The two subpopulations were also observed in 
experiments performed on rabbit ventricular muscle fibres (Hooijman, Stewart, and Cooke 
2011).  Intriguingly, the proportion of SRX can be fully abolished in skeletal fibres upon 
activation of myosin heads, although this is not observed in cardiac muscle fibres (Hooijman, 
Stewart, and Cooke 2011). This suggests a subset of myosin molecules remain in the SRX 
even during activation of the muscle and thus may slightly reduce the total metabolic rate 
of working cardiac muscle. It should be noted that the definition of the SRX is the state of 
myosin with an extremely slow ATPase turnover rate; it is not defined as a folded-back state 
of myosin.   
 
Both SRX and IHM are becoming increasingly discussed in the field. It has been 
suggested that hypercontractility may arise from an increase in the number of functionally 
accessible heads in the sarcomere for interaction with actin (Trivedi et al. 2018; Spudich 
2019). It has been observed that a number of HCM-causing mutations are located close to 
the junction of the myosin S2 tail and the IHM. One of these mutations occur in an area of 
the “free” myosin head termed the cardiomyopathy loop, while others occur in the region of 
the S2 rod with which this loop interacts (Alamo et al. 2008). Mutations near this interface 
may destabilise the ordered structure of the thick filaments thereby reducing the proportion 
of SRX. Spudich and colleagues have also hypothesised how the number of available 
myosin heads available to interact with actin may lead to hypercontractility (Nag et al. 2017). 
They reported that myosin contains a relatively flat surface on the S1 domain which is a hot-
spot for HCM mutations (Spudich 2015; Homburger et al. 2016). This surface has a 
positively charged cluster of arginine residues, all of which when mutated are causative of 
HCM (Homburger et al. 2016). This cluster was suggested to act as a binding interface for 
MyBP-C and the proximal S2 region of myosin (Spudich 2015; Spudich et al. 2016). The 
authors suggested that such binding interactions could sequester myosin heads in an ‘off-
state,’ thereby regulating the number of myosin heads functionally accessible for interaction 
with actin. A primary effect of HCM mutations could be to weaken such associations, 
causing an increase in the number of heads available to bind to actin, thereby explaining 
the hypercontractility observed in HCM patients. 
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It is currently beyond the scope of our kinetic measurements to predict the number 
of myosin heads that may exist in the SRX. Similarly, the MUSICO programme does not 
take into account the proportion of myosin in a sequestered state. However, as discussed 
in 7.1, the ability to measure the K3 parameter would be crucial for elucidating the equilibrium 
between myosin heads in active and relaxed stated. The myosin heads in the SRX would 
exist in the pre-stroke state, with ADP and Pi in the nucleotide pocket, before interaction 
with actin accelerates the ATPase activity releasing the heads out of the SRX. A shift in 
either the rate or equilibrium constant of this state could alter the amount of myosin that is 
able to form the SRX. Studies mentioned above indicate that HCM mutations may weaken 
the IHM, which would result in an increased number of active myosin heads. Measuring the 
K3 parameter would test this hypothesis.  
 
The stopped-flow experiments described were performed with sS1 protein (the 
myosin motor domain with a single IQ domain and myosin ELC). This means that head-
head and head-tail interactions of the IHM cannot occur, and their effects not observed. To 
address this, work should now focus on performing experiments with HMM. The presence 
of the S2 region would provide the myosin head with a platform to fold onto, and the dimeric 
structure would bring the two S1 heads into close proximity to interact. Adhikari et al have 
recently performed ATPase and in vitro motility experiments for 5 HCM mutations with 
HMM-like two-headed molecules (Adhikari et al. 2019). This is the first study to describe 
functional parameters of HCM mutations using HMM-like constructs. The H251N, D382Y 
and R719W mutations studied in Chapter 5 were included in the Adhikari study. They found 
that the mutations do indeed decrease the level of SRX and make more heads available for 
interaction with actin.  
 
The stopped-flow experiments were performed with homogenous solutions of 
protein. Whilst this is not representative of the mixture of protein found in patient muscle 
fibres, this is required to understand the fundamental parameters of mutated protein. None 
of the mutations studied in Chapter 5 have been reported in homozygous patients, 
suggesting that homozygous mutations are incompatible with life. Patients will contain a 
mixture of both WT and mutated protein in their cardiomyocytes. As both genes are co-
dominantly expressed, an equimolar ratio of WT and mutated protein would be expected. 
However, a study by Tripathi et al found that the ratios of five different HCM-causing MyHC-
β mutations showed an allelic imbalance at both the mRNA and protein level (Tripathi et al. 
2011). Two of the mutations included in the study included R719W and R723G, which were 
analysed in Chapter 5. Both of these mutations accounted for 2/3 of total MYH7 mRNA 
transcripts. It has been suggested that this is due to increase splicing efficacy, as the 
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mutations are located at hairpin structures at intron-exon boundaries (Tripathi et al. 2011). 
The kinetic properties of a myosin solution containing a combination of WT and mutated 
protein is yet to be elucidated. 
 
As mutations are found in many regions within the motor domain, it is unlikely there 
is one single mechanism by which mutations cause disease. The question as to how the 
large number of reported mutations lead to the same phenotype remains a valid question. 
Robert-Paganin et al recently classified HCM and DCM mutations in MYH7, based on the 
resulting effects on the motor (Robert-Paganin, Auguin, and Houdusse 2018). The 
classification of the seven mutations studied in this thesis are summarised in Table 7.1. All 
3 late onset mutations were described as destabilising the sequestered state destabilized 
due to effect on IHM contacts. All seven mutations had different resulting impairments on 
the protein. This again highlights that it is unlikely there exists a common mechanism for 
disease progression that arises from the presence of these mutations alone. The prediction 
of the H251N and the three late onset mutations affecting motor function is consistent with 
our observations. Whilst the Robert-Paganin study was comprehensive, many of the 
mutations included in the analysis are reported as VUS. This is true for the H251N, P710R 
and V763M early onset mutations that we characterised. Thus, caution must be taken to 
describe these mutations as causative of disease. 
 
The study of MyHC-β and its role in HCM has changed the field of myosin research 
from one of basic science to a relevant subject for clinical study. However, the field remains 
limited by the lack of protein in order to conduct large-scale studies on the molecular basis 
of disease and therapeutic target design. We attempted to address this issue in Chapter 6, 






Early or  
late onset? 
Predicted effect of mutation Resulting impairment 
H251N Early 
Sequestered state destabilized due to effect on IHM  
contacts. Motor function altered 
Interaction with U50 linker within the transducer. May affect 
 the motor transitions and the stability of the PPS state 
Involved in stabilisation of the IHM motif 
D382Y Early 
Sequestered state destabilized by direct effect on IHM 
 without impairment in motor activity 
Surface – no effect on motor function  
(unless the tyrosine side chain gets buried and  
allosterically changes this actin-binding interface) 
P710R Early 
Sequestered state destabilized due to effect on PPS  
stability or off state formation. Motor function altered 
Alters the transitions of the SH1 helix and the stability of the  
primed lever arm –likely alters motor function 
PPS stability affected 
V763M Early 
Protein stability likely altered as well as motor function 
 possible effect on the off state if the PPS stability is altered 
Destabilisation of the converter fold 
Would affect function and the stability of the sequestered state 
R719W Late 
Sequestered state destabilized due to effect on IHM 
 contacts. Motor function altered 
Modifies the top-loop conformation 
Small effect on compliance 
R723G Late 
Sequestered state destabilized due to effect on IHM 
 contacts. Motor function altered 
Change in top-loop conformation 
Change in lever arm compliance 
G741R Late 
Sequestered state destabilized due to effect on IHM 
 contacts. Motor function altered 
No major effect on the compliance of the lever arm 
Destabilised the converter at the top loop 
 





7.4 Molecular features of the UNC-45 chaperone critical for binding and folding 
muscle myosin 
 
The fourth aim of this thesis was to improve the current recombinant myosin expression and 
production system. The importance of UNC-45 in myosin folding has been utilised to 
produce recombinant myosin over the past two decades. Winkelmann and colleagues 
demonstrated that muscle myosin requires a muscle environment to fold into a functional 
molecule (Srikakulam and Winkelmann 1999; Chow et al. 2002; Srikakulam and 
Winkelmann 2004). As shown by Price et al, skeletal muscle UNC-45 is expressed 
specifically in cardiac and skeletal muscle (Price et al. 2002). The current system to produce 
recombinant myosin uses an immortalised mouse myoblast cell line, called C2C12 
(Resnicow et al. 2010). The C2C12 cell line differentiates rapidly upon hormonal treatment, 
forming contractile myotubes and produces characteristic muscle proteins. As the protein is 
being produced in a muscle environment, all necessary chaperones and folding factors are 
present to enable fully folded motor domain to be extracted.  
 
The work of the Winkelmann and Leinwand labs revolutionised the field, as it 
became possible to study single myosin class II isoforms for the first time. Whilst Regianni 
showed that a single muscle fibre typically expresses one myosin isoform, a muscle may 
consist of multiple fibre types (Bottinelli and Reggiani 2000), making the isolation of a single 
isoform difficult. The C2C12 cell methodology enabled the characterisation of seven of the 
class II isoforms (Deacon et al. 2012; Bloemink et al. 2013; Walklate et al. 2016). In Chapter 
3, we characterised another developmental class II isoform; MyHC-Peri. Despite the 
achievements of this production system, there are limitations. Firstly, the process is time 
consuming. The time from viral expression to protein purification is typically three months. 
Secondly, the protocol requires specialist equipment and expertise; a methodology that 
uses standard lab chemicals would be advantageous. Furthermore, little protein is 
generated; typically, 1 mg from a 1 litre culture. To address these issues, and utilise the 
information we have about the role of UNC-45 in myosin folding, colleagues in the Clausen 
lab in Vienna attempted to produce sarcomeric myosin using a standard baculoviral 
expression system in a non-muscle environment. 
 
Using the High Five insect cell line and baculovirus expression system, the motor 
domain of a sarcomeric C. elegans myosin was successfully produced. Baculovirus has 
been used previously to produce smooth non-muscle myosins, but this is the first time it has 
been used to produce a sarcomeric myosin. The gene for the body wall myosin, MHC-B, 
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was co-expressed with the gene for UNC-45. The expression and purification system were 
able to generate 15 mg protein per litre of insect cell culture. This is almost 15x the yield of 
that obtained from the C2C12 system. Not only was the protein produced folded and 
soluble, it was also fully active. We confirmed this by stopped-flow spectroscopy to 
characterise the activity of the protein. This characterisation is novel, as no kinetic 
measurements have been performed on a C. elegans myosin previously. The data in 
Supplementary Table 1 of Chapter 6 demonstrates that the C. elegans MHC-B has similar 
properties to the slow-type MyHC-β. The two proteins had a similar affinity for actin (KA), 
second order rate constant of ATP binding to S1 (K1k+2) and actin.S1 (K’1k’+2), and ATP 
affinity for acto.S1 (1/K’1). The major differences were the ADP affinity for S1 (K6K7) value - 
which was 14-fold weaker - and the ADP affinity for actin.S1 (K’6K’7) value, which was 2-
fold weaker. The ADP release rate from acto.S1 (k’+6) was over three times faster, with a 
value of 189 s-1, compared to 59 s-1 for the MyHC-β (Deacon et al. 2012; Bloemink et al. 
2013). This is rather surprising, due to the very similar nucleotide binding sites between the 
two proteins. To validate the results of the recombinant MHC-B, a characterisation of 
endogenous MHC-B purified from C. elegans would be required. 
 
It is worth noting that the MHC-B construct was expressed in the absence of any IQ 
domains, and hence light chains, whereas the MyHC- β was co-expressed with the human 
essential light chain, MYL3. However, this is unlikely to cause the differences in ADP affinity 
or ADP off-rate reported. Deacon et al compared MyHC-β with 1 and 2 light chains (Deacon 
et al. 2012), and saw no significant differences in these parameters. Similarly, Woodward 
et al demonstrated that removal of the light chain in Dictyostelium discoideum myosin did 
not alter enzymatic properties of the motor domain (Woodward, Geeves, and Manstein 
1995). As mentioned above, Lowey et al showed with rabbit skeletal S1 that the absence 
of light chains altered velocity but not ATPase activity (Lowey, Waller, and Trybus 1993b). 
Therefore, it is unlikely that the lack of IQ domains and light chains altered the kinetic 
properties of the purified MHC-B. 
 
The limitation of the production system is the so-far inability to produce mammalian 
myosin. Attempts to produce the motor domain of human MyHC-β resulted in successful 
expression of the gene, but when purified the protein aggregated and no-soluble myosin 
was present. To address this, a chaperone screen using a proteomics approach could be 
employed to identify chaperones that are required for mammalian myosin folding that are 
not present in simpler model systems, such as C. elegans. It could also be that the 
recombinant protein is lacking in PTMs that would exist if the myosin was produced in a 
muscle environment – this could be critical for correct myosin folding, and has yet to be 
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explored. Another potential use of the insect cell system would be the ability to produce 
HMM, rather than S1. As discussed above, the HCM mutations studied to date are often 
conducted on S1, which is not representative of the double headed conformation that exists 
within a sarcomere. Work to produce HMM using the insect cell system is not presented 
here, but is on-going in the Clausen laboratory. 
 
An inherent limitation in characterising the substrate-targeting mechanism of UNC-
45 thus far has been the lack of sufficient quantities of its substrate (due to reasons outlined 
above). The higher protein yields from the insect cell system therefore enabled the 
importance of various folding factors in myosin folding to be explored. Soluble myosin was 
only obtained during co-expression with UNC-45, not with Hsp70 or Hsp90, highlighting the 
essential requirement of UNC-45 even in the absence of its co-chaperones. Because of the 
high protein yield we propose that it would also be easier to obtain high resolution crystal 
structures of human cardiac myosins in multiple states, attempts of which have yet to 
produce such structures. This is also important for the elucidation of the previously 
mentioned SRX state of myosin, which has yet to be crystallised. Obtaining a crystal 
structure of the SRX state is challenging due to the requirement of the sample containing 
intact filament. A technique such as cryo-electron microscopy is more likely to reveal the 
3D-structure of such a complex. This technique would still require HMM constructs, so that 
the sequestered heads folded back onto the myosin tail can be resolved. 
 
Whilst no mammalian myosin has been expressed, as noted above, the work on 
HCM could benefit from a model organism. A DALI search (a database for comparing 3D 
structures of proteins) found that of 36 related protein structures in the Protein Data Bank, 
the human MyHC-β myosin was the closest structural homolog of the MHC-B structure. The 
two motor domains are 59% identical and 72% similar.  The work of Bernstein and 
colleagues use Drosophila melanogaster as a model for cardiomyopathy, which they have 
successfully used to characterise the K146N and R2249Q HCM mutations (Kronert et al. 
2018; Bell et al. 2019). Since D. melanogaster is 58% identical to human MyHC-β, which is 
comparable to the C. elegans MHC-B, and because C. elegans is a widely used genetic 
model for muscle biology, we propose that C. elegans could be used as a model organism 
for both myosin folding and disease. To test the suitability of C. elegans as a model 
organism, a well-studied HCM-causing mutation, such as R403Q or R453C, could be 
inserted into the MHC-B, and observe if the same kinetic parameters are changed 
compared to WT. Further, the role of UNC-45 in cardiomyopathies could be explored using 
this system. Melkani et al showed the importance of UNC-45 in maintaining cardiac 
contractility during remodelling of the myocardium in fly heart muscle (Melkani et al. 2011). 
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The study showed that UNC-45 knockdown in Drosophila heart leads to conditions similar 
to cardiomyopathies. The precise mechanism that generates this phenotype is not yet fully 
understood.  
An interesting question that still remains is how the UNC-45b isoform is specific for 
myosin, compared to the more generic UNC-45a. The two isoforms have a 57% sequence 
homology. Studying the isoform-specific activities of UNC-45 and their regulation will be 
critical to enhance our understanding of myosin chaperone function in health and disease. 
It is also currently unknown if they are differentially regulated. Another interesting question 
is whether or not the assembly of UNC-45 oligomers regulates chaperone activity. The 
equilibrium between monomeric and oligomeric UNC-45 has yet to be defined, and 
transition between the two states may direct different chaperone activities. Whether this 
equilibrium is altered when a muscle undergoes stress may further yield insights into the 
protective role of UNC-45 in stress response.  
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7.5  Concluding remarks and future perspectives  
 
The work of this thesis has elucidated how sarcomeric myosins have fine-tuned their 
properties to give rise to different physiological functions. Disruption of these processes in 
diseased-states is crucial for understanding the mechanism of disease onset and 
progression. There are still a number of interesting questions that remain within the fields 
of muscle physiology and myosin biochemistry. I have outlined below a few areas I think 
will shape these fields in the coming years. 
 
Fundamental to myosin biochemistry is the mechanochemical cycle, which is 
conserved across myosin classes. As discussed in 1.6.2, force generation during the 
working stroke of the cross-bridge cycle includes phosphate release and movement of the 
lever arm, although the precise order of these two events remains under debate. It is also 
unknown whether this order varies between different classes of myosin. Elucidating the 
precise process of force generation remains a challenge in the field.  
 
The design and testing of small molecules or MyHC-β inhibitors to treat HCM is 
required to advance the current therapeutic options available to patients. It is unlikely there 
is one single modulator of MyHC-β that could successfully treat all cases of HCM, due to 
the array of different impairments reported in the protein (see Table 7.1). The phenomenon 
of myosin in a SRX may pose a potential mechanism to target for both prevention of disease 
progression and treatment of existing cardiac conditions. The structural state of the SRX is 
yet to be elucidated. Whilst not only advancing our potential understanding of cardiac 
disease pathology, it will yield insights into fundamental thick filament behaviour and 
regulation. 
 
The IHM and SRX state of myosin heads which are unable to bind to actin and 
hydrolyse ATP raises the question of how the motors can sense the state of the thin filament 
during activation. A thick-filament mechanosensing mechanism in skeletal muscle has been 
proposed (Linari et al. 2015), whereby a small fraction of constitutively active motors allows 
the muscle to respond immediately to calcium activation and  initiates a positive feedback 
loop. Such a mechanism in cardiac muscle may represent a potential target for therapeutic 
intervention in disease. 
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